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Critical limb ischemia (CLI), the end-stage of lower limb peripheral arterial disease, is 
characterized by a lack of oxygen/nutrient supply and subsequent tissue death. CLI patients with 
comorbidities are often ineligible for open bypass surgery. As an alternative approach, we 
developed pre-vascularized microbeads to jump-start inosculation with host vasculature after 
minimally invasive delivery and quickly restore blood flow to the ischemic tissue.  
Endothelial cells and fibroblasts were encapsulated in two microbead types – fibrin (FIB) 
and collagen-fibrin (COL-FIB) – and embedded immediately in FIB hydrogels to determine which 
initiated endothelial sprout formation to a greater extent. Cell viability in both microbead types 
was high (≥75%). Two weeks after embedding, cells in FIB microbeads produced a higher network 
length than those in COL-FIB microbeads. Cells pre-cultured in FIB microbeads for three days 
prior to embedding in larger hydrogels exhibited the most extensive endothelial tube area coverage 
in vitro.  
Fibrin microbead formulations were also evaluated for their ability to initiate vessel 
formation in vivo by injection into subcutaneous pockets on the dorsal surface of immuno-
compromised mice. Implants containing microbeads pre-cultured for 3 days had greater vessel 
coverage, higher total number of vessels, and less implant compaction at D3, and more mature 
vessels at D7 in situ, compared to other conditions. The improved distribution of mature vessels 
generated by the implants containing pre-cultured microbeads was attributed to the preservation 
of implant volume, which was confirmed with ultrasound imaging of model implants in vitro. 
Furthermore, implants containing pre-cultured microbeads displayed lower bulk elastic moduli 
xx 
 
compared to controls, but higher local stiffness near the microbeads, suggesting the distribution of 
cells within the implants plays a role in construct compaction and volume maintenance. 
Collectively, these findings show cellular microbeads pre-cultured for 3 days in vitro are more 
effectively able to nucleate vascularization in vivo.  
FIB microbead aggregation increased with pre-culture time. Agarose-based microbeads 
reduced aggregation and provided the most distributed endothelial network post-embedding when 
made with hydroxyapatite and fibrinogen. These microbeads supported pre-culture, which helped 
to increase the network length post-embedding. Overall, this work demonstrates the therapeutic 




     Introduction 
 
1.1  Clinical Motivation 
Peripheral arterial disease (PAD) is caused by the obstruction of blood due to plaque 
formation  in the arterial wall [1]. Plaque formation is initiated by the accumulation of lipoproteins, 
particularly of low-density lipoprotein (LDL), which causes an inflammatory response and the 
recruitment of macrophages which in turn leads to LDL modification and storage. Subsequent 
steps include the recruitment and death of smooth muscle cells (SMCs) and other inflammatory 
cells, the replacement and expansion of collagen matrix secreted by SMCs, and  plaque 
calcification. [2] This blockage prevents or reduces the normal blood flow through the body, 
limiting the oxygen and nutrient diffusion downstream of the affected regions. Cells and tissues 
residing in these ischemic regions – lacking oxygen and nutrients – often die and lose functionality, 
causing additional problems including ischemic ulcers and gangrene. [1] 
The most frequent and main symptom in patients who suffer from lower extremity PAD  is 
intermittent claudication (IC) [1]. IC is pain and/or cramping in the legs and especially calf muscles 
while exercising. This pain is likely to go away with rest within a 10-minute frame [3]. Perhaps 
because the pain subsides so quickly, 10 to 50% of patients with IC do not seek medical attention 
for this symptom [3].  In addition, 75 to 80% of PAD patients do not present clinical intermittent 
claudication [3].  
2 
Non-invasive techniques such as ankle-brachial systolic pressure index (ABI), are often 
utilized to test for PAD in patients who have higher risks of suffering from this disease, but don’t 
present IC [3]. Risk factors are based on age, gender, smoking, sex, ethnicity, and diabetes [3-5]. 
Patients who suffer from PAD also have higher risks of suffering a heart attack, stroke, or death 
due to other cardiovascular diseases, independent of whether patients display any PAD symptoms 
[5].   
As lower limb PAD progresses and worsens, it reaches its end stage, known as critical limb 
ischemia (CLI) [6]. CLI patients feel pain while moving and resting [7]. It is estimated that about 
18 million Americans suffer from PAD, and 2 million of these patients also develop critical limb 
ischemia (CLI) [8, 9]. The Sage research and consulting group reported that “in 2007, there were 
approximately 2.8 million people in Western Europe who suffered from CLI”, and they have 
predicted that about 3.4 million people in that region will have this disease by 2020 [10]. In 
addition, the president of the Sage group acknowledged that “because of the global epidemic of 
diabetes and the fact that diabetics represent 60% to 80% of CLI patients, we believe that critical 
limb ischemia represents a major and significantly underestimated worldwide problem” [10]. 
Other studies have also shown that diabetics have double the chance of developing IC while their 
probability of developing PAD is three to four times higher than other patients [3].    
As of now, approximately 20% of patients who suffer from chronic CLI will die after one 
year of their diagnosis; this mortality rate has been found to stay constant in long term studies [3]. 
Patients who are inoperable or whose reconstructions were unsuccessful are often part of 
pharmacotherapy trials. Unfortunately, 40% of these patients will lose a lower limb while 20% 
will die within 6 months [3]. For this reason, multiple therapies and technologies are being 
investigated and utilized to develop solutions/preventions to this disease. 
3 
1.2  Treatments 
The management of a patient with PAD depends on the severity of the disease. If the 
disease is not limiting the patient’s lifestyle (mild to moderate symptoms) then it can be managed 
with exercise and pharmaceutical therapy. On the other hand, if the disease is more severe, an 
arteriograph or arteriogram, is performed to assess the ischemic wound size and determine the 
surgical treatment. Arteriography (or angiography) is a technique that uses a contrast dye to 
facilitate vessel imaging which can be done with x-rays or magnetic resonance imaging [11]. 
 
1.2.1  Pharmaceutical Therapies 
Pharmaceutical therapies use different drugs to reduce cholesterol and lipid accumulation 
in the circulation, thereby reducing the formation of atherosclerotic plaques and maintaining vessel 
patency. Physical therapy may be combined with drug therapy to prevent further vessel damage.  
Vasodilators are drugs that augment the blood flow in peripheral vessels of humans with normal 
health, but they are ineffective at treating CLI [12]. Some vasodilators like tolazoline, reserpine, 
guanethidine, and methyldopa affect the sympathetic nervous system, while papaverine, niacin, 
isoxsuprine, and cyclandelate are categorized as direct-acting drugs. None of these vasodilators 
have been shown to have any benefits when employed in clinical studies of obstructive vascular 
diseases [12]. A 1959 blood flow study found that vasodilators were not useful for CLI treatment; 
instead of increasing blood flow in ischemic regions, they decreased blood flow no matter how 
they were administered to the patient (oral dose or intravenous injection) [13]. 
Other drugs such as naftidrofuryl (serotonin/neurotransmitter antagonist), buflomedil 
(adrenolytic agent/adrenaline inhibitor), and cilostazol (phosphodiesterase inhibitor) have 
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improved patients’ walking distances and lifestyles. Although these agents provide positive 
effects, they are more beneficial for patients with acute limb ischemia. [1] 
 
1.2.2 Surgical Interventions 
Surgery is more likely to be performed in patients with severe PAD – that is, with CLI. 
The type of surgical intervention is determined based on the location and severity of the occlusive 
area. When lesions are small and localized within a specific area, they can be treated with 
endovascular interventions such as percutaneous transluminal angioplasty; however, bypass 
surgery or other re-vascularization surgeries must be done when dealing with more severe critical 
ischemic areas. [1, 14]  
Percutaneous transluminal angioplasty was introduced in 1964 by Dotter and Judkins as a 
replacement for open surgical procedures. This technique employs catheterization and 
arteriography. [15]  In brief, a balloon catheter (tube) is inserted into an artery using angiography 
to track its location through the vessel in real time. The physician moves the balloon close to the 
plaque, prior to inflating it. Once it’s inflated, the balloon will dilate the vessel, dislodge (or 
compress) the plaque, and thereby relieve the blockage. [16] Even though this technique prevents 
amputations and continues to be improved with catheter/balloon modifications, it has not been 
demonstrated to provide better outcomes when compared to open surgery [1, 14]. 
Re-vascularization interventions are performed on 50-90% of CLI patients [3]. Bypass 
surgery is an open surgical technique that create new vessels from existing ones. Surgeons 
surgically create a new blood flow channel to bypass the obstructive area which allows blood flow 
to return. Depending on the severity of the surgery, patients will take 4 weeks to 12 weeks to return 
to their regular work schedule [17].  
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Unfortunately, patients who undergo open surgery have a risk of needing additional 
interventions due to hematomas or ineffective grafts. In addition, if the vein quality is poor (e.g 
vein is too calcified), surgeons may be unable to perform distal anastomosis in the patient and are 
unlikely to determine this problem prior to starting the surgery. Patients with successful surgeries, 
however, are less likely to have a future amputation or death. [14]  
 
1.3  Vascular Development/Vascularization 
The cardiovascular system is the first organ system that is functional during human 
development [18]. This system is responsible for supplying oxygen and nutrients to the tissues 
while removing waste to sustain cells and tissues within the body. The arteries and veins comprise 
the cardiovascular system [19]. The arteries carry oxygenated blood away from the heart. The 
blood is then carried into smaller arteries, arterioles (80 to 100 µm) and eventually to capillaries 
(10 to 15 µm) [20]. The venous system carries the deoxygenated blood from the capillaries back 
to the heart via the large venules and veins. [18] 
Blood vessels have an inner lining (endothelium) made up of endothelial cells (ECs). Mural 
cells cover the endothelium and provide structural support to vessels [18, 19, 21, 22]. They also 
have important roles in vessel functionality, blood vessel maturation, and the angiogenesis process. 
Mural cell density irregularity and improper attachment to the endothelium can lead to vessel 
deformities and multiple vascular diseases. 
Mural cells stabilize and participate in endothelial vessel formation [18]. These mural cells 
are divided into two groups: pericytes and vascular smooth muscle cells. Capillaries and smaller 
vessels are covered by pericytes, whereas larger vessels like arteries and veins are surrounded by 
vascular smooth muscle cells [18, 23]. The larger vessels contain different layers: the tunica intima, 
6 
tunica media, and tunica adventitia. These layers are made with endothelial cells, vascular smooth 
muscle cells, and/or extracellular matrix secreted by the vascular smooth muscle cells. The 
thickness of the vessel walls is dependent on the vessel type. [18, 19, 21, 22] Pericyte recruitment 
and differentiation are driven by many growth factors such as platelet-derived growth factors 
(PDGF) and transforming growth factor-β (TGF-β) [21]. These will be discussed in more detail in 
the angiogenic factor delivery section (section 1.4.1). 
Vascular assembly of endothelial cells usually occurs through one of two complementary 
processes: vasculogenesis and angiogenesis. Vasculogenesis involves the de novo formation of 
vessels from non-existing ones by differentiation and proliferation of EC, while angiogenesis is 
defined as the formation of new interconnected vessels from pre-existing ones by network 
modification [24]. These two processes are key to vascularization and will be discussed in more 
detail in Chapter 2. 
Once vessel formation and remodeling occur, vessels begin to mature. Mural cells provide 
key molecular signals to maintain vessel integrity, allowing blood vessels to withstand different 
blood pressures depending on the vessel type and their location in the body. Endothelial cells 
residing in the arteries withstand higher shear stresses as the blood is carried from the heart into 
the body. More supporting cells are recruited to arterial vessels to provide arterial wall strength 
and distribute the force of the blood flow. [18, 25] 
 
1.4  Regenerative Medicine Strategies for Re-vascularization 
As previously mentioned, lack of oxygen prevents cells residing in tissues from performing 
their regular function and, in the case of CLI, can eventually result in amputation due to tissue 
death/necrosis. For this reason, new therapeutic approaches exploiting principles of tissue 
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engineering are being developed to treat ischemic conditions and prevent tissue death and organ 
failure. Approaches such as angiogenic factor delivery, in vivo pre-vascularization, and in vitro 
pre-vascularization have all shown some potential to re-vascularize ischemic regions.  
 
1.4.1 Angiogenic Factor Delivery 
Growth factors are important in the vascular development process and have been explored 
therapeutically with the goal of re-vascularizing ischemic regions. Vascular endothelial growth 
factor (VEGF) is the most commonly used growth factor in studies examining angiogenic factor 
delivery. VEGF increases vessel formation, ensures viability of immature blood vessels, facilitates 
recruitment of pericytes, accelerates pericyte coverage of vessels, recruits endothelial cells, and 
promotes their proliferation. [24, 26] However, vessel regression occurs less than a month after 
VEGF delivery, and high VEGF concentrations have been found to provide abnormal vessel 
formation [27]. In addition, VEGF dosage and delivery time/ frequency must be very controlled 
for proper vessel formation to occur [28, 29]. 
Transforming growth factor-β (TGF-β) aids vascular development by inducing pericyte 
adhesion and differentiation [30]. It also inhibits the proliferation of both mural and endothelial 
cells and increases the secretion of elastin from many cells such as smooth muscle cells and 
fibroblasts [18, 30-32]. The platelet-derived growth factor subunit B (PDGF-B) is secreted by 
endothelial cells to recruit mural cells and induce their proliferation for vessel maturation [18, 25, 
33].  
Basic fibroblasts growth factor (bFGF) is a mitogenic cationic polypeptide known for 
stimulating endothelial cells, vascular smooth muscle cells, and other cells [34, 35]. bFGF is found 
in adrenal glands, bovine and human brains, retinas, kidney, and other tissues [35]. This mitogen 
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produces plasminogen (plasmin pre-cursor) activators, and is responsible for inducing EC 
invasion, migration, proliferation, and sprout formation [36]. A study showed that bFGF is a self-
stimulating growth factor since ECs not only express it, but also produce it and secrete it to induce 
their own proliferation [37].  
Expression of bFGF in serum has been to be higher in cancer patients than normal patients 
[38]. In addition, patients responding to cancer treatment tend to have lower levels of hepatocyte 
growth factor [38]. Hepatocyte growth factor (HGF) has a role in vessel formation and EC 
invasion, which has been linked to tight junction disruption [38]. It also stimulates EC growth and 
wound healing repair [39]. 
Many growth factors and their combinations have been explored for angiogenic delivery 
with the goal of creating vessels within an ischemic region and facilitating vessel maturation. 
Although these aforementioned growth factors as well as others are important in vascular 
development and have the potential to improve blood perfusion [20], appropriate dosages must be 
employed to form mature and organized vessels to improve blood perfusion without causing 
negative side effects such as vessel leakage. In addition, controlling growth factor release 
temporally is very complex since growth factors must be delivered in a specific order to mimic the 
natural vessel development process [20, 40, 41]. Due to the complexity of vascular development 
as well as the limitations of growth factor delivery, human clinical trials for ischemic conditions 
have had limited success with this technique [24, 41-43].  
 
1.4.2 Pre-vascularization 
Tissue engineering, also known as regenerative medicine, focuses on developing 
techniques that can prevent diseases and/or replace organs/tissues damaged due to illnesses. This 
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field includes many areas, such as cells and materials [44]. Cells have been reprogrammed to 
differentiate into different lineages depending on the tissue being investigated. Scaffolds can be 
modified chemically, mechanically, and/or biologically with the introduction of multiple materials 
including proteins and growth factors. [44] Additional tissue engineering background is discussed 
in Chapter 2. 
One major hurdle in vascularization techniques is cell survival after in vivo implantation, 
since it takes multiple days for new vasculature to reach the cells within the implant and deliver 
the necessary oxygen and nutrients for their viability [22, 45]. For this reason, pre-vascularization 
techniques focus on developing scaffolds containing vasculature to improve cell viability and 
reduce re-vascularization time within an ischemic region.  
 
In Vitro Pre-vascularization 
The scaffold matrix developed for vascular tissue engineering must be biocompatible to 
minimize an inflammatory response in the host which can ultimately lead to additional problems 
rather than provide solutions. It must also permit the infiltration of cells (endothelial sprout 
infiltration), and support cell adhesion and proliferation to allow vessel formation to occur 
(biomimetic characteristics). [20, 46-48]  
Different endothelial cells including human umbilical vein endothelial cells (HUVECs), 
endothelial progenitor cells (EPCs), and microvascular endothelial cells (MVECs) are co-cultured 
with mural cells such as normal human lung fibroblasts (NHLFs) and mesenchymal stem cells 
(MSCs) in three-dimensional (3D) matrices to develop vascularized tissues prior to implantation 
[49-52]. A common material employed to develop in vitro vascularized tissues is fibrin. Fibrin is 
the primary constituent of the provisional matrix that forms during wound healing. This protein is 
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often used in vascularization studies because of its ability to stimulate the ingrowth of new vessels. 
[51, 53-55]  
Pre-vascularized in vitro tissues can accelerate both inosculation between the host and the 
implant vasculature [52, 56] and also vessel maturation in the implant [57]. This pre-
vascularization not only provides better vascularization in situ, but it also improves viability of 
cells residing in the in vitro implants [58]. Although there are multiple benefits for employing this 
in vitro pre-vascularization technique, blood perfusion in the implant does not necessarily occur 
instantaneously since the implant is typically not connected to the host vasculature micro surgically 
during implantation [59].  
 
In Vivo Pre-vascularization 
In this technique, acellular porous scaffolds are designed to allow host vessel infiltration 
and formation to occur within their matrices. To do so, these scaffolds are injected or implanted in 
vivo. Once the scaffold is perfused in situ, it can be transplanted in another region reducing blood 
perfusion time in the new implanted area [60]. This approach to develop new tissues has been 
studied for bone formation applications [61].  
Arteriovenous (AV) loops can also be used for in vivo pre-vascularization, tissue 
replacement, transfer, and/or reconstruction [46, 62]. AV loops are made surgically by connecting 
a vein and artery using a graft [62]. This loop is then placed within a circular groove of a designed 
acellular scaffold to promote vascularization. The AV loop and scaffold can then be placed in a 
chamber, and then removed at different time points to access vascularization within implant. [63]  
One of the most common in vivo pre-vascularization tissues are bone flaps. They are made 
by implanting bone segments near blood vessels such as epigastric vascular bundle [64] and 
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saphenous vessel bundle [65]. The vessels vascularize the implant region, are then removed by the 
surgeon and placed in the ischemic region [59, 66]. Tanaka et al. investigated the differences 
between arteriovenous shunt loop and arteriovenous bundles and determined that even though the 
AV loops had more potential in vascularizing an implant, the arteriovenous bundle could also 
vascularize the implant and was a simpler vascular carrier for skin flaps [67]. 
In vivo pre-vascularization of scaffolds has shown potential for ischemic re-
vascularization. However, fats, donor cells, pathogens, and other toxic agents must be removed if 
scaffolds are transplanted from a donor to a patient suffering from ischemia (allograft) to prevent 
a negative inflammatory response. In addition, hematomas and infections can occur after the 
scaffolds are implanted in situ. Although these negative effects don’t cause deaths, hematomas 
yield a lower blood vessel density when compared to scaffolds with successful vascular carriers 
(i.e. AV loops) interventions. [63] Once the vascularized in vivo implant is excised, the implant 
must then be placed in the ischemic region and connected to the host vasculature with 
microsurgery, providing immediate vascularization in the ischemic region [59].  
Unfortunately, complex surgical procedures limit the feasibility of pre-vascularization 
techniques as therapeutic solutions. Therefore, we propose a technique that has the potential to 
vascularize tissue by combining positive aspects of these existing techniques while overcoming 
some of their major surgical limitations.  
 
1.5  Hypothesis 
The long-term goal of this project is to develop a new therapy that will restore blood flow 
to damaged tissue by creating pre-vascularized tissue modules containing human endothelial cells 
(ECs) and supporting stromal cells that act like pericytes, to jump-start inosculation with the host 
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vasculature after being injected in a minimally invasive manner. This dissertation aims both to 
develop pre-vascularized microbeads containing human umbilical vein endothelial cells 
(HUVECs) co-cultured with normal human lung fibroblasts (NHLFs), and also to demonstrate the 
microbeads’ ability to improve blood perfusion in a subcutaneous animal model. Previous in vivo 
studies have shown that pre-vascularized macro tissues have the potential to vascularize ischemic 
regions faster than the delivery of cells with or without an additional matrix (macro tissues) [68-
70]. We hypothesize that pre-vascularized microbeads, delivered in a minimally invasive 
manner, will form microvasculature in vivo at a faster rate than fresh EC- fibroblast co-cultures 
embedded in microbeads (control microbeads) and pure fibrin matrices (cellular hydrogels).  
 
1.6  Specific Aims  
The following aims outline how the overall project will be accomplished:  
Aim 1: Develop microbeads that can be delivered in a minimally invasive manner and 
are capable of supporting endothelial sprout formation within a model matrix. Prior to 
starting any pre-vascularization studies, it is necessary to first design efficient way(s) to create 
control (fresh ECs-NHLFs) microbeads. Quantification of sprout formation within and from 
control microbeads will be done to analyze the effects of microbead size, cell density, and 
microtissue matrix.  
Aim 2: Investigate the effects of microbead pre-culture on the formation of vessel 
network in vitro and in a subcutaneous model in vivo. Design and apply an in vitro platform to 
compare the degree of vessel formation (vascularization) between control and pre-vascularized 
microbeads. This aim will also assess the capability of the proposed vasculogenic therapy in an in 
vivo environment. Laser Doppler Perfusion Imaging (LDPI) will be employed to quantify blood 
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perfusion occurring from the implanted constructs. The microbead pre-culture time that will be 
used in subcutaneous studies will be determined by embedding pre-cultured microbeads in fibrin 
hydrogels for one week. Fluorescent images of the hydrogels will then be taken to quantify the 
endothelial tube area coverage within the fibrin hydrogel. HUVECs will be stained with Ulex 
Europaeus Agglutinin I (UEA I) prior to measuring tube area coverage.  
Aim 3: Investigate alternative microbead formulations that enhance endothelial 
vessel distribution. This aim will explore a combination of materials to improve microbead 
injectability and handling by augmenting microbead sphericity, providing a higher microbead 
production yield by limiting their adhesion and aggregation, and supplying a more homogenous 
network distribution in an “ischemic-like region”. 
By evaluating the capability of the pre-vascularized microbeads to inosculate with host 
vasculature, these aims will allow us to investigate the re-vascularization potential of the proposed 
minimally-invasive technique. The proposed technique may not only stimulate inosculation post-
implantation, but it may also minimize negative post-surgical side-effects that may arise from open 
surgery vascularization techniques. 
 
1.7  Preliminary Studies 
Previous in vitro [49, 51] and in vivo [53, 71] studies published by the Putnam lab have 
demonstrated that network formation occurs when co-culture of HUVECs and stromal cells (e.g. 
mesenchymal stem cells, fibroblasts, etc.) are embedded in natural materials, such as fibrin.         
Although fibrin promotes vasculogenesis, it is mechanically weak and had not been employed 
alone in the microbead development process established in the Stegemann lab [55]. Therefore, 
type-I collagen, the most abundant extracellular protein in the body, was incorporated in the 
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microbead recipe to enhance the microbead mechanical properties and determine if its addition 
was beneficial for vascular microbead development (see chapter 3). The collagen-fibrin microbead 
processing protocol was adjusted based on previous work done by the Stegemann lab on collagen-
fibrin matrices [72], collagen-agarose microbeads [73], and chitosan-fibrin microbead processing 
[55]. 
 
1.8  Translational Potential 
The long-term goal of this line of regenerative medicine research is to develop a new 
therapy that will restore blood flow to damaged tissue by creating pre-vascularized tissue modules 
to jump-start inosculation with the host vasculature after being injected in a minimally invasive 
manner. Therefore, we recognize that the simpler the final therapy is, the higher the probability 
that it will be approved by the US Food and Drug Administration (FDA). Products composed of 
acellular biomaterials are more commercially successful in regenerative medicine than products 
composed of biomaterials and cells [74, 75]. 
While scaffolds’ regulatory path to the clinic is comparatively straightforward, 
development of cell-based treatments requires consideration of cell culture effectiveness, the most 
relevant animal model, and the future clinical trials. These clinical trials depend on the FDA 
categorization of the final product (e.g. drug, medical device) [74]. Complexity increases as cells 
are introduced to the biomaterial. For this reason, there are no FDA-approved cell-based 
regenerative biomaterials currently employed clinically in the cardiovascular area. [74, 75] 
Prestwich et al. [75] stated that biotech companies prefer developing cell products in 
approved materials even if a new cell-biomaterial approach is more likely to be clinically effective. 
We employed FDA-approved biomaterials along with HUVECs and NHLFs in our study.  
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Acellular microbeads in a fibrin precursor were also used to demonstrate that cells are needed for 
the final therapeutic approach. 
 
1.9  Scope of Thesis 
Chapter 1 motivates the dissertation, describes the background of previous work, current 
treatments employed to address CLI, the overall hypothesis of this work, and the aims addressing 
the hypothesis. Chapter 2 defines the vascularization processes: vasculogenesis, angiogenesis, 
arteriogenesis, and inosculation; and it introduces the tissue engineering field and its strategies to 
study vasculogenesis, angiogenesis, and re-vascularization. Chapter 3 was published in 2016 in 
Acta Biomaterialia following peer review, and it addresses aim 1 by first developing control 
microbeads (fresh HUVECs-NHLFs) that support endothelial sprouting. Endothelial cells and 
fibroblasts were encapsulated in two different microbead materials – pure fibrin and 40-60 wt.% 
collagen-fibrin – to determine matrix effects on endothelial sprouting and network formation. 
HUVEC-NHLF microbeads were characterized in vitro in terms of cell density, cell viability, and 
cell proliferation to find any differences between these two matrices.  
Chapter 4 (aim 2) presents pure fibrin microbead pre-culture in vitro studies and mouse 
subcutaneous studies. This chapter addresses aim 2 by evaluating endothelial vessel formation and 
inosculation to host vasculature from four different constructs: (1) control (fresh ECs-NHLFs) 
microbeads, (2) pre-cultured microbeads, (3) cells, and (4) acellular microbeads. These implants 
were injected with fibrin subcutaneously in the backs of mice. The goal of this study was to 
determine if there was value in pre-culturing microtissues prior to injecting them in the 
subcutaneous mouse model. Vessel density, vessel area, and total number of vessels were also 
quantified in this chapter. Chapter 5 addresses aim 3 by demonstrating how the microbead matrix 
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and pre-culture not only affects endothelial vessel distribution, but also affects microbead 
production yield, viability of encapsulated cells, and distribution homogeneity. This chapter was 
accepted for publication this year in the Acta Biomaterialia journal. The overall summary, future 
work, and preliminary studies for future work can be found in Chapter 6. The appendices contain 
the experimental protocols that will facilitate future reproducibility of the main experimental work.  
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Vascularization Strategies in Tissue Engineering 
 
 
 Chapter 2 will describe the vascular processes: vasculogenesis, angiogenesis, 
arteriogenesis, and inosculation. The three main components used in tissue engineering 
applications are cells, materials, and growth factors; and these components as applied in vascular 
tissue engineering will also be described. This chapter also lists different in vitro and in vivo 




Vasculogenesis is the process of de novo formation of blood vessels. This process 
encompasses endothelial cell (EC) differentiation, proliferation, migration, and organization into 
a primary capillary plexus [1-4]. During early development, progenitor cells residing in the middle 
layer of the embryo known as the mesoderm begin to differentiate into endothelial and hemopoietic 
(blood) cells by the initiation of fibroblast-derived growth factors [2, 5, 6]. Endothelial and 
hemopoietic progenitor cells begin their differentiation close to each other in areas known as blood 
islands. These islands have hemopoietic progenitor cells in their core with angioblasts (endothelial 
progenitor cells) located on the periphery [3].  
23 
The two progenitor cells can differentiate on their own or in association with each other, 
depending on the anatomical region of vascular development [3]. Vesicle formation occurs from 
these islands and vascular channel formation occurs as vesicles merge, while angioblasts 
differentiate into endothelial cells [7]. Angioblasts won’t stain with certain endothelial cell markers 
until complete endothelial cell differentiation has occurred and they are able to form lumens [3]. 
Some of these endothelial cell markers include vascular endothelial growth factor receptors and 
vascular endothelial cadherin [2]. 
In addition to vessel formation, extracellular matrix (ECM) is deposited in the endothelial 
vessel outer walls, and the lumen forms, leading to formation of basement membrane and blood 
flow (vessel maturation) [3]. Although EC proliferation is very common during embryogenesis, 
EC proliferation rate decreases significantly during adulthood [3, 8]. Since EC comprise the inner 
layer of the vessels and they are involved in multiple vascular processes in the body, they are often 
studied in the tissue engineering field and will be discussed in more detail throughout this chapter.  
 
2.2 Angiogenesis 
Angiogenesis is a multifaceted biological process where new vessels form from existing 
ones [9]. There are two types of angiogenesis: sprouting angiogenesis and intussusceptive (also 
known as non-sprouting or splitting) angiogenesis [6]. Sprouting angiogenesis is the most common 
type of angiogenesis and occurs when new sprouts are formed from existing parent vessels. The 
key publications that introduced this process were Hertig in 1935 and Folkman in 1971 [10]. 
Sprouting angiogenesis is triggered by a local angiogenic stimulus that activates neighboring 
endothelial cells that make up the inner vessels [11]. This EC activation leads to a cascade of 
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events including vessel dilation, higher vessel permeability, and basement membrane degradation 
of the parent vessel [12].  
Many factors can trigger angiogenesis including the reduction or complete lack of oxygen 
within a region in the body, an inflammatory response, changes in the extracellular matrix, growth 
factors, and/or mechanical or intercellular stimuli [13]. As the endothelial cells are triggered, they 
begin to migrate, proliferate and/or differentiate in order to form new vessels and return the tissue 
to homeostasis. [14]   
Cells in the body use different pathways to communicate with each other for proper 
tissue/body functionality. Notch signaling is involved in various processes, including 
angiogenesis, that depend on the activation of a notch cell receptor with a ligand. There are four 
Notch receptors (Notch 1-4) and two types of notch ligands, the Delta and Serrate families, that 
are classified based on their structures. Delta-like-4 (DLL4) is part of the Delta family and has 
been shown to play an important role in vascular development. [15] 
Vascular endothelial growth factor A (VEGF-A) binds to the EC VEGF receptor 2 
(VEGFR2). The endothelial cell which is most activated by VEGF-A, known as the tip cell, forms 
filopodia or cytoplasmic projections that extend toward the angiogenic stimulus that releases 
VEGF-A [16]. The formation of the tip cell(s) caused by VEGF-A release leads to the DLL4-
Notch 1 signaling; the EC neighboring the tip cell will have their Notch 1 receptor activated by 
DLL4. This Notch activation suppresses the VEGF response in cells next to a tip cell, preventing 
the formation of multiple tip cells from a single parent vessel [17, 18]. 
As the non-proliferating leading tip cell migrates, the proliferating endothelial cells follow 
and fill up the gap between the tip cell and their two original neighboring cells that still reside in 
the parent vessel. These proliferative cells identified as stalk cells are in charge of elongating the 
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newly formed sprout. The VEGF-A spatial distribution alters the tip cell migration while VEGF-
A concentration modifies the proliferation of the stalk cells. [16] Since stalk cells are not part of 
the original parent vessel, no lumen exists in the sprout elongation area. [12, 16]  
Studies have shown that EC proliferation and migration occur near the tip cell and that EC 
migration from the parent vessel decreases EC-EC interaction. This disruption in the cell-cell 
contact causes an increase in vessel permeability [13, 19]. Although both migration and 
proliferation occur during this process, EC proliferation is not necessary for EC sprouting to occur, 
but it is necessary for further vessel growth [20]. 
Lumen formation occurs in the formed sprouts (tubulogenesis), and once two tip cells find 
each other and connect (inosculation), a new capillary/vessel is formed [12]. During the 
angiogenesis process, the basement membrane of the parent vessels are degraded with proteolytic 
enzymes in the regions where the tip cells and stalk cells formed the new sprouts. Therefore, after 
the new capillary/vessel is formed, a new basement membrane is synthesized and pericytes and 
vascular smooth muscle cells are recruited to stabilize the vessel. [21] 
Intussusceptive angiogenesis also known as non-sprouting or splitting angiogenesis is a 
relatively newly discovered process that describes how a pre-existing vessel splits into two. The 
pre-existing vessel increases its size due to continuous insertion of small trans-capillary tissue 
pillars (capillary wall) into its lumen, changing their morphology and forming a new capillary 
network inside of the original vessel [22, 23]. 
 
2.3 Arteriogenesis 
Arteriogenesis is the third of the three processes responsible for vascularization in the body. 
This process was named by a group of scientists in 1996, and describes the process of an arteriole 
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maturing into an artery [24]. As a major vessel becomes obstructed,  proliferation and remodeling 
of pre-existing collateral arterial vessels occur in order to increase their lumen size and provide 
better blood perfusion to ischemic tissues. [10, 13] 
A pressure gradient created by blood obstruction in a region in the body causes blood 
velocity to increase and higher blood shear stress inside the vessels. As this occurs, the 
endothelium becomes activated and a cascade of events causes cells such as endothelial and 
vascular smooth muscle cells to take part of vascular remodeling in this arteriogenesis process. 
[10] 
While angiogenesis is initiated by transcription factors known as hypoxia inducible factors 
(HIF) that are activated in regions with not enough oxygen supply (hypoxic regions) [25], 
arteriogenesis is triggered by inflammation and shear stress. Unlike angiogenesis, arteriogenesis 
can occur in areas where oxygen levels are normal and this process can last from days to weeks 
[10]. After the angiogenesis process occurs, blood flow can increase by a factor of 1.5 to 1.7; while 
in arteriogenesis the increase in blood can be as high as 10 to 20 times more [24]. The 
arteriogenesis process also relies on multiple growth factors in addition to VEGF and other cells 
that are triggered during the inflammatory process [24].     
 
2.4  Inosculation 
Inosculation is the process that describes the connection between vessels. Plastic surgeons 
use this process to connect the host vasculature with blood vessels located within the implanted 
graft for instantaneous blood flow to occur [26]. Skin grafts [26, 27] and nerve grafts [28, 29] have 
been implanted successfully using the inosculation process. Pre-vascularization techniques, 
described in Chapter 1, depend on the inosculation between the pre-vascularized tissues and the 
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host vasculature. Anastomoses between vessels formed in vitro (pre-vascularized tissue) and the 
animal vasculature were first shown in 2005 by Tremblay et al [30].  
There are two types of inosculation processes that can occur once the scaffold is implanted: 
internal and external inosculation [26, 31]. Internal inosculation occurs when host and pre-formed 
vessels residing in the implant connect within the implant. This type of inosculation occurs when 
vascular regression/shrinkage takes place within the implant causing the host vessels to first 
infiltrate into the implant prior to inosculating with the implant vessels [32]. On the other hand, 
external inosculation occurs when pre-formed vessels that originated from the graft come out of 
the graft and inosculate with the host vasculature outside of the graft, then this is referred as 
external inosculation [33]. In addition to connecting to the host vasculature outside the graft, the 
pre-formed vessels are able form new vessels within the pre-vascularized implant region [33].  
As vascular grafts are implanted, an inflammatory and angiogenic response can occur 
within the implant region [34]. Damaged tissue can initiate the wound healing cascade causing the 
release of pro-angiogenic growth factors [35]. Unlike angiogenesis which takes weeks to occur, 
anastomoses can happen as early as four to five days [26, 36].  
In addition to surgical anastomoses, natural anastomoses also occur during the 
angiogenesis process, described in section 2.2. Phng et al.  [37] suggest that both Notch and Wnt 
signaling control the stabilization of vessel anastomoses and vessel pruning during the 
angiogenesis process. Studies suggest that exploring the link between the two signaling pathways 
can lead to controlling the number of vessels (vessel density) within constructs prior to 
implantation. [31, 37]   
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2.5  Vascularization Techniques in Tissue Engineering 
Regenerative medicine – also known as tissue engineering – was proposed as a solution in 
the middle of the 1980s, due to the limited number of organs available for donation [38]. This 
multidisciplinary field encompasses many disciplines including biology, materials science, 
medicine, and engineering and focuses on developing different tissues that can be used in research, 
tissue/organ repair, or replacement [39, 40].    
Cellular and acellular tissue engineering are two of the main strategies being explored in 
this field. Cellular strategies rely on implanting different cells in engineered scaffolds prior to in 
vivo implantation [39]. In the case of re-vascularization, the scaffolds are designed to permit sprout 
infiltration into the scaffolds and to allow anastomoses between the host and endothelial sprouts 
residing in the implant. These scaffolds are then expected to degrade with time without causing 
negative effects in the host. Acellular tissue engineering focuses on developing materials and 
embedding signaling molecules such as growth factors that can recruit and/or stimulate the host 
cells within the implant area [39]. Cell removal from tissues is also a method being explored in 
order to use the structure of the tissue without worrying about immunological response from 
foreign cells within the host [39].   
To test hypotheses related to vascular tissue engineering, researchers employ various cells 
(ECs, pericytes, etc.), materials, and growth factors in an array of in vivo and in vitro models. This 
section will describe the main cells and materials used for vascularization, and the main in vitro 




Stem cells are often used in tissue engineering since they have the ability of differentiating 
into different lineages. Their differentiation capability is dependent on their classification. 
Embryonic stem cells (ES) can differentiate into all the three germ layers – endoderm, mesoderm, 
and ectoderm – that are formed during embryonic development [41]. The endoderm forms the 
epithelial layer of multiple organs including the pancreas, pharynx, and liver; the mesoderm makes 
the skeleton, muscle, and other systems including the circulatory system; and the ectoderm makes 
the nervous system [42]. Adult stem cells are more specialized and constrained in their ability to 
differentiate based on their origin [43].  
Endothelial Cells 
Endothelial cells are the first cells to form and the dominant cell in the vascular system 
[44]. EC fibers are affected by blood flow properties including velocity, pressure, turbulence, and 
viscosity [45, 46]. There are many different endothelial cells employed to engineer vascular 
tissues. Endothelial progenitor cells, human umbilical vein endothelial cells, and microvascular 
endothelial cells, all described below, are the EC types used in this dissertation. Although all of 
the aforementioned cells are endothelial cells, they each come from different locations in the body, 
and their shape, function, and other properties are also different [47, 48].  
Endothelial progenitor cells (EPCs) are a type of adult stem cell that can form vessels [49]. 
EPCs circulate in the blood and adhere to the vessel walls when the endothelium lining is deprived 
or has limited amount of oxygen [50]. EPCs derived from bone marrow behave differently than 
the ones circulating in the blood. In general, EPC identification, function, and source(s) are still 
being investigated [51].  
30 
In the body, ECs that make up microvessels such as microvascular endothelial cells 
(MVECs) are more elongated and flatter than ECs comprising large vessels, like HUVECs, which 
have a cobblestone shape [48]. ECs from microvessels also proliferate slower than ECs from 
bigger vessels [48]. HUVECs were more often employed than MVECs in the past because they 
were easier to harvest and proliferate [47].  
Two-dimensional characterization of human umbilical vein endothelial cell (HUVECs) 
was first done in 1963 [52] followed by additional characterization and long term studies [53]. 
Long term capillary endothelial 2D culture originated in 1979 [54]. It has been demonstrated that 
sprouting venous endothelial cells are able to differentiate into arteries and capillaries during 
development [55]. Therefore, HUVECs are still often employed in vasculogenesis and 
angiogenesis studies. This field continues to explore all these EC types to determine which one 
creates a better vascular tissue for tissue/organ regeneration.  
Mural Cells 
Mural cells help form and stabilize blood vessels by secretion of basal membrane 
components [13]. In vascularization strategies, mural cells such as mesenchymal stem cells 
(MSCs), fibroblasts, and vascular smooth muscle cells (vSMCs) are co-cultured with endothelial 
cells in both in vivo and in vitro systems [56-59]. Mural cells are divided into pericytes and vascular 
smooth muscle cells based on their location. Pericytes surround capillaries, while bigger vessels 
such as arteries and veins are surrounded by one or more layers of basement membrane/tissue, 
depending on the vessel, and a layer of vascular smooth muscle cells. [60] 
Mesenchymal stem cells (MSCs) are formed in the connective tissue developed in the 
middle layer of the embryo [38]. They are one of the most researched adult stem cells in areas such 
as liver and cardiovascular diseases [41]. MSC isolation can be done from placenta, umbilical 
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cords, blood, and fatty tissues [41]. However, the source of MSC isolation will alter the behavior 
of MSCs. A study found that MSCs derived from bone marrow supports vessel formation in a 3D 
in vitro system; however MSCs isolated from umbilical cord arteries and veins did not function in 
the same manner [57].  
Like MSCs, fibroblasts are also used as pericytes in both in vitro and in vivo systems. They 
secrete extracellular matrix components like collagen I, angiogenic growth factors like fibroblast 
growth factor (FGF), and matrix metalloproteinases which play a role in vascularization [61]. 
Dermal fibroblasts and normal human lung fibroblasts are two types of fibroblast that promote 
vessel formation in vitro and in vivo [62, 63]. Our groups employ normal human lung fibroblasts 
(NHLFs) and MSCs for vasculogenesis and angiogenesis assays. However, previous work has also 
utilized vascular smooth muscle cells. 
Vascular smooth muscle cells (vSMCs) support the larger vessels, and due to their 
contractile properties, they can regulate the blood flow through those vessels [60]. vSMCs 
proliferate and produce extracellular matrix components that are part of the vessel wall [64]. A 
study showed that the incorporation of smooth muscle cells within an implant scaffold resulted in 
similar physiological functionality and mechanical properties found in normal vessels [38]. 
Endothelial cells and different stimuli like vessel injury affect the phenotype and behavior of 
vSMCs [64].  
In addition to endothelial cells and stromal cells, bone marrow-derived mononuclear cells 
(BMMNCs), embryonic stem cells (ES), and induced pluripotent stem cells (iPS) are other cells 
being studied for tissue regeneration [38]. Current cell therapies being explored include the 
injection of BMMNCs and other mononuclear cells into ischemic areas with the goal of re-
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vascularizing those regions  [9, 14]. These BMMNCs can differentiate into multiple lineages and 
have many cytokines that aid in vascular development [38].  
 
2.5.2 Biomaterials 
Biomaterials are employed in tissue engineering with the ultimate goal of repairing a 
tissue/organ in the body. Prior to developing a scaffold or material, it is important to first determine 
the target tissue. Choice of material depends on which properties can provide more benefits for 
that specific tissue or disease. Polymers are most often used as biomaterials due to their structural 
similarities to various tissues and their adjustable mechanical properties [40]. However, ceramics, 
composites, and metals are also used as biomaterials [39].   
The US Food and Drug Administration (FDA) categorizes any material that will be 
implanted in the body as a class II medical device [65]. However, due to their complexity some 
biomaterials are no longer considered class II medical devices by the FDA and must be tested 
separately to determine their FDA classification [65]. Biocompatibility and biodegradability are 
also important when designing biomaterials [66, 67]. Tissue replacements must be designed to 
prevent any extreme reactions in the body after implantation. The criteria for biocompatibility 
varies depending on the targeted tissue application [39]. As the implant inside the body degrades 
with time, it begins leaching extra components that must also be biocompatible or else additional 
complications can occur [66].   
Natural Materials 
Biomaterials can be synthetic, natural, or a combination of both and can be made into 
scaffolds for tissue and/or organ replacement [39, 65]. Two main natural materials that are often 
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used in vasculogenesis and angiogenesis assays are fibrin and collagen [68]. Although there are 
other natural materials including alginate [69] employed to promote vascularization, fibrin and 
collagen are highlighted in this section since they are the ones mainly used in this dissertation. 
Fibrin plays an important role in the blood clotting cascade which occurs during the wound 
healing process [70-73]. The polymerization of fibrin is dependent on multiple steps and factors 
that affect the physical and structural properties [58, 59, 71, 74] of the resulting fibrin 
hydrogel/scaffold [70]. For this reason, this viscoelastic material [75] is often utilized in tissue 
engineering to study vasculogenesis, angigonesis, and inosculation processes both in vitro and in 
vivo. However, proper understanding of in vivo fibrin polymerization is necessary to engineer these 
fibrin scaffolds. 
The polymerization of fibrin occurs in several steps including the formation of fibrin 
monomers, fibrin oligomers, protofibrils, fibrin fibers, and the final fibrin network [70]. The fibrin 
precursor, fibrinogen, has six chains made up of two identical polypeptide sets (Aα Bβ γ)2 that are 
connected by 24 disulfide bonds (R-S-S-R) and result in a 45 nm length [70]. This protein (340 
kDa) circulates in the blood at 3 mg/mL concentration [71, 76] and is converted into fibrin (α β γ)2  
via thrombin [77]. In brief, the formation of  fibrin monomers (α β γ)2 occurs when the 
fibrinopeptides A and B (FpA, and FpB) located in the N-termini of the Aα and Bβ chains of 
fibrinogen are cleaved by thrombin [70]. The fibrinogen conformation alters the access of 
thrombin to FpA and FpB, affecting their thrombin cleavage rate [70]. Oligomer and protofibril 
production occurs with the polymerization of the fibrin monomers [70, 78]. As protofibrils grow 
to a specific length, they begin the packing process and side-by-side association to form fibrin 
fibers [79]. Finally, fiber branching creates a fibrin network, allowing fibrin to form either as a 
clot (in vivo) or a hydrogel (in vitro) [70, 78, 79].  
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Factor XIII (FXIII, A2B2) is an oligomer that has four subunits – half are A-subunits and 
the other half are B-subunits [80]. Thrombin also plays an additional role in the fibrin 
polymerization process by activating Factor XIII. Once activated, Factor XIIIa is in charge of 
covalently crosslinking fibrin to stabilize and strengthen it [70, 77]. It can also reduce fiber 
thickness and increase fiber density during fibrin formation to strengthen them and make them 
more resistant to fibrinolysis [80]. 
This complex fibrin mechanism can be affected by genetic variations of the 
fibrinogen/fibrin structure, the components and their concentrations used in the polymerization 
process, and the exposure to different cell type(s) and blood flow rates [70]. For example, if only 
one fibrinopeptide is cleaved instead of both during the polymerization process, then thinner fibers 
are formed in the fibrin clot [70]. Myocardial infarction and ischemic stroke are some of the many 
diseases that can cause or be caused by improper fibrin polymerization [70].  
Collagen is the main constituent of connective tissues’ ECM [81]. There are more than 20 
types of collagen that are present in the body. Collagen IV is present in the basement membrane 
around the vessels. [81] The most abundant protein in the body, collagen I, is most often used in 
vascularization strategies due to its strength and other structural properties [82, 83]. Type I 
collagen has a triple helix structure with an approximately 1 to 5 nm width and 300 nm length, 
with over 1000 amino acids [82]. Both ECs and pericytes can produce and secrete collagen in 2D 
assays [84, 85].  
Synthetic Materials 
Synthetic materials are designed to have specific strength, degradation rates, and many 
other properties that can be independently modulated without affecting other properties, unlike in 
the case of natural materials [69]. Polyglycolic acid (PGA) is a synthetic material often used due 
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to its hydrolysis degradation which can be tuned by combining it with other materials [86]. 
Polyethylene glycol (PEG) is another synthetic material that is often used in vascular studies 
because it is biocompatible and it does not interact with the body unless it’s first functionalized 
with peptides or other molecules/materials [69]. PEG has also been shown to reduce 
immunological reactions, and its mechanical and degradation properties can be chemically altered 
[69].  
 
2.5.3 In Vivo Models 
Many in vivo models have been created to study angiogenesis and drug development [87]. 
Some of these models are more popular than others because they are more cost-effective and 
facilitate screening of multiple drugs at a time. These models can be qualitative and/or quantitative 
and often introduce a tumor or a scaffold/implant into animal(s). These procedures create 
wound/inflammatory response that promote new sprout formation within the affected regions. [87]  
In 1974, both tumor growth and angiogenesis were investigated by implanting tumors into 
rabbits’ corneas due to their avascular and transparent properties [88, 89]. This in vivo assay is still 
being utilized nowadays to study angiogenesis mechanisms and drug delivery formulations [89]. 
Transparent chambers have also been implanted in vivo to investigate and monitor angiogenesis. 
The first chamber was introduced in 1924 in the rabbit’s ear [90]. Some other implantation areas 
of these chambers include hamster cheek [91], rodent cranial windows, and dorsal skinfold in mice 
[92], hamsters, rabbits, and rats [93]. There are many additional in vivo angiogenesis models 
including the chick chorioallantoic membrane (CAM) [93, 94], the sponge implant model [95], 
muscle angiogenesis assay [96], and the zebrafish model [97, 98].  
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The CAM assay is one of the most popular angiogenesis assays due to its very low cost 
[93, 94]. This assay was mainly used to screen different materials to determine if they could inhibit 
or induce angiogenesis; however, it was later adapted for quantitative measurements [99]. There 
are various protocols for this assay including the creation of a small window in the shell of the 
chicken egg, or the entire shell removal during incubation [93]. For the quantitative assay, the eggs 
are first incubated for multiple days, followed by the removal of the entire shell and placement of 
the egg into a Petri dish. A scaffold is then created by loading growth factor(s) into hydrogels that 
are placed between two meshes and later on top of chick embryos [99]. Vessel quantification is 
done by determining the number of vessels formed within the top mesh of the hydrogel [99].  
Another method to measure vessel formation is the sponge implant model. This model 
requires the implantation of a sponge into animals such as dogs [100], rabbits [101], and rats [102] 
to allow vessel ingrowth into the sponge. Sponges are made of different materials such as cellulose 
acetate, polyether, polyester, polyurethane, or polyvinyl [95]. After vessel ingrowth occurs, the 
sponge is removed, and many parameters including blood vessels, cytokines, chemokines, 
hemoglobin, collagen deposition found within the sponge are quantified [95].  
The muscle angiogenesis model consists of implanting either an electrode or an electrical 
stimulator subcutaneously [96]. A set voltage and stimulation time is chosen to contract muscles 
once the electrode is implanted. This stimulation increases angiogenesis (vessel density) and 
remains constant even after stimulation is suspended. [103]  
One of the newest angiogenesis models, uses zebrafish since it develops many transparent 
embryos at a time, facilitating visualization at different stages of embryonic development. Even 
though these animals are not mammals, the zebrafish assays provide results that can be used in 
humans. This fish is not only used for cardiovascular drug studies, but also to model other diseases 
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including cancer, diabetes, muscular dystrophy, and Huntington’s disease. Fluorescent labelling 
of vessels is often done in this model to facilitate angiogenesis studies. [97, 98] 
 
2.5.4 In Vitro Models 
Cellular Scaffolds  
As previously mentioned, fibrin is a natural polymer used in many tissue engineering 
applications because its physical properties can be altered by varying multiple factors including 
fibrin fiber diameter and density, the number and distance of branch points, and the porosity of the 
material [70]. Multiple cells including endothelial and mural cells discussed above bind to fibrin 
and form sprouts within the fibrillar fibrin network. Fibrin can also be used as a delivery vehicle 
transporting cells, growth factors, drugs, and other materials to specific areas in the body [75]. 
However, this section will focus on its use in vasculogenesis and angiogenesis in vitro assays. 
Angiogenesis studies were first done in animal models as described in the section above. 
Folkman and Haudenschild published the first in vitro angiogenesis model in 1980 [104]. This 
two-dimensional (2D) model showed that tube formation occurred after capillary endothelial cells 
were isolated and cultured on gelatin-coated plates using tumor-conditioned media [104]. Three-
dimensional models are more useful than 2D models since cells embedded in 3D hydrogels behave 
more like in vivo conditions than cells seeded on top of 2D surfaces [105].  
Nehls and Drenckhahn [106] developed an in vitro angiogenesis system that could facilitate 
sprout quantification. This system uses microcarrier beads coated with gelatin to allow endothelial 
attachment. Once attached, the cellular microcarrier beads are embedded in fibrin hydrogels where 
they migrate and form sprouts within the hydrogel. This angiogenesis model is still being 
employed to study endothelial sprouting, inosculation, and other vascular mechanisms which are 
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affected when adjusting parameters including but not limited to cell type(s), their proximity to 
each other, and matrix properties [58, 107-110]. Other angiogenesis assays include the human 
arterial ring angiogenesis assay which entails embedding human umbilical artery rings in basement 
membrane extracts [111], and the human aortic ring assays which are aortic rings embedded in 
fibrin or collagen hydrogels [112]. 
Many researchers continue to investigate how to develop vascular tissues and 
vasculogenesis/angiogenesis in vitro assays by combining different cells and materials [36, 108, 
113]. Some of the cells employed in these assays include adipose tissue fragments (ATF) [114], 
bovine aortic endothelial cells (BAEC) [115-117], bovine capillary endothelial cells (BCEC) [118, 
119], embryonic stem cells (ES) [120, 121], endothelial progenitor cells (EPCs) [122], 
microvascular endothelial cells (MVECs) [123], and human umbilical vein endothelial cells [124]. 
In addition to fibrin, other biomaterials like collagen, Matrigel, and plasma clots are also used to 
encapsulate cells and study their functionality [125].  
Vasculogenesis studies in the Putnam and Stegemann labs have shown the potential of 
human umbilical vein endothelial cells (HUVECs) and stromal cells (e.g. mesenchymal stem cells 
- MSCs, NHLFs, etc.) to form networks when embedded in 3D fibrin macro gels [58, 108, 126-
128]. Higher fibrinogen concentrations have been shown to increase the number of fibers and 
branch points formed within the matrix resulting in higher hydrogel stiffness. [79] Other 
biomaterials such as collagen are also used with fibrin to increase the overall matrix stiffness.  
A previous study from the Stegemann lab [126] demonstrated that HUVECs-MSCs co-
cultures form vascular networks of different network lengths depending on the collagen-fibrin 
concentrations, as well as the HUVECs-MSCs co-culture ratio utilized to make these gels. The 
study demonstrated that HUVECs-MSCs co-cultures embedded in 40-60 collagen-fibrin macro 
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gels achieved a network formation comparable to when this same co-culture was embedded in 
fibrin alone. However, the strengths of these two matrices were different. Fig. 2-1 displays the 
results of HUVECs-NHLFs experiments, which qualitatively demonstrate that HUVECs-NHLFs 
co-cultures can also form networks similarly in pure fibrin and 40-60 collagen-fibrin systems even 
though their mechanical properties are different.  
 
 
Figure 2-1  HUVECs-NHLFs (1:1) co-culture in 3D fibrin (left) and collagen-fibrin (right) gels at 4x, 10x, and 20x 
magnifications. 
 
Modular Tissue Engineering Technique 
Cells residing in most tissues in the body receive oxygen and nutrients via blood from 
capillaries that are spaced approximately 100 to 200 µm apart [129, 130]. Although oxygen can 
diffuse further, cell apoptosis occurs in constructs larger than 200 μm due to oxygen and nutrient 
consumption limitations. Creating small microtissues diminishes mass transfer limitations while 
permitting cells residing within the microtissues to attach, spread, and function depending on the 
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tissue type. The modular tissue engineering technique assembles these microtissues by aggregation 
or by printing them in specific regions to develops larger tissues [131].  
These microtissues can also be injected into disease areas to regenerate tissue [132]. In the 
case of vascularization, the idea is to encapsulate endothelial and mural cells within the microbeads 
to allow sprout formation to occur prior to implantation in ischemic areas. Preliminary studies 
done in our labs showed that HUVECs-NHLFs collagen-fibrin microbeads embedded in fibrin 
hydrogels containing fibroblasts (in vivo like condition) or lacking fibroblasts can form sprouts 
(Fig. 2-2). To distinguish the microbeads from the surrounding hydrogel, microbeads were made 
with FITC fibrinogen. Samples were stained with UEA-I (endothelial cell marker, red) and DAPI 
(nuclei, blue) to distinguish the two cell types. 
 
 
Figure 2-2: Demonstration of sprouting of HUVECs-NHLFs collagen-fibrin microbeads. HUVEC marker (red): UEA-
I, cell nuclei (blue): DAPI, microbeads (green): FITC, scale bar = 200 μm. 
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Cell Patterning Techniques 
Cell patterning techniques for tissue development are also employed in tissue engineering 
[133]. The idea of using microfabrication is that tissues can be built with the necessary blood 
supply for cells to survive, and ultimately develop an entire organ such as the heart [133]. 
Photolithography, microcontact printing and microfluidic devices (MFD) are some of the 
microfabrication techniques employed. In particular, MFDs are often used since cells can be 
localized within different channels to study their functionality based on biomaterials being used 
and local effects of flow within the system [133].  
 
2.6 Conclusion 
There are multiple processes that occur in vascular tissues including vasculogenesis, 
angiogenesis, and arteriogenesis. This chapter describes these important processes and the main 
cells that are part of these processes. Some of the natural materials, e.g. fibrin and collagen, used 
in tissue engineering are described along with some synthetic materials. There are also multiple in 
vitro/in vivo models developed in the tissue engineering field, including the ones developed in this 
work, to study the cells, materials, and vascular processes. The goal is that someday one or a 
combination of these strategies will lead to vascular tissue regeneration in ischemic regions.  
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3.1 Introduction 
It is estimated that two million Americans suffer from critical limb ischemia (CLI) caused 
by peripheral arterial disease, chronic kidney disease, and severe diabetes [1-3]. CLI occurs when 
there is a poor supply of oxygenated blood to the lower extremities of the body due to artery 
blockage. CLI is a chronic condition and current treatments are aimed mainly at preventing 
progression of the disease or salvaging existing vasculature to provide partial flow to the affected 
limb. However, there is a need for more permanent and effective solutions that can create new 
vasculature to provide sufficient oxygen and nutrients to cells in the affected tissue, and thereby 
prevent tissue necrosis and amputation. 
A variety of strategies have been investigated to improve tissue vascularization [4]. 
Delivery of vascular endothelial growth factor (VEGF) is a direct approach based on the known 
ability of this signaling molecule to stimulate endothelial cell recruitment and subsequent 
neovessel formation [5-7]. Other growth factors that facilitate and increase capillary formation 
include basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), and transforming 
growth factor beta (TGF-β) [8-11] Gene delivery has also been used to upregulate production of 
pro-angiogenic factors [12, 13]. A challenge in applying gene and/or growth factor delivery is 
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determining the dosage needed to improve blood perfusion while preventing overproduction of 
leaky and disorganized vessels, which can occur at high dosages [5, 14, 15].  
Attempts have also been made to re-vascularize ischemic tissue using transplanted cells in 
animal studies as well as in patients with progressed ischemic conditions [16, 17]. Although cell-
based therapies have the potential to treat CLI, protocols for selection and delivery of these 
progenitor cells via injection into ischemic regions create challenges in terms of cell survival and 
engraftment. Patients are also less likely to respond to this treatment after a single dose, 
emphasizing the importance of optimizing the dose as well as the cell functionality being delivered 
to the patient [18]. 
Pre-vascularization of engineered tissues is a strategy that has been explored to allow more 
rapid engraftment after transplantation. In vitro pre-vascularization is typically achieved by 
designing and fabricating tissue constructs using appropriate extracellular matrix materials, cell 
types, and culture conditions to allow self-assembly of a microvascular network [19-21], or via 
cell seeding of a pre-defined architecture [22]. In vivo pre-vascularization relies on implanting an 
engineered scaffold in a region close to an artery to allow vessel ingrowth and network formation 
within the implant. A major advantage of pre-vascularized tissue constructs is that the host 
vasculature can rapidly inosculate with the pre-formed vascular network of the construct [23-25], 
thereby accelerating the wound healing and remodeling needed to restore tissue functionality [21, 
26, 27]. However, a major limitation with current pre-vascularization strategies is the requirement 
for invasive surgery to implant the engineered tissue at the target site. 
Fibrin is the primary structural component of blood clots and plays an important role in the 
provisional matrix that is remodeled during wound healing [28]. Type I collagen is a well 
characterized structural protein and an important component of the extracellular matrix of many 
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tissues [29]. Each of these materials has been used separately as 3D matrices for vascularization 
because of their demonstrated ability to support the formation of endothelial networks [30-34]. 
These natural matrices provide cell-adhesion sites and can be enzymatically remodeled by cells.  
However, combinations have also been used to support vascularization, in part to harness their 
composite mechanical and biochemical functionalities [31, 35, 36]. 
Elongation and vascular network formation by endothelial cells embedded in fibrin, 
collagen, and COL-FIB composite materials has been shown to be influenced by the properties of 
the matrix [31, 36, 37], and by the presence of stromal cells. Mesenchymal stem cells (MSCs), 
smooth muscle cells, and fibroblasts are stromal cells that interact with endothelial cells and 
contribute to the formation, remodeling, and stabilization of blood vessels in part by providing 
paracrine cues [38-43]. 
In the present study, we developed and characterized modular protein microbeads designed 
as a minimally invasive, cell-based therapy for re-vascularization of ischemic tissue. Human 
endothelial cells and fibroblasts were embedded in pure fibrin and collagen-fibrin microbeads 
using a simple water-in-oil emulsification process. We examined how cell concentration and 
matrix composition influenced cell incorporation into microbeads, and characterized cell viability 
and proliferation in the matrix. Selected microbeads were subsequently embedded into 
surrounding fibrin hydrogels to study vascular network formation. The morphology and extent of 
endothelial sprout formation inside and outside microbeads was quantitatively assessed over time 
in culture. In addition, anastomosis of vessel segments from neighboring microbeads was 
characterized. The overall goal of this work was to combine cell-based approaches to 
vasculogenesis with pre-vascularization strategies to produce a potential therapy for the rapid and 
efficient restoration of blood flow to regions of tissue ischemia. 
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3.2 Materials and Methods 
3.2.1 Cell Culture 
Umbilical cords were obtained from the University of Michigan Mott Children’s Hospital 
via an IRB-exempt protocol and human umbilical vein endothelial cells (HUVECs) were isolated 
via methods similar to those previously described [30]. In brief, the umbilical cord was washed in 
phosphate buffer saline (PBS) and digested in collagenase type I solution (195 U/mL, Worthington 
Biochemical, Lakewood, NJ) at 37 °C for 20 min. The digested tissue was washed in PBS and 
subsequently centrifuged (200xg for 5 min). HUVECs were plated in tissue culture flasks and 
supplied with endothelial growth media (EGM-2, Lonza). After 24 hours, HUVECs were rinsed 
with PBS thrice to remove non-adherent cells and supplied with fresh media that was changed 
every 48 hours. Cells from passages 3 and 4 were utilized for experiments. Normal human lung 
fibroblasts (NHLFs, Lonza Inc., Walkersville, MD) were cultured in Media 199 (M199, Life 
Technologies, Grand Island, NY) with 10% fetal bovine serum (FBS), and 1% 
penicillin/streptomycin (Life Tech). Culture media was replaced every 48 hours and cells from 
passages 7-12 were used in experiments. 
 
3.2.2 Microbead Fabrication 
The process used to create protein microbeads is shown schematically in Figure 3-1. Two 
matrix formulations were used: 100% fibrin (FIB) and 40/60 wt% collagen/fibrin (COL-FIB). 
Collagen stock solution (4.0 mg/mL) was made under sterile conditions by dissolving lyophilized 
type I bovine collagen (MP Biomedicals, Solon, OH) in 0.02 N acetic acid. Fibrinogen stock 
solution (4.0 mg/mL clottable protein) was made by dissolving bovine fibrinogen (Sigma Aldrich, 
56 
St. Louis MO) in serum-free endothelial growth medium (SFEGM-2) at 37 °C. The solution was 
then filter sterilized after completely dissolving the protein. Equal numbers of HUVECs and 
NHLFs were suspended in FIB or COL-FIB composite hydrogel solutions at specific cell 
concentrations (Low: 5x105 cells/mL, High: 2x106 cells/mL). To make 1.0 mL of cellular FIB 
hydrogel solution, the following components were added to the cell pellet and mixed thoroughly: 
255 µL SFEGM-2, 100 µL of FBS (10% final), 20 µL of 50 U/mL thrombin (1 U/mL final), and 
625 µL fibrinogen stock solution (2.5 mg/mL final). To make 1.0 mL of cellular COL-FIB 
composite hydrogel solution, the following components were added to the cell pellet and mixed 
thoroughly: 93 µL SFEGM-2, 100 µL FBS (10% final), 100 µL of 5X Dulbecco’s Modified Eagle 
Medium (DMEM (10% Final), 12 µL of 87.5 mM glyoxal (1 mM Final, Sigma) for crosslinking 
collagen, 50 µL of 0.1 N NaOH to neutralize acidic collagen, 20 µL of 50 U/mL thrombin (1 U/mL 
final), 250 µL collagen stock solution (1.25 mg/mL final), and 375 µL fibrinogen stock solution 
(1.5 mg/mL final). 
To create protein microbeads, 3.0 mL of matrix/cell suspension was quickly added to a 
stirred bath (600 rpm) containing 75 mL of 100 cSt polydimethylsiloxane (PDMS, Dow Corning) 
cooled in an ice bath. Emulsification proceeded for 5 min, and the temperature of the PDMS bath 
was then increased to 37 °C to induce gelling for an additional 25 min. The mixture of PDMS and 
formed microbeads was then transferred to 50 mL centrifuge tubes and 5 mL of PBS containing 
0.1% L101 surfactant (PBS-L101; BASF, Florham Park, NJ) was added to each tube and mixed 
gently by inverting for 5 min. The mixture was then centrifuged at 200xg for 5 min. The PDMS 
layer was carefully removed and then pelleted microbeads were washed again using PBS-L101. 
Once the microbeads were thoroughly washed, they were supplied with an appropriate amount of 
culture medium (EGM-2) and used for further experiments. 
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Figure 3-1: Microbead fabrication process. HUVECs and NHLFs were incorporated in a 1:1 ratio at an initial cell 
density of 5*105 cells/mL or 2*106 cells/mL in either pure fibrin or collagen-fibrin (40-60) microbeads via an oil-and-
water emulsification process. Resultant microbeads were subsequently embedded in fibrin hydrogels, cultured for 7 
or 14 days, and then analyzed.  
 
3.2.3 Characterization of Cell Incorporation and Microbead Morphology 
The number of cells incorporated within microbeads was determined by staining with 4′,6-
diamidino-2-phenylindole (DAPI, Life Technologies). The FIB and COL-FIB samples were 
collected and fixed with zinc-buffered formalin solution (Z-fix, Anatech, Battle Creek, MI) for 5 
min. Fixed samples were washed in PBS and stained with 10 nM DAPI solution for 10 min. Bright 
field and fluorescent images were taken using an optical microscope (Olympus IX81, Olympus, 
Center Valley, PA). The number of cells per microbead and microbead diameters were determined 
from these images using ImageJ (National Institutes of Health, Bethesda, MD). 
At least 100 randomly selected microbeads per condition and per experiment were used for 
image analysis to determine microbead diameter, cell distribution, and number of cells 
incorporated into the microbeads. 
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3.2.4 Cell Viability and Proliferation Assays 
The viability of cells encapsulated in microbeads and in bulk gels was determined using 
the Live/Dead® staining kit (Life Technologies). Bulk gel samples with the same protein and cell 
concentration as the microbeads were also prepared by allowing the hydrogel/cell mixture to gel 
in 24-well plates (500 µL per well) at room temperature for 5 minutes, followed by an additional 
20 to 25 min at 37 °C in an incubator. Samples were collected, washed in 10 mM PBS and re-
suspended in PBS containing 1 µM calcein-AM and 2 µM ethidium homodimer for 45 min at 37 
°C. Samples were then imaged using a fluorescence microscope. 
Both cell seeded COL-FIB and FIB microbeads were embedded in fibrin gels after their 
fabrication process. To embed microbeads in gels, one tenth of a 3 mL microbead preparation was 
collected and pelleted to make three fibrin hydrogels with microbeads per time point (~500 µL per 
hydrogel). These hydrogels were made by adding the following components to the microbead 
pellet and mixing thoroughly: 382.5 µL SFEGM-2, 150 µL of FBS (10% final), 30 µL of 50 U/mL 
thrombin (1 U/mL final), and 937.5 µL fibrinogen stock solution (2.5 mg/mL final). Hydrogels 
were molded into standard 24-well culture plates, and were left at room temperature for 5 min 
before being placed in an incubator for 25 minutes at 37 °C. One milliliter of EGM-2 was added 
to each hydrogel containing the cellular microbeads. Culture medium was replaced the next day 
and then on every second day for the duration of the culture period. 
Cell proliferation was determined by quantifying total DNA in samples collected at specific 
time intervals. To isolate the total DNA from the samples, fibrin gels containing microbeads were 
digested in 10 mM Tris-HCL/0.4 M Guanidine hydrochloride solution for 3 hours. The digested 
samples were then centrifuged at 10,000  g for 10 min and the supernatant containing the DNA 
was aspirated, and then diluted with water to reduce Guanidine-HCL interference with the DNA 
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assay. DNA content was determined using the PicoGreen® DNA assay kit (Invitrogen). Calf 
thymus DNA standards were used to generate standard curves. 
 
3.2.5 Imaging and Analysis of Endothelial Sprouts 
To distinguish the microbeads from the 3D fibrin environment in which they were 
embedded, FIB and COL-FIB microbeads fabricated as described above were subsequently coated 
with a FITC-fibrinogen layer by incubating them in FITC-fibrinogen (9 µg/mL, Life 
Technologies) in EGM-2 at 37 °C for 25 min prior to embedding within the larger hydrogel. The 
same embedding process utilized for the proliferation assay (Section 3.2.4) was employed to 
incorporate the cellular microbeads within acellular fibrin hydrogels. To visualize vascular sprouts, 
the endothelial cell-specific marker Ulex Europaeus Agglutinin I (UEA-I, Vector Laboratories, 
Burlingame, CA) was used. In brief, samples were collected at specified time intervals, washed 
twice in PBS, and fixed in zinc-buffered formalin (Z-fix, Anatech) at room temperature. Fixed 
samples were then washed and incubated in staining solution containing 1% BSA, 20 µg/mL 
rhodamine-labeled UEA-I, and 10 nM DAPI in PBS for 45 min at room temperature. Before 
imaging, samples were rinsed twice with PBS for 5 min to remove unbound residual stains. 
Endothelial sprouts were characterized by measuring average sprout lengths, numbers of 
segments (branching), branch points, and lengths of each segment both inside and outside the 
microbeads through image analysis using a protocol similar to previous studies [30, 37, 44]. 
Inosculation of adjacent sprouts protruding from adjacent microbeads was assessed qualitatively. 
Fluorescence images were acquired using an optical microscope and randomly selected 
microbeads were used for quantification using ImageJ. All image analysis was performed using a 
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blinded image evaluation method in which random images were provided to the evaluator with no 
information about the experimental conditions.  
 
3.2.6 Statistical Analysis 
Statistical analyses were performed using STATISTICA (StatSoft. Inc, Tulsa, OK) 
software. At least 3 independent experiments were performed for each assay and data are reported 
as mean ± standard error of the mean (SEM). One-way ANOVA followed by unequal N post-test 




3.3.1 Cell Encapsulation and Retention in Microbeads  
HUVECs and NHLFs were encapsulated at a 1:1 ratio in FIB and COL-FIB microbeads, 
at either low cell concentration (LC: 5.0x105 cells/mL) or high concentration (HC: 2.0x106 
cells/mL). At the same starting concentration, larger microbeads contained greater total numbers 
of cells, as expected (Fig. 3-2A). The average microbead diameter was approximately 140 µm for 
both FIB formulations and the low cell concentration COL-FIB formulation; however, the high 
cell concentration COL-FIB microbeads were significantly larger (approximately 200 µm in 
diameter, Fig. 3-2B, p<0.05). The distribution in the number of cells per microbead of the 
treatment populations was broader for the high cell concentration conditions, in contrast to 
microbeads containing the low cell concentration, which exhibited a sharper peak and a more 
homogeneous distribution (Fig. 3-2C). Overall cell incorporation increased as higher cell 
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concentrations were used with the same material formulation (Fig. 3-2D, p<0.05). Microbeads 
with high cell concentration contained an average of 30-35 cells per microbead, while those with 
low cell concentration contained 5-10 cells per microbead. There was no statistical difference in 
the total number of cells incorporated between COL-FIB and pure FIB microbeads, when 
comparing at either the low concentration or high cell concentration conditions.  
 
 
Figure 3-2: Microbead characterization.  (A) The number of cells per microbead was quantified as a function of 
microbead diameter. Average microbead diameters (B), cell number distributions (C), and average number of cells 
(D) within COL-FIB and FIB microbeads at low (LC) and high (HC) cell densities were quantified. Statistical 
differences (p<0.05) between conditions are denoted by *, while differences between one group and the remaining 
groups are denoted by ***.  (n=3, at least 100 microbeads per n). 
 
3.3.2 Viability and Proliferation of Cells Encapsulated in Microbeads 
The viability of cells encapsulated in FIB and COL-FIB microbeads in the high cell 
concentration (2.0x106 cells/mL) was quantified and compared to values from bulk macroscopic 
hydrogels (Fig. 3-3). Representative live (green)/dead (red) images of COL-FIB microbeads (Fig. 
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3-3A), FIB microbeads (Fig. 3-3B), COL-FIB bulk hydrogels (Fig. 3-3C), and FIB bulk hydrogels 
(Fig. 3-3D) show uniform cell distributions in both the microbeads and the hydrogels, with no 
spatial variations in viability evident.  
 
 
Figure 3-3: Cell viability in microbeads. Representative live (green)/dead (red) images of cells (HUVECs:NHLFs co-
cultures) incorporated in (A) COL:FIB microbeads, (B) FIB microbeads, (C) COL-FIB, and (D) FIB hydrogels after 
their respective fabrication process. (E) Images were quantified to compare the viabilities of cells in microbeads and 
hydrogels. Statistical differences between conditions are denoted by * (p<0.05). (n=3). Scale bar = 200 µm. 
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Figure 3-4: Cell proliferation in microbeads. (A) Schematic depicting experimental procedure for cell proliferation 
studies in which either COL-FIB or FIB microbeads were embedded in FIB hydrogels and cultured for 7 and 14 days. 
(B) Representative bright-field and fluorescence images of FIB microbeads (green in the fluorescent image) embedded 
at day 0 and cultured for 7 days. (Microbeads were fabricated with FITC-fibrinogen to illustrate the location of the 
microbeads within the fibrin matrix in this image. However, non-fluorescent fibrinogen was employed in the actual 
proliferation studies.) (C) DNA content of cells embedded within COL-FIB or FIB microbeads was quantified after 1 
and 2 weeks in culture. Statistical differences between microbead types at both day 7 and day 14 are denoted by * 
(p<0.05, n≥3). Scale bar = 500 µm. 
 
Cell viabilities in both COL-FIB and FIB microbeads were high (75% and 79% viable 
cells, respectively), with no statistically significant differences between the formulations. 
However, cell viability was significantly lower in the microbeads compared to their bulk hydrogel 
counterparts, which exhibited 87% and 85% viable cells, respectively (Fig. 3-3E). 
COL-FIB and FIB microbeads made at the high cell concentration (2.0x106 cells/mL) were 
embedded in surrounding 2.5 mg/mL fibrin hydrogels to examine cell proliferation and endothelial 
sprout formation. Figure 3-4A shows a schematic of the protocol used for cell proliferation studies. 
Microbeads were visualized inside the larger fibrin matrix using bright-field and fluorescent 
microscopy (Fig. 3-4B). In these images, FIB microbeads were embedded in a FIB hydrogel 
immediately after fabrication and were cultured for 7 days before imaging. In the fluorescence 
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image, microbeads were tagged with FITC to distinguish the microbead matrix from the 
surrounding fibrin. At day 0, both microbead formulations showed equal DNA content, which then 
increased over time in culture as cells proliferated. At day 7, there was a significant difference 
(p<0.05) in the DNA content between FIB and COL-FIB microbeads. By day 14, the DNA content 
was 2.5-fold higher (p<0.05) in COL-FIB microbeads than in corresponding FIB microbeads, 
indicating a significantly higher number of cells within these beads (Fig. 3-4C).  
 
3.3.3 Endothelial Sprouting from Microbeads Embedded in Fibrin Matrix 
 
Figure 3-5: Endothelial sprouting within and from microbeads. Representative images of HUVECs (red) and 
microbeads (green) in either COL-FIB (A, C) or FIB microbeads (B, D) embedded immediately after processing, and 
cultured for an additional 7 and 14 days within FIB constructs. Sprouts originate from within the beads and invade the 
surrounding matrix. Scale bar = 500 µm. 
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COL-FIB microbeads made with the lower cell concentration did not support endothelial 
sprouting when embedded in fibrin hydrogels (data not shown), while those made with the higher 
cell concentration retained the capacity for sprout formation when embedded in fibrin hydrogels. 
Therefore, the vasculogenic capacity of COL-FIB and FIB microbeads were compared only at the 
higher initial cell concentration. COL-FIB and FIB microbeads containing HUVECs and NHLFs 
were embedded in fibrin hydrogels and cultured for 7 and 14 days (representative images shown 
in Fig. 3-5). The microbead matrix was tagged with FITC (green) and the endothelial cells were 
identified by UEA-1 staining (red). In both microbead formulations, endothelial sprouts initially 
formed inside the microbead matrix and then invaded into the surrounding fibrin hydrogel. 
The extent of sprouting both within the microbeads and in the surrounding matrix were 
characterized in terms of the number of segments (Fig. 3-6A), the average segment length (Fig. 3-
6B), the number of branch points (Fig. 3-6C), and the total sprout length (Fig. 3-6D) (see also 
Tables 3-1 and 3-2). Microbeads contained an average of 4 to 5 vessel segments by the end of 7 
days in culture, with no further change in the number of segments within the microbeads by day 
14 (Fig. 3-6A, “inside microbead”). The number of segments that extended from the FIB 
microbeads was significantly higher compared to COL-FIB microbeads at both time points. A 
higher number of segments protruding the COL-FIB microbeads was found with an additional 
week of culture (Fig. 3-6A, “outside microbead”). By day 14, the total number of vessel segments 
per microbead was 10-14, and this measure was significantly higher in FIB microbeads than in 




Figure 3-6: Quantification of endothelial sprout lengths and branching. (A) The numbers of vessel segments, (B) 
average segment lengths, (C) numbers of branch points, and (D) sprout lengths for the nascent microvessel-like 
networks originating from COL-FIB and FIB microbeads embedded in fibrin gels at day 0, and cultured for an 
additional 7 and 14 days. Statistical differences (p<0.05) are denoted by the following symbols: * for the differences 
between microbeads at D7, $ for the differences between microbeads at D14, ^ for differences across culture time (D7 
vs. D14) for microbeads of the same composition, and # for differences in culture time and microbead composition 
(n≥3). 
 
Table 3-1: Endothelial sprouting measurements inside microbeads 
            






FIB and COL-FIB  




3.7 ± 0.3 
SEM 
3.9 ± 0.3 
SEM 
4.5 ± 0.3 
SEM 







No. of branch 
points 
1.0 ± 0.1 
SEM 
1.0 ± 0.1 
SEM 
1.2 ± 0.2 
SEM 









87 ± 3 
SEM 
87 ± 4 
SEM 
93 ± 4 








315 ± 25 
SEM 
344 ± 33 
SEM 
420 ± 36 
SEM 









The average vessel segment length inside microbeads was approximately 90 µm, with no 
significant differences across matrix formulations or time points (Fig. 3-6B, “inside microbead”). 
Outside the microbeads, longer segments were produced by FIB microbeads than COL-FIB 
microbeads (p<0.05), and segment length increased significantly outside FIB microbeads between 
7 and 14 days (Fig. 3-6B, p<0.05). Both COL-FIB and FIB microbeads on average contained at 
least one branch point, and the number of branch points was significantly higher in FIB microbeads 
at day 14 (Fig. 3-6C, p<0.05), compared to the other formulation and time point. The number of 
branch points outside the microbeads and the total number of branch points were also significantly 
higher in FIB microbeads compared to COL-FIB at both time points (Fig. 3-6C, p<0.05). 
 
Table 3-2: Endothelial sprouting measurements protruding from the microbeads into the surrounding fibrin matrix 
           






between FIB and 
COL-FIB  




4.6 ± 0.5 
SEM 
6.4 ± 0.6 
SEM 
8.5 ± 0.6 
SEM 





No. of branch 
points 
0.8 ± 0.1 
SEM 
1.2 ± 0.2 
SEM 
1.8 ± 0.2 
SEM 







131 ± 6 
SEM 
142 ± 8 
SEM 
189 ± 8 
SEM 







544 ± 90 
SEM 









             
The combination of vessel network characteristics described also resulted in differences in 
the total sprout network length (Fig. 3-6D). The average total sprout length inside microbeads was 
315-460 µm, and there were no statistically significant differences between matrix formulations 
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or time points. However, the vessel networks that penetrated into the surrounding fibrin hydrogel 
were significantly longer when emerging from FIB microbeads compared to COL-FIB microbeads 
at both day 7 and 14 (Fig. 3-6D, “outside microbeads”, p<0.05). Total sprout length increased 
significantly in COL-FIB microbeads over time, but was lower than in FIB microbeads at all time 
points (Fig. 3-6D, “total per microbead”, p<0.05). By day 14, the microvascular network produced 
by HUVECs and NHLFs encapsulated within FIB microbeads approached 2500 µm in total length. 
See Table 3-1, and 3-2 for numerical values graphed in Figure 3.6. 
 
3.3.4 Inosculation Between Endothelial Sprouts from Adjacent Microbeads 
 
 
Figure 3-7: Formation of anastomoses between sprouts to form larger microvascular networks. Connections (white 
arrows) formed via inosculation of endothelial sprouts from adjacent COL-FIB (A, B, E, F) or FIB (C, D, G, H) 
microbeads embedded in FIB hydrogels immediately post fabrication, and cultured for 7 days (A-D) and 14 days (E-
H). Images are 4x and 10x magnification. HUVECs are displayed in red, microbeads in green, and cell (both HUVECs 
and NHLFs) nuclei in blue. Scale bar = 500 µm. 
 
COL-FIB and FIB microbeads embedded in fibrin hydrogels were cultured for 1 or 2 
weeks. The microbead matrix was tagged green prior to the embedding process to distinguish them 
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from the surrounding fibrin matrix, while the HUVECs were stained in red (Fig. 3-7). Microbeads 
were generally separated from each other in the surrounding gel, though some clumping was 
observed. As described quantitatively in Figure 3-6, endothelial cell networks extended from the 
embedded microbeads by day 7 (Fig. 3-7 A-D), and were more prominent in the pure FIB samples. 
The arrows in Figure 3-7 show anastomoses between endothelial sprouts from adjacent 
microbeads. This phenomenon is evident in both microbead formulations at both day 7 and day 14 
and at 4x and 10x magnification. The nuclei of both ECs and NHLFs were stained in blue (Fig. 3-
7B, D, F, and H). It can be seen that NHLFs migrated out of the microbeads and into the 
surrounding matrix, and that endothelial sprouts extended and anastomosed between microbeads. 
By day 14, relatively long distances (1000-2000 µm) were traversed by joined endothelial sprouts 
(Fig. 3-7 E-H). 
 
3.4 Discussion 
Cells in most tissues in the body receive oxygen and nutrients via blood from capillaries 
that are spaced approximately 100-200 μm apart [24, 45, 46]. In larger engineered tissue 
constructs, oxygen and nutrients are consumed by cells that reside within this diffusion limit, while 
those cells that reside beyond the limit typically undergo apoptosis. Therefore, modular approaches 
are being explored to reduce diffusion limitations that occur in large engineered tissues [47-52]. 
One strategy has been to create very small “microtissues” with diffusion path lengths on the scale 
of 10-100 µm. These building blocks are designed to avoid mass transfer limitations, and in some 
cases can be delivered minimally invasively and assembled into larger tissue structures [53-60].  
In the present study, a simple water-in-oil emulsification technique was used to fabricate 
protein microbeads with diameters in the range of 100-200 µm. Endothelial cells and fibroblasts 
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were fully embedded within the microbeads. These cell types have been used widely to initiate 
vasculogenesis and angiogenesis [37, 61], through a process in which fibroblast-derived factors 
provide signals to promote and stabilize network formation by the endothelial cells [42, 43]. 
Collagen and fibrin were used in microbeads as extracellular matrix proteins because of their 
demonstrated ability to support vascular network formation [35, 36, 62]. It has been shown that 
the composition of the matrix affects the process of neovessel formation [31, 36], and that fibrin 
is a particularly permissive environment for angiogenesis [20, 30, 32]. However, most studies have 
been performed in bulk hydrogel materials, and the properties and dynamics of the extracellular 
matrix in microtissues may be different from larger-scale models. Therefore, this study focused on 
determining a suitable cell and matrix composition to achieve sprout formation by endothelial cells 
within collagen-fibrin and pure fibrin microbeads.  
The microbeads produced by the emulsification and collection process were generally 
spheroidal with a diameter of 100-200 µm, and therefore the maximum diffusion path length to a 
cell in the interior was approximately 100 µm. Cells were incorporated into the microbead matrix 
in general proportion to the starting cell concentration; however, cell loss did occur during 
processing. Microbeads fabricated with an initial concentration of 5.0x105 cells/mL contained an 
average of only 5-10 cells, which was not supportive of the creation of vascular networks within 
the microbead volume. The low cell number meant that there were insufficient endothelial cells to 
connect and form networks, as well as reduced paracrine signaling from the relatively few 
supporting fibroblasts. Therefore, subsequent experiments on vessel network formation were 
performed using only microbeads fabricated at higher cell concentration. With a starting 
concentration of 2.0x106 cells/mL of protein matrix, microbeads contained an average of 30-35 
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cells. Approximately half of these cells could be expected to be endothelial cells, which provided 
a number sufficient to initiate the formation of small vascular structures within the microbeads. 
Cell viability in microbeads was lower than in bulk hydrogels of corresponding 
composition, but was still in the range of 75-80%. The decrease in cell viability was most likely 
due to the processing required to fabricate and collect the microbeads, which included multiple 
wash and centrifugation steps to separate the microbeads from the silicone oil. However, cells 
survived within microbeads over time in culture, as evidenced by their maintained ability to 
proliferate and change morphology in the matrix. Cells in both microbead types proliferated in 
culture, but over the 14-day period studied there was a significantly greater degree of cell 
proliferation in COL-FIB microbeads, as compared to pure FIB microbeads. Tracking of total 
DNA content did not allow discrimination of which cell types were proliferating. However 
endothelial network length was greater in FIB microbeads than in COL-FIB microbeads, 
suggesting that the increased DNA content in the latter formulation was predominantly the result 
of fibroblast proliferation. 
Endothelial sprout formation and anastomosis between sprouts was examined by 
embedding microbeads in an acellular surrounding hydrogel consisting of pure fibrin. The 
surrounding matrix isolated the microbeads from each other and allowed the examination of 
endothelial network extension outside of the microbeads. Using this system, both COL-FIB and 
FIB materials supported endothelial network formation inside the microbead matrix, as well as 
their extension into the surrounding fibrin hydrogel. Over time, anastomosis of endothelial sprouts 
from adjacent microbeads was also observed in both microbead formulations. The extent of the 
internal networks was generally the same regardless of microbead composition, but the extension 
of sprouts into the surrounding matrix was significantly enhanced using pure FIB microbeads. The 
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networks in FIB microbeads also were more branched with longer inter-branch segments than their 
COL-FIB counterparts. The longer and more extensive networks produced by FIB microbeads 
may have a greater chance of creating inter-network connectivity. 
Endothelial cell sprouting and migration have been shown to be dependent on matrix 
composition, stromal cell type, and serum concentration [43, 63, 64]. Since our studies used the 
same stromal cell type and serum concentration in both microbead formulations, the differences 
in sprouting in our study are mainly attributable to matrix composition. Previous studies have 
shown that collagen, fibrin, and their composites support endothelial network formation to 
different extents [62], and these effects have been correlated to matrix mechanical properties [31]. 
In addition, fibrin(ogen) (through its heparin-binding domain) binds to many growth factors that 
stimulate angiogenesis [65] and enhance wound healing [66, 67]. In contrast, the growth factor 
binding affinity of type I collagen is very low since no growth factor binding sites have been 
identified in this structural matrix protein [68]. Therefore, both compositional differences and the 
degree of local growth factor sequestration may explain the increased propensity of vessel 
networks to extend from pure fibrin microbeads. 
 
3.5 Conclusion 
These studies (Fig. 3-8) demonstrate that protein-based microbeads containing endothelial 
cells and fibroblasts can support the formation of vascular networks by sprouting from individual 
microbeads, and that adjacent networks can inosculate by anastomoses to produce larger 
structures. Pure fibrin microbeads triggered the formation of more branched and longer networks, 
compared to collagen-fibrin composite microbeads. The use of pure protein microbeads has the 
advantage that the matrix composition is simpler and more readily developed as a cell therapy. 
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Such microbeads may find utility as a method to deliver vascularizing modules to treat ischemic 
conditions, and may also be useful to study the processes of vasculogenesis and angiogenesis. 
 
 
Figure 3-8: Chapter 3 graphical summary.  Summary of study in graphical form; from fibrin and collagen-fibrin 
microbead fabrication to embedding of microbeads into fibrin gel for vessel length quantification. 
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In vitro and In vivo Vessel Formation from Vascular Modular 
Microtissues 
 
4.1  Introduction 
Peripheral arterial disease (PAD) is most commonly caused by atherosclerosis, plaque 
formation in the arterial wall that prevents or limits normal blood flow in the body [1].  Risk factors 
for PAD include smoking and diabetes [2]. Diabetic patients who suffer from PAD have a higher 
rate of ischemic events than non-diabetic PAD patients [3]. In the United States, 82% of lower 
limb amputations are related to diabetes [4]. This increase in limb amputations in diabetics is 
usually due to patients having infected foot ulcers [5]. Ulcers and gangrene are more common in 
diabetic PAD patients than in non-diabetic PAD patients [6]. Bypass surgeries can directly re-
vascularize the affected region(s) in PAD patients’ bodies and prevent long term damage [7]. 
Unfortunately, diabetic PAD patients are often unable to receive invasive surgeries due to other 
comorbidities. For this reason, it is important to develop therapeutic techniques that can re-
vascularize ischemic regions without the need for open surgery.  
Pre-vascularization is a technique that can restore microvasculature by accelerating 
inosculation with host vessels in non-healthy tissue. The survival of the implant can be enhanced 
by introducing pre-formed vascular networks and its ability to re-vascularize ischemic regions [8]. 
In addition to accelerating re-vascularization, pre-vascularization has been shown to improve cell 
viability after transplantation procedures [9]. Both in vivo and in vitro pre-vascularization 
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techniques are being explored to improve blood perfusion and provide sufficient oxygen and 
nutrients for host cells to survive and prevent and/or limit tissue necrosis. These techniques 
typically involve vascularizing a scaffold prior to implantation in the ischemic region. In the in 
vivo technique, scaffolds are implanted close to an artery and/or vein allowing sprout infiltration 
and formation to occur within the implant, which occurs several weeks’ post implantation [10, 11]. 
The vascularized scaffolds are then transferred to the ischemic region where the implant and the 
host vessels are connected surgically via sutures, returning regular blood flow within the affected 
area. The number of surgeries (three) and the lengthy time for the implanted scaffold to vascularize 
reduces the likelihood of using this technique in human clinical studies, especially since major 
surgical complications including damage to the vasculature and nerves can occur as surgeons 
search for the best location to implant the construct [10,11].  
In vitro pre-vascularization, on the other hand, limits the number of surgical interventions 
by developing vascularized tissues outside of the body. Multiple proteins with different endothelial 
and stromal cell co-cultures have been combined to develop vascularized macro tissues in vitro. 
Fibrin has been commonly used as a three-dimensional (3D) matrix in this approach since it 
supports endothelial vessel formation. Multiple 3D vascular macro tissues have been developed 
by combining this protein with other biomaterials and/or cell types [12-16]. Stromal cells and/or 
fibroblasts are often included in these tissues as they provide paracrine signals that are important 
for endothelial vessel formation and stabilization [17-24]. Endothelial sprout length has been found 
to depend not only on the stromal cell type employed, but also on the properties of the extracellular 
matrix properties to which the endothelial cells are exposed [25, 26]. In in vitro pre-
vascularization, the host vasculature is only required to grow and inosculate with the outer regions 
of the construct, where many sprouts are found. Once this occurs, the entire construct is supplied 
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with oxygen and nutrients via the vessel network assembled within the implant [10-12]. Studies 
have shown that these pre-vascularized networks created in vitro connect to the host vasculature 
post-implantation [13-15]. Although this technique proposes a solution to limit re-vascularization 
time, one surgery is still required to improve blood vessel perfusion.  
Modular approaches to tissue re-vascularization represent a new approach to restoring 
vasculature in ischemic tissues. The small sizes of tissue modules provide an advantage over 
macroscopic tissue constructs in terms of size-related oxygen and nutrient diffusion limitations, as 
cells within modules 100-300 m in diameter are better sustained with diffusion alone [27-32]. 
Furthermore, modular approaches may change the way that diabetic PAD patients can be treated 
since microtissues can be delivered in a minimally invasive manner and subsequently self-
assemble into macroscale vascularized networks in situ. Like macroscale tissue constructs, 
microtissue modules can be fabricated with different materials and cells to engineer tissues, 
depending on the tissue type and disease being treated [33-40]. Microtissues’ matrices may also 
allow the encapsulated cells to better survive tissue implantation and regeneration [41, 42].  
We have shown that EC encapsulated with fibroblasts in modular microbeads fabricated 
from natural proteins can initiate sprouting both inside and outside the microtissues when 
embedded in 3D fibrin hydrogels. These EC sprouts also inosculate with sprouts from neighboring 
microtissues in this 3D model [25]. Although cells encapsulated within these engineered modular 
constructs may survive because of their small diameters [32], their viability is likely to decrease 
when implanted in large ischemic regions. For this reason, it is necessary to develop vascular 
microtissues that (1) can be delivered in a minimally invasive manner via injection, (2) can be pre-
cultured for multiple days while fostering endothelial sprout formation to occur, and (3) can 
inosculate with sprouts from neighboring microbeads as well as with the host vasculature. These 
83 
 
pre-vascularized microbeads will already have existing networks, which we expect will facilitate 
oxygen diffusion throughout the construct immediately upon inosculation with the host 
vasculature. The oxygen diffusion will prevent cell apoptosis within the constructs and ultimately 
decrease the time it takes to regenerate vasculature in the ischemic region. 
 
4.2  Materials and Methods 
4.2.1 Cell Culture 
Human umbilical vein endothelial cells (HUVECs) and normal human lung fibroblasts 
(NHLFs) from Lonza Inc, Walkersville, MD were purchased and passaged. Endothelial cells were 
grown in endothelial growth media (EGM-2, Lonza), while fibroblasts were cultured in Media 199 
(M199, Life Technologies, Grand Island, NY) with 10% fetal bovine serum (FBS). Passages 4-7 
of HUVECs and passages 9-14 of NHLFs were employed in in vitro and in vivo experiments.  
 
4.2.2 Fibrin Microbead Production 
HUVECs and NHLFs were cultured and trypsinized using 0.05% Trypsin-EDTA (Gibco). 
Both cell types were re-suspended in their appropriate media. An automated cell counter 
(Multisizer 3, Beckman Coulter, Brea, CA) was utilized to count the number of cells. For 
preliminary in vitro studies, 2x106 of each cell type was used to make 3 mL of the initial fibrin 
microbead stock (2x106 total cells/mL). The cell density was increased from 2x106 total cells/mL 
to 5x106 total cells/mL for in vivo studies and in vitro implant characterization. 
Fibrin microbeads were made in a water-in-oil emulsification process, as previously 
described [25]. Prior to starting the emulsification process, 75 mL of 100 cSt polydimethylsiloxane 
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(PDMS) oil (Clearco Products Co. Inc. Bensalem, PA) was placed into a 100 mL beaker and left 
on ice. Cells were pipetted in a conical tube at the initial cell density of 2x106 total cells/mL (in 
vitro studies) or 5x106 total cells/mL (in vivo studies). Each batch of microbeads was made by 
mixing 765 µL serum-free endothelial growth media (SFEGM-2), 300 µL fetal bovine serum 
(FBS, 10% final), 60 µL of 50 U/mL thrombin (1 U/mL final), and 1875 µL of clottable fibrinogen 
protein stock (2.5 mg/mL final) with the HUVECs-NHLFs pellet. The cell and protein mixture 
was then added to the PDMS bath, which was kept on ice at 0 °C. Fibrinogen (FGN) stock was 
made by mixing protein with SFEGM-2 at 37 °C.  
The cell-fibrin solution was mixed at 600 RPM for 5 min at 0 °C, and then stirred at the 
same speed for 25 min at 37 °C. The microbeads and PDMS solution were collected and separated 
with the addition of PBS with 100 ppm of L101 surfactant (PBS-L101; BASF, Florham Park, NJ), 
inversion mixing, followed by 4-5 centrifugation steps (200 g for 5 min/each). After each 
centrifugation step, PDMS was removed from the FIB microbeads. The microbeads were then re-
suspended with EGM-2 and placed in vented 15 mL conical tubes with filters (CELLTREAT 
Scientific Products, Shirley, MA) prior to starting any experimental procedures. Media were 
changed the day after microbead fabrication and every other day. 
 
4.2.3 Embedding of Microbeads in FIB Hydrogels (3D in vitro model) 
FIB microbeads were embedded in fibrin hydrogels immediately, 1, 3, 5, or 7 days after 
their fabrication process. 300 μL of the 3 mL microbead stock was utilized to make 3 fibrin 
hydrogels, ∼100 μL of microbeads per hydrogel. FIB hydrogels were made by mixing the cell 
pellet thoroughly with 382.5 μL of SFEGM-2, 150 μL of FBS (10% final), 30 μL of 50 U/mL 
thrombin (1 U/mL final), and 937.5 μL of fibrinogen stock solution (2.5 mg/mL final). 500 μL of 
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the cell-protein mixture was added per well of a standard 24-well culture plate, and left at room 
temperature for 5 min before being placed in the incubator for 25 min at 37 °C. EGM-2 was added 
to each hydrogel after the complete gelation process (1 mL per well). Media were replaced the 
next day and every other day for the duration of the culture. 
 
4.2.4 Endothelial Cell Staining, Imaging, and Quantification 
Prior to staining, microbeads alone or embedded in FIB hydrogel were fixed with the zinc-
buffered formalin solution (Z-fix, Anatech, battle Creek, MI). After 10 min, the fixative was 
removed and the samples were washed two times with phosphate buffer saline (PBS). The 
endothelial cell specific marker Ulex Europaeus Aglutinin I (UEA-I, Vector Laboratories, 
Burlingame, CA) was utilized to stain the endothelial cells. The staining solution was made of 1% 
BSA, 20 µg/mL rhodamine-labeled UEA-I, and 10 nM DAPI in PBS. The staining solution was 
then added to microbead samples and left for 45 min at room temperature. Samples were then 
washed with PBS for 2-4 times prior to imaging.  
FIB hydrogels were taken out of the wells of the 24-well plate and placed in a microscope 
slide (Superfrost Plus precleaned, Fisher Scientific, Pittsburgh, PA), a microscope cover glass 
(Vista Vision cover glass, VWR International, LLC, Radnor, PA) was then added on top, in order 
to keep the hydrogel in the center. Fluorescent images of endothelial networks formed in fibrin 
microbeads that had been embedded in FIB hydrogels were then captured using an Olympus IX81 
microscope (Olympus, Center Valley, PA) using the “scan slide” tool in the Metamorph software 
to image the entire construct. NIH ImageJ software (National Institutes of Health, Bethesda, MD) 
was utilized to merge fluorescent and bright-field images. Prior to quantification, all endothelial 
images were cropped and processed using the Kirsch filter to detect edges of endothelial sprouts. 
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The processing and imaging settings were kept constant for all conditions. The Angiogenesis Tube 
Formation module within the Metamorph software was then used to quantify the total area covered 
by endothelial tubes within each fibrin hydrogel containing microbeads.  
 
4.2.5 Preparation of Samples for Subcutaneous Studies 
To ensure equal numbers of cells were injected into mice for each of the different 3 cellular 
experimental groups, a method was developed to quantify the number of cells within the microbead 
preparations after fabrication. After microbeads were fabricated, the microbead pellet from each 
batch was re-suspended in 1 mL of EGM-2 and transferred into vented 15 mL conical tube with 
filters (CELLTREAT Scientific Products, Shirley, MA). The total volume of the microbead and 
media was noted, and 100 µL of it was taken out and placed in a well of a 96-well plate. 100 µL 
of nattokinase solution was then added on top and mixed. The plate was then transferred into the 
incubator for 30 minutes to allow the microbeads to dissociate and facilitate cell count. The 
nattokinase solution was prepared as published [43]. 
Briefly, nattokinase (NSK-SD, Japan Bio Science Laboratory Co., Ltd) and EDTA were 
dissolved in Dulbecco's phosphate-buffered saline (DPBS, no Calcium, no Magnesium) at a 
concentration of 50 FU (fibrin degradation units) per mL and 1 mM respectively. Using a 
hemacytometer, a cell count was found and adjusted based on the original volume. Each implant 
contained approximately 2.4x106 total cells, half HUVECs and half NHLFs. This number was 
adjusted for each batch prior to injection, except for the pre-cultured implants. 
Nattokinase didn’t degrade the entire microbead matrix after 3 days of pre-culture. For this 
reason, the number of cells in the pre-cultured microbeads were quantified a day after they were 
made (day 1). Prior to cell quantification, pre-cultured microbeads were centrifuged at 200 g for 1 
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min, supernatant was removed, and 1 mL of media/microbead pellet was left in each tube. 10 mL 
of EGM-2 was replaced after cell counts of each batch were adjusted to 2.4x106 total cells/batch, 
and cultured for an additional two days (total 3 days).  
Acellular microbeads, cells only, or microbeads containing cells were centrifuged at 200 g 
for 1-5 min, supernatant was then removed. Samples were re-suspended in FIB hydrogel pre-
cursors. Each FIB hydrogel precursor was composed of 270 µL of SFEGM-2, 60 µL of FBS (10% 
final), 12 µL of thrombin (1 U/mL final), and 258 µL of fibrinogen stock solution (2.5 mg/mL 
final).  
The solution with the samples was well mixed and placed into a 5-mL syringe with a 20-
gauge x 1 inch BD PrecisionGlideTM Needle. Roughly 500 µL of the 600 µL solution was then 
injected into the animal, delivering approximately 2.0x106 total cells per cellular implant. 
 
4.2.6 Subcutaneous Injections 
CB17/SCID mice, 6 to 8 weeks old, (Taconic Labs, Hudson, NY) were acclimated for 72 
hours prior to beginning any surgical procedures. The animal protocol employed in this study was 
approved by the University of Michigan Committee on Use and Care of Animals. An 
analgesic/anesthetic drug mixture of ketamine (80-120 mg/kg), xylazine (5-10 mg/kg), and 
buprenorphine (0.05-0.01 mg/kg) was administered to each animal via intraperitoneal injection. 
Animals were returned to cages placed on top of a warm blanket until the anesthesia took effect. 
Ophthalmic ointment (Puralube® vet ointment, Dechra, Overland Park, KS) was applied to the 
eyes of each mouse. The dorsal lumbar flanks were shaved, and depilatory agent (Nair, Fisher 
Scientific, Pittsburg, PA) was applied to remove any remaining hair. The injection sites were 
sterilized by wiping the flanks with ethanol and betadine (Thermo Fisher Scientific, Fremont, CA).  
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A sterile surgical field was created prior to each injection, and the researchers followed sterile 
protocol (gloves, gowns, masks, etc.).  
Four experimental conditions were injected into the mice: Acellular microbeads, cellular 
hydrogel, control (freshly made, D0) microbeads, and pre-cultured (3 days post-fabrication) 
microbeads. The samples were prepared, mixed, and injected subcutaneously into the dorsal flank 
of the mouse. The needle was left in the injection site for ~30 seconds to allow the solution to gel. 
Two implants were injected per animal, one on each flank. A second dose of buprenorphine (0.05-
0.01 mg/kg) was administered to each animal 12 hours after subcutaneous injections. Animals 
were monitored every day post-surgery. 
 
4.2.7 Laser Doppler Perfusion Imaging (LDPI) 
Laser Doppler Perfusion Imaging (LDPI, Perimed AB, Sweden) was employed at discrete 
time points to non-invasively characterize blood perfusion to the implant regions. A minimum of 
three scans per animal were performed and then averaged to determine average blood perfusion 
through each implant. Scans were performed before implants were injected, immediately after 
implant injection, and at 3 and 7 days after injection. Animals were anesthetized (described in the 
previous section) prior to imaging.   
 
4.2.8 Implant Retrieval and Post-Processing 
After 3 or 7 days, animals were euthanized. Implants were removed with scissors and 
forceps and placed immediately in 20 mL glass bottles with Z-fix. Implants were fixed for 24 hours 
at 4 °C. Z-fix was removed, and implants were washed with PBS 3 to 4 times (5 min/wash). 70% 
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ethanol was then added to implants and left at 4 °C until further processing. Samples were then 
placed in pink cassettes (UNISETTE cassette with lid, Simport, Canada), embedded in paraffin 
using the tissue embedding processor (KD-BM II, KEDEE, China), and sectioned with a Thermo 
Scientific™ HM 325 rotary microtome (6 µm sections) for further analysis.  
 
4.2.9 Hematoxylin and Eosin (H&E) staining  
Sections were stained with Mayer’s Hematoxylin (Electron Microscopy Sciences 26252) 
and Eosin Y (Sigma HT110132). Slides were dewaxed with xylene twice (5 minutes/wash), and 
then transferred to 100%, 95%, 70% ethanol, and deionized baths (3 minutes/wash, two baths per 
ethanol concentration). Slides were submerged in hematoxylin bath for 15 minutes, and then rinsed 
with tap water for an additional 15 minutes. Slides were then placed in 95% ethanol for 30 seconds, 
followed by their immersion in Eosin for 1 minute. Slides were subsequently transferred into 95% 
ethanol bath for 1 minute, and 2 separate 100% ethanol baths (1 minute/bath). Samples were 
cleared by submerging them into 2 xylene baths (3 minutes/wash). Toluene mounting solution was 
added to each slide prior to placing the cover-slips. Slides were left to dry prior to imaging. 
 
4.2.10 CD31 and Alpha-Smooth Muscle Actin (α-SMA) Staining  
The location of each implant within the explanted tissue section was first identified with 
H&E staining. The subsequent serial section of each implant was then deparrafinized with xylene 
and then rehydrated through a series of graded ethanol washes and ending with water. Slides were 
placed in antigen retrieval solution (Dako, Carpinteria, CA) and placed in steamer (95- 99 °C) for 
35 minutes. The antigen retrieval solution with the samples was then removed and left until room 
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temperature was reached. Slides were rinsed 3x with tris-buffered saline (TBS-T), 2 min/wash. 
The area around the tissue was marked with an ImmEdge™ pen (Vector Laboratories, Inc., 
Burlingame, CA). The Dako EnVision System-HRP (DAB) kit (Dako) was utilized for CD31 
staining. Slides were rinsed with TBS-T (3 times, 2 minutes/wash) before any solution from the 
Dako kit was added to the samples. First, peroxidase blocking solution was added to each tissue 
for 5 minutes. Dako mouse anti-human CD31 primary antibody (1:50 dilution in TBS-T) was then 
added to each tissue and kept at 4 °C for 16 hours.  
The HRP-conjugated anti-mouse secondary antibody was added to each sample and left 
for 30 minutes. Samples were then kept with DAB+ substrate-chromogen buffer solution for 5 
minutes. A negative control reagent was used in some samples to confirm the specificity of the 
staining. Most samples were counter-stained with hematoxylin and/or eosin. Slides were then 
washed with 95% ethanol, 100% ethanol, and xylene. Toluene mounting medium was added prior 
to covering the samples with cover-slips.  
The Dako EnVision System-HRP (DAB) kit (Dako, Carpinteria, CA), antigen retrieval, 
dewaxing, and dehydration/hydration steps described above were also used in the alpha-smooth 
muscle actin (α-SMA) staining process. The only differences between the CD31 staining and the 
α-SMA staining were that smooth muscle actin monoclonal antibody (1A4 (asm-1)) (Invitrogen: 
Thermo Fisher Scientific) was used as the primary antibody, and its two-hour incubation time was 
at room temperature.  
 
4.2.11 Vessel Quantification 
Bright-field images (4x and 20x) of each complete implant were taken with an inverted 
Nikon microscope (Nikon Instruments Inc., Melville, NJ). A minimum of four 20x CD31 images 
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from each implant were quantified to determine average vessels per implant. A vessel was 
considered any area defined by the presence of a lumen with red blood cells inside and marked 
with a complete brown rim of positive human CD31 staining. A one-sided blinded study was 
performed by re-labeling all samples to prevent any bias by those assigned to manually count 
vessels. Auto stitch software, developed by Brown and Lowe [44], was utilized to create complete 
images of each implant from the 4x images taken. The total area of each implant was quantified 
using ImageJ. The number of vessels per selected implant area was found by multiplying the 
average vessel number times the number of times a 20x image fitted into each complete implant 
region. 
 
4.2.12 Implant Shear Modulus Measurement 
Implant preparation was done similarly to the protocol employed for subcutaneous 
injections (see section 4.2.5). Once the samples were re-suspended in fibrin hydrogel precursors, 
rather than injecting them into the animal, they were pipetted into wells of 24-well plates and left 
in the incubator for 25 to 30 minutes for gelation to occur. EGM-2 media was added on top of 
hydrogels, and samples were left in the incubator overnight. The shear modulus of the hydrogels 
was characterized using a TA instruments AR-G2 rheometer with an 8-mm parallel-plate 
geometry. The top plate was lowered towards a sample hydrogel in a stepwise manner (50 to 100 
microns) from a height that is greater than the theoretical height of a 500 µL hydrogel in a 24-well 
plate. At each step height, the shear modulus of the hydrogel was evaluated and recorded. As the 
gap decreased, the shear modulus versus height curve switched from a gradual linear regime to a 
steeper linear regime. The nominal hydrogel shear modulus and height were evaluated by finding 
the intersection of these two linear regime tangent lines. Samples were kept at 37 °C while 
92 
 
measurements were being taken to prevent changes in the samples’ properties while measurements 
were recorded. Shear moduli of D0 implants were measured by pipetting the implant and fibrin 
solution directly on top of the rheometer stage prior to gelation. The sample was left on the stage 
for 45 minutes to allow for complete gelation and to acquire the shear modulus curve.  
 
4.2.13 Measurement of Implant Volumes  
Cellular implants were prepared the same way as described in section 4.2.5. Instead of 
injecting them into the animals, the same implant volume (500 µL) was pipetted into transparent 
caps of 5 mL Eppendorf Tubes® that had been placed in wells of 6-well plates. Samples were then 
placed in the incubator for 25 to 30 minutes at 37 °C to allow complete gelation. To prevent 
samples from drying, 6 mL of EGM-2 was added to each construct, and constructs were then 
flipped upside-down and left in the incubator overnight. Spectral ultrasound imaging (SUSI) was 
employed using the Vevo 770 (VisualSonics Inc., Toronto, Canada) with the same 
parameters described previously [45] to image cellular implants and quantify their volumes. The 
implant volumes were normalized to the volume of the pre-cultured condition, which was found 
to be close to 500 µL, the expected initial implant volume. Implant volume for each test condition 
was averaged over three implants.   
 
4.2.14 Regional Mechanical Testing using Dual-Mode Ultrasound 
Elastography (DUE) 
After the samples were imaged with the Vevo 700 system (section 4.2.13), the viscoelastic 
properties of the fibrin hydrogels with microbeads and cells were measured using the dual-mode 
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ultrasound elastography (DUE) technique. This technique can measure viscoelastic properties at 
the microscale, non-invasively. Samples were compressed using acoustic radiation force (ARF) 
produced by a 2 MHz focused ultrasound (FUS) transducer with a circular aperture (H148; Sonic 
Concepts, Woodinville, WA). Simultaneously, an ultrasound imaging system ran in M-mode with 
a 10 MHz transducer (Olympus, Waltham, MA; 55 mm focal distance, - 6 dB beam width of 1 
mm) measured the samples’ deformation caused by the compression. This methodology along with 
additional information on experimental set-up and calibration has been previously published [46]. 
Prior to starting FUS compressions, a pulser-receiver (5900 PR; Olympus) was used to 
drive the imaging transducer at a 1 Hz pulse repetition frequency (PRF) for 20 seconds to first 
determine the base-line signals for the sample at undeformed state. FUS pulses (pulse duration: 
0.99 seconds or 99% duty cycle) at 1 Hz PRF were then applied for 3 minutes while ultrasound 
imaging pulses (pulse duration of 0.4 µs or duty cycle of 0.00004%) were applied simultaneously, 
to assess the deformation done by the FUS pulses. A pulse/delay generator (Model 565; BNC, San 
Rafael, CA) and two waveform generators (33220A; Agilent, Santa Clara, CA) synchronized the 
FUS and imaging pulses. 
The 99% duty cycle for the FUS pulses put the sample under a nearly constant compression 
load while permitting detection of sample deformation with ultrasound imaging. The transducer 
received the backscattered radio frequency (RF) signals during, before, and after FUS compression 
to determine deformation (strain) of the material. Three individual samples for each condition were 
analyzed; four different locations from each implant were averaged to obtain the average 




4.2.15 Viscoelastic Properties’ Analysis and Burger's Viscoelastic Model 
Fitting 
The viscoelastic properties of each implant were determined by fitting the creep data to the 
Burger’s viscoelastic model, as previously shown [46, 47]. This model combines both the spring 
and dashpot in series (Maxwell model) and the spring and dashpot in parallel (Voigt Model) (Fig. 
4-1). 
 
Figure 4-1: Burger’s viscoelastic model 
 
These viscous (𝜂1 and 𝜂2) and elastic (𝑅1 and 𝑅2) parameters as well as the viscoelastic 
creep constant, 𝜂2/𝑅2 [46, 48] – elements in the Burger model – are acquired by fitting the creep 
data to the following strain response equation [49] 
 



















4.2.16 Statistical Analysis 
Statistical analyses were performed using one-way ANOVA with Unequal N post hoc test 
using STATISTICA software (StatSoft. Inc, Tulsa, OK). For in vitro studies, 12 individual 
hydrogels were quantified to determine if there were differences between conditions, while 4 to 5 
random images of each implant (3 to 4 implants/condition) were quantified for in vivo studies. 
Data are reported as mean ± standard error. Values of p ≤ 0.05 were considered statistically 
significant. 
 
4.3  Results 
4.3.1 Overview of Microbead Study 
 
Figure 4-2: Experimental design of in vitro and in vivo vascular study. Fibrin microbeads containing human umbilical 
vein endothelial (HUVECs) and normal human lung fibroblasts (NHLFs) were made via emulsification process. Initial 
cell density was increased from 2M cells/mL for in vitro studies to 5M cells/mL for in vivo studies. Microbeads were 
embedded in fibrin hydrogels to determine the optimal microbead pre-culture condition for in vivo subcutaneous 
studies. Left and right implants show the acellular microbeads and cellular D0 microbeads after 7 days of injection, 




Fibrin microbeads containing HUVECs-NHLFs co-cultures were made via an 
emulsification process, and were immediately embedded in acellular fibrin hydrogels immediately 
or after being pre-cultured (Fig. 4-2). For in vitro studies, microbeads were pre-cultured for 1, 3, 
5, and 7 days and embedded and kept in culture for an additional 7 days. In subcutaneous studies, 
cellular microbeads were injected right away or after 3 days in culture. Acellular microbeads 
(negative control) and cells (positive control) were also injected. All implants were first re-
suspended in a fibrin hydrogel precursor prior to injection. Implants were left in mice for 3 and 7 
days. The left and right panels under the in vivo model in Fig. 4-2 show acellular microbeads (left) 
and D0 cellular microbeads (right) extracted 7 days after being injected subcutaneously. 
 
4.3.2 Microbead Pre-culture and In Vitro Characterization 
 
Figure 4-3: Endothelial sprout formation occurred inside HUVECs-NHLFs fibrin microbeads without the need of an 
additional fibrin microenvironment. Bright-field images show that cells from microbeads migrated into the 
surrounding fibrin hydrogels (A-D), while cells from microbeads with no additional surrounding matrix had limited 
mobility (E-H). Merged images of microbeads (D) embedded in fibrin hydrogels for 1 week, or (H) kept in tube culture 
for 7 days without embedding show endothelial sprouting formation within the microbeads. Nuclei of endothelial cells 
and fibroblasts were stained with DAPI - blue (A, E), and endothelial cells were stained in red with UEA-I (B, F).  




As previously shown [25], endothelial cells encapsulated with fibroblasts in fibrin 
microbeads form sprouts within the microbead and outside the microbeads when embedded in 
fibrin hydrogels right after being made. The nuclei of endothelial cells and fibroblasts within and 
around the microbeads (Fig. 4-3E) and within and around the microbeads and fibrin hydrogel can 
be seen (Fig. 4-3A). UEA-I images show that endothelial cells will remain in the microbeads (Fig. 
4-3F) unless microbeads are embedded in an additional fibrin matrix (Fig. 4-3B). Bright-field 
images were taken to demonstrate that some microbeads were (Fig. 4-3C) embedded in a fibrin 
hydrogel, while others were cultured statically in a tube for 7 days without an additional matrix, 
and then transferred to a tissue culture dish for imaging (Fig. 4-3 E-H). The DAPI/UEA-I/bright-
field merged images are shown in Fig. 4-3D, H. It can be observed in Fig. 4-3H that although 
microbeads are not embedded in an additional extracellular matrix, cells within the microbeads 
still migrate towards each other during the pre-culture period. 
 
 
Figure 4-4: Proof of concept - Pre-cultured microbeads form endothelial sprouts and can inosculate with other sprouts 
from neighboring microbeads after being embedded in 3D fibrin hydrogels. (A) Microbeads were pre-cultured for 7 
days and (B) embedded in a fibrin hydrogel for an additional week to allow inosculation to occur. Scale bar – 100 µm. 
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After FIB microbeads were kept in static culture for 7 days, endothelial sprouts formed 
within the FIB matrix (Fig. 4-4A). The D7 fibrin microbeads were then embedded in fibrin 
hydrogels and kept in culture for an additional week (Fig. 4-4B). Similar to the endothelial cells 
encapsulated in microbeads and embedded in fibrin hydrogels immediately after fabrication (Fig. 
4-4 A-D), the endothelial cells in the D7 microbeads also formed sprouts after being embedded for 
7 days (Fig. 4-4B). 
 
 
Figure 4-5: Pre-culture time affects endothelial tube coverage. Microbeads were pre-cultured for (A) 1 day, (B) 3 days, 
(C) 5 days, and (D) 7 days, and then embedded in fibrin hydrogels for an additional 7 days. (E) The pre-culture time 
with the most endothelial network coverage was found to be 3 days. Inset shows regions of the hydrogel that were 
magnified and adjusted with a Kirsch filter to facilitate edge detection and software quantification. Scale bar of 
hydrogels is 4 mm, and 500 µm for insets. 
 
Fibrin microbeads were then pre-cultured for 1 (Fig. 4-5A), 3 (Fig. 4-5B), 5 (Fig. 4-5C), 
and 7 days (Fig. 4-5D) and embedded in fibrin hydrogels for an additional week to determine the 
pre-culture time that would provide higher endothelial coverage within the fibrin hydrogels. Insets 
show close-up regions in the hydrogels where endothelial sprouting occurred. A reduction in 
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endothelial cell coverage within the fibrin hydrogel was found with longer pre-culture times (Fig. 
4-5E). D3 pre-culture time was employed in subcutaneous studies as it produced a higher tube area 
coverage. 
 
4.3.3 Laser Doppler Perfusion Imaging  
Laser Doppler perfusion images were taken immediately after implant injection (Fig. 4-
6A, B), creating a pocket in the implant site and preventing blood perfusion from occurring within 
the injection areas. The left implant contained acellular microbeads in a fibrin hydrogel, while the 
right implant was the cellular hydrogels. It appears, qualitatively that after 3 days (Fig. 4-6C), 
blood perfusion did not seem to differ between the acellular and cellular implants. In addition, it 
did not differ much from the blood perfusion image of the mouse with no implants (Fig. 4-6D). 
  
 
Figure 4-6: Laser Doppler Perfusion Imaging. Image of mice implant selection immediately after implantation (A), 
LDPI image of the implants: acellular microbeads on the left and cellular hydrogel on the right (B) immediately after 
injection, (C) 3 days after injection, and (D) with no implant injection – normal blood perfusion. 
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Quantification of the images are shown in Fig. 4-7. As seen from the images, the percent 
relative perfusion decreased by about 50% after the injections of the implants. After 3 and 7 days, 
the percent relative perfusion returned to normal. No statistical differences were found between 
the percent relative perfusion between D3 and D7 implants.    
 
 
Figure 4-7: Percent relative perfusion decreased after implants were injected, and returned to normal after 3 days in 
the animal.  
 
4.3.4 Vessel Formation and Cell Infiltration in Subcutaneous Implants   
Acellular microbeads (Fig. 4-8 A, E), cellular hydrogels (Fig. 4-8B, F), control microbeads 
(Fig. 4-8C, D), and pre-cultured microbeads were extracted from the mouse after 3 (Fig. 4-8 A-
D), and 7 days (Fig. 4-8 E-H) post injection. Tissues were processed, stained with H&E, and 
imaged at 20x. Eosin stained the fibrin microbeads and the surrounding hydrogel injected, while 
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the Hematoxylin stained the human endothelial cells and fibroblasts in the implants as well as the 
host cells. Host cells infiltrate between acellular microbeads both after 3 and 7 days (Fig. 4-8A, 
E). Endothelial vessels were found in cellular hydrogels, control microbeads, and pre-cultured 
microbeads after 7 days in situ (Fig. 4-8 F-H). Some endothelial vessels were also distinguishable 
after 3 days in situ in the pre-cultured microbead condition. Black circles with a “B” next to them 
highlight microbeads in the implants. Black asterisks show mouse red blood cells, while black 
arrows point at blood vessels formed within the implants. 
 
 
Figure 4-8: Hematoxylin and Eosin staining show vessel formation and cell infiltration in implants. Control 
microbeads (A, G), pre-cultured microbeads (B, H), acellular microbeads (C, E), and cellular hydrogels (D, F) were 
injected in the back of the mice for 3 days (A-D) and 7 days (E-H). Black dashed circles with a letter “B” highlight 
microbeads within the implants, black asterisks identify red blood cells within the implant regions, while black arrows 
show vessels. Scale bar – 100 µm. 
 
4.3.5 Pre-cultured Microbeads Inosculate with the Host Vasculature    
Pre-cultured microbeads were injected into the animal and extracted after 3 (Fig. 4-9 A-C) 
and 7 days (Fig. 4-9 D-G). The implant region was found by staining the samples with CD31 to 
locate the microbeads containing human endothelial cells (brown). Tissues were counter-stained 
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with hematoxylin and eosin to facilitate the visualization of the implant and the host cells and 
vasculature. Fig. 4-9A shows the implant region with the endothelial cells along with the mouse 
tissue and vasculature. The mouse vessels (white arrows) are not stained with anti-human CD31. 
This demonstrates that anti-human CD31 is only specific to human endothelial cells. A magnified 
image of the pre-cultured microbead implant (Fig. 4-9B) shows a vessel (white asterisk) 
characterized by a brown anti-human CD31 rim surrounding red blood cells (white asterisks). 
 
 
Figure 4-9: Pre-cultured microbeads injected in the animal for 3 and 7 days inosculate with the host vasculature and 
form endothelial vessels.  Hematoxylin, eosin, and CD31 staining of D3 pre-cultured microbead implants and 
surrounding tissue 3 days (A-C) and 7 days (D-G) post-implantation. White arrows show mouse vasculature, white 
asterisks highlight regions of red blood cells, and black arrows display the mouse nerve, “N”, artery, “A”, and vein, 
“V”, close to the microbead implant. Black rectangles show connections formed with mouse and human cells (F, G). 
The inset in G shows a magnified version of the chimeric vessel to demonstrate that there are red blood cells within 




Eosin staining is not necessary to locate the implant and the host tissue/ vasculature (Fig. 
4-9C). In addition to the implant, the mouse vein “V”, artery “A”, and nerve “N” complex was 
found close to the implant (black arrows). Mouse and human endothelial vessels were found near 
each other after pre-cultured microbeads were in the host for 7 days (Fig. 4-9 D-E). Black 
rectangles (Fig. 4-9 F-G) show a connection between human endothelial cells (in brown) and 
mouse endothelial cells (not stained). A vessel formed from human and mouse endothelial cells 
with red blood cells was found in Fig. 4-9G (chimeric vessel). A magnified version of the rectangle 
is shown in the bottom left corner of the image as an inset to highlight the red blood cells (Fig. 4-
9G). 
 
4.3.6 Quantification of Vessel Density, Area, and Total Vessel Count 
Average vessel quantification was done by staining samples with CD31 and hematoxylin 
(Fig. 4-10). Acellular microbeads (Fig. 4-10 A-D), cellular fibrin hydrogels (Fig. 4-10 E-H), 
control microbeads (Fig. 4-10 I-L), and pre-cultured microbeads (Fig. 4-10 M-P) were extracted 3 
days (Fig. 4-10 A, B, E, F, I, J, M, N) and 7 days (Fig. 4-10C, D, G, H, K, L, O, P) after being 
injected in mice. The second (Fig. 4-10B, F, J, N) and fourth columns (Fig. 4-10 D, H, L, P) show 
magnified areas (40x) of the first and third column, respectively. No significant differences in the 
average vessel count per mm2 (vessel density) were found between any cellular implant type at 
day 3 (Fig. 4-10Q) or day 7 (Fig. 4-10R).  
Representative images of CD31 positive (+) areas were measured in control microbeads 
(Fig. 4-11A, D), pre-cultured microbeads (Fig. 4-11B, E), and cellular hydrogels (Fig. 4-11C, F). 
The differences in the average CD31+ area, mm2, and the total number of vessels per implant area 
after 3 and 7 days are displayed in Fig. 4-11G and H. Control microbeads and fibrin hydrogels had 
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a similar CD31+ areas (Fig. 4-11G) and total number of vessels within these areas (Fig. 4-11I) 
after 3 days’ post implantation. Whereas, pre-cultured microbeads had a wider CD31+ area and 
higher total number of vessels per selected implant area at the same time point. Statistical 
differences were found between pre-cultured microbeads and the other cellular conditions as well 
as the acellular microbeads (p ≤ 0.05). After 7 days in the host, control microbeads (Fig. 4-11D) 
and pre-cultured microbeads (Fig. 4-11E) had similar CD31+ areas that were higher than both the 
acellular microbeads and cellular hydrogels (Fig. 4-11F). However, statistical differences in 
CD31+ area after 7 days were only found between the two cellular microbead conditions and the 
acellular one (Fig. 4-11H). In addition, statistical differences in number of vessels per implant 





Figure 4-10: No significant differences were found in the average number of vessels per area between any of the 
implants that contained human endothelial cells after 3 and 7 days after injection. Control microbeads (A-D), pre-
cultured microbeads (E-H), acellular microbeads (I-L), and cellular hydrogels (M-P) were injected in the back of mice 
for 3 days (A, B, E, F, I, J, M, N) and 7 days (C, D, G, H, K, L, O, P) and stained with CD31. Human endothelial cells 
were found (brown) within all implants except for acellular microbeads. Quantification of endothelial vessels for each 
condition after 3 days (Q) and 7 days (R) is displayed in rectangular plots. The average is shown in black dots, the 
standard error is highlighted by the bottom and top of the rectangles, and the min and max points are displayed with 
the whiskers. No differences between cellular conditions were found at day 3 or day 7. Scale bar – 100 µm (20x 




Figure 4-11:  Pre-cultured microbeads, on average, had a bigger implant area and higher number of vessels in implant 
than other cellular conditions. Representative images of entire implant areas were taken (A-F). Control microbeads 
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(A, D), pre-cultured microbeads (B, E), and cellular hydrogels (C, F) were left in the animal for 3 (A-C), and 7 days 
(D-F). All implants were labeled differently during experiment to avoid tissue processing bias. All tissues were excised 
and average implant areas were found after 3 days (G) and 7 days (H). Total numbers of vessels in selected implant 
areas were then calculated and displayed (I, J). After 3 days in subcutaneous model, D3 microbead implant size was 
found to be bigger than the other conditions. The total number of vessels per implant was also higher in D3 microbead 
implants compared to control microbeads (p = .04 < 0.05) and cellular hydrogels (p = 0.08 < 0.10). No significant 
differences were found between implant areas or total number of vessels of D7 implants. The average is shown in 
black dots, the standard error is highlighted by the bottom and top of the rectangles, and the min and max points are 
displayed with the whiskers. 
 
4.3.7 Vessel Maturity via Alpha-Smooth Muscle Actin Staining 
 
Figure 4-12: Alpha-smooth muscle actin staining (black arrows) in Day 3 (A,E) control microbeads, (B,F) pre-cultured 
microbeads, (C,G) acellular microbeads, (D,H) cellular hydrogels at (A-D) 10x and (E-I) 40x magnification. (I) 
Animal tissue with vessel surrounded by smooth muscle cells at 40x magnification. Black scale bar – 100 µm, and 
white scale bar – 50 µm.  
 
Day 3 and 7 implants were stained with alpha-smooth muscle actin (α-SMA) antibody to 
assess the presence of smooth muscles within these implants. There was little to no presence of 
smooth muscle cells (α-SMA, brown stain with black arrows) within day 3 (Fig. 4-12A, E) control 
microbeads, (Fig. 4-12B, F) pre-cultured microbeads, (Fig. 4-12C, G) acellular microbeads, and 
(Fig. 4-12D, H) cellular hydrogels (Fig. 4-12). Images were magnified from (Fig. 4-12 A-D) 10x 
to (Fig. 4-12 E-I) 40x to highlight the stain. Positive α-SMA staining was observed in the outer 
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region of a vessel found outside of the cellular implant area, displayed at the top left corner of Fig. 
4-12D, and magnified in Fig. 4-12I.  
 After an additional 4 days, 7-day (Fig. 4-13A, E) control microbeads, (Fig. 4-13B, F) pre-
cultured microbeads, (Fig. 4-13 C, G) acellular microbeads, and (Fig. 4-13D, H) cellular hydrogels 
implants displayed a stronger α-SMA staining compared to day 3 (Fig. 4-12). Once again, 10x 
images (Fig. 4-13 A-D) were magnified (Fig. 4-13 E-H) to highlight the staining while black 
arrows indicated α-SMA positive regions within the implant. Pre-cultured microbeads (Fig. 4-13B, 
F) had the highest amount of stromal cell presence within their implant, followed by cellular 
hydrogels (Fig. 4-13D, H), and control microbeads (Fig. 4-13A, E). A weak α-SMA staining was 
found in some of the outer areas of the acellular microbeads (Fig. 4-13C, G). 
 
 
Figure 4-13: Day 7 (A, E) control microbeads, (B,F) pre-cultured microbeads, (C, G) acellular microbeads, (D,H) and 
cellular hydrogels containing smooth muscle cells (black arrows) around or inside the implant at (A-D) 10x and (E-
H) 40x magnification. Black scale bar – 100 µm, and white scale bar – 50 µm. 
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4.3.8 In Vitro Mechanical Characterization of Implants 
Volume Measurements (Implant Compaction) 
In vitro implant volume was measured the day after implant production. There were no 
changes in volume of the fibrin gels containing the pre-cultured microbeads (Fig. 4-14A). The 
implant volumes of the control microbeads and cellular hydrogels were normalized to the pre-
cultured volume and found to be lower. There was an approximately 0.17 relative decrease in the 
volume of control (not pre-cultured) microbeads (Fig. 4-14B) and 0.47 decrease in volume of 
cellular hydrogel implants (Fig. 4-14C), compared to the pre-cultured microbeads. All volumes 
were found to be statistically different from one another (Fig. 4-14D). 
 
 
Figure 4-14: Pre-cultured microbeads implants don’t compact after 1 day of in vitro culture. Ultrasound 3D images of 
pre-cultured microbeads (A), control microbeads (B), cellular hydrogels (C). Black lines and arrows show the bottom 
of the implant and 3 mm scale bars are displayed as white vertical lines. (D) Relative implant volume was calculated 
based on pre-cultured microbead implants which volumes were not altered after 24 hours of in vitro culture.   
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Implant Macro/Bulk Rheology Measurements 
As cellular samples gelled, their shear moduli were measured. Acellular hydrogels were 
also measured and compared to previously collected data for measurement validation (data not 
shown). Fig. 4-15 shows the shear modulus versus time for implants during the gelation process. 
Cellular hydrogels had the highest shear modulus (G’), followed by the control microbeads, pre-
cultured microbeads, and acellular hydrogels, which had the lowest shear modulus (Fig. 4-16). All 
implants were statistically different from each other, with the exception of the pre-cultured 
microbeads and acellular fibrin hydrogels (Fig. 4-16A). 
 
 
Figure 4-15: Addition of cells and cellular microbeads into fibrin hydrogels increases the implants’ shear modulus (in 
vitro study). Cellular hydrogels and control microbeads have a higher shear modulus (G’, Pascal) than acellular fibrin 
hydrogels (control microbeads>cellular hydrogels>acellular hydrogels). Pre-culturing the microbeads decreases the 
shear modulus, lower than both control microbeads and cellular hydrogels. Graph shows average and standard error 
of the mean.   
 
The shear modulus of the implants left overnight increase, except for the cellular hydrogels 
(Fig. 4-16). However, the only statistical difference found after one day was the shear modulus of 
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control microbeads (Fig. 4-16). The shear modulus of the pre-cultured microbeads was also higher 
when the implants were left overnight, but not statistically different.  
 
Figure 4-16: Shear modulus of all implants, except of cellular hydrogels, increased when left in-culture overnight. 
Shear modulus of all the cellular implants and acellular hydrogels were found immediately during their gelation (A) 
or after being in-culture overnight (B).  
 
 
Figure 4-17: Cells migrate from microbeads into fibrin hydrogels. Bright-field images of control (A,B)  and pre-
cultured (C,D) microbeads (3x106 total cells/mL - initial  cell density) embedded in fibrin hydrogels for 3 (A,C) and 
7 days (B,D). Scale bar – 500 µm. 
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Control and pre-cultured microbeads were embedded in fibrin hydrogel for 3 and 7 days. 
Cells encapsulated in the acellular hydrogel begin to move out of the microbeads into the 
hydrogels. The bright-field images show that fewer cells are coming out of the pre-cultured 
microbeads than the control microbeads (Fig. 4-17). This observation is more clear when 
microbeads are left in the fibrin hydrogels for 3 days (Fig. 4-17A, C) rather than 7 days (Fig. 4-
17B, D) since there is less time for cells to remodel the matrix.   
For these observations, a lower initial cell density (2x106 cells/mL of microbead volume) 
was used to enhance visible differences in the number of migrated cells. At the higher density used 
for the implants (5x106 cells/mL of microbead volume), the fibrin hydrogel was crowded in all 
cases, and migration differences were obscured (data not shown). 
 
Microscale Implant Characterization  
 
Figure 4-18: Pre-cultured microbeads had lower strain % compared to both control microbeads and cellular hydrogels. 
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To determine what the cells can sense within a region of the implant, regional mechanical 
measurements were taken using the dual-mode ultrasound elastography (DUE). This technique 
allows for surface deformation measurements within the microbead and hydrogel interface, rather 
than the entire deformation measured with the rheometer. Strain % versus time of the cellular 
implants are shown in Fig. 4-18. The strain was highest in the implants containing cells only 




Figure 4-19: Parameters of implants calculated using the Burger’s Viscoelastic model. (A) R1, (B) 𝜂1, (C) R2, and (D) 
the creep time constant (𝜂2/R2).  
 
The immediate elastic response of the material to stress is controlled by the elastic modulus 
𝑅1. Therefore, a stiffer material has a bigger R1, and a smaller strain results. Pre-cultured 
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microbeads have the highest R1, followed by control microbeads and cellular hydrogels with the 
lowest R1 value (Fig. 4-19A).  
The viscous damping parameter in the Burger’s model, η1, was higher in the pre-cultured 
microbeads than the other two cellular implants (Fig. 4-19B). This parameter is theoretically the 
zero-shear viscosity (viscosity for a very weak stress), and it controls the rate of plastic (non-
recoverable) deformation in creep. The larger the value of η1, the more viscous the material is. Pre-
cultured microbeads seem to be more viscous than the control microbeads and the cellular 
hydrogels (statistically higher). R2 is the retarded modulus and controls the long-term viscoelastic 
creep response. At long time, R2 behaves like the stiffness R1, but achieving the strain requires 
maintaining the stress long enough to overcome a viscous resistance. Once again, the pre-cultured 
microbeads had a statistically higher R2 value than the control microbeads, and cellular hydrogels 
(Fig. 4-19C). The creep time constant, 𝜂2/𝑅2, controls the rate of viscoelastic response. The smaller 
the time constant, the faster the material responds after the immediate strain [46]. No statistical 
differences were found between the creep time constants of the three cellular implants (Fig. 4-
19D).     
 
4.4  Discussion 
Although current tissue engineering approaches including in vivo and in vitro pre-
vascularization techniques have potential to re-vascularize ischemic regions, open surgery is still 
required to implant the pre-vascularized tissue in the injured site. Unfortunately, CLI patients who 
suffer from other chronic diseases such as diabetes may be ineligible for open surgery due to 
additional complications. Therefore, it is important to develop an alternative solution to re-
vascularize ischemic regions without the need of major surgery.  
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Modular vascular tissue engineering approaches may provide an alternative path to open 
surgery, since these microtissues can be injected via syringe. The microtissue approach meets the 
requirements and flexibility of macro tissues such as being developed with different cell types, 
densities, and biomaterials; and they permit sprout formation and/or blood perfusion. In addition, 
these modular microtissues are scalable and moldable into different vascularized constructs. [31-
33, 50]  
Even though modular microtissues with an exterior coating of endothelial cells have shown 
vascular potential in vitro and in vivo [51], we sought to pre-vascularize microtissues by 
encapsulating cells within a matrix. We encapsulated HUVECs and NHLFs in a 1:1 ratio in fibrin 
microbeads to form vessels within the microtissues via pre-culture, to allow for minimally invasive 
delivery via injection, and to inosculate with the host vasculature. Fibrin was employed because it 
improves cell survival during injection [42], and it promotes wound healing and endothelial sprout 
formation in particular [25, 52]. Additionally, fibrin structure, permeability, clotting rate, and 
polymerization rate can be modified [53, 54], making it an ideal material for microtissue 
development. 
Endothelial sprouting occurred after control microbeads (freshly made, D0) were 
embedded in a fibrin matrix and cultured for one to two weeks in vitro. Cells encapsulated in fibrin 
microbeads formed vessels in static pre-culture for up to 7 days without the need of embedding 
them in an additional fibrin matrix. And once embedded, like control microbeads, endothelial 
sprouts from adjacent pre-cultured microbeads also formed connections with each other within the 
fibrin matrix in vitro.  
Pre-culture time was investigated by quantifying the percent area covered by endothelial 
tubules in a model tissue. Microbeads were pre-cultured for 1, 3, 5, and 7 days prior to being 
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embedded in acellular fibrin hydrogels. The percent tube coverage area was greatest with 3 days 
of microbead pre-culture time; longer pre-culture times led to lower tube area coverage, which 
could be due to aggregation of microbeads, causing a more localized and less homogenous 
microbead distribution within the fibrin hydrogel (see Chapter 5).  
Microbeads and/or cells (control microbeads, pre-cultured microbeads, acellular 
microbeads, and cells) were delivered with a mixture of fibrin precursor, FBS, and thrombin into 
the animal. Blood perfusion within the resulting implants was measured using LDPI immediately 
after implantation and prior to implant removal (days 3 and 7). The results from this technique 
were not accurate when compared to the histological data. This could be because the implants are 
surrounded by vascularized host tissue, and they compact differently, making it difficult to track 
their locations with time and obtain accurate blood perfusion readings.  
The implant regions were excised, embedded in paraffin, and sectioned 3 and 7 days after 
implant injections. Samples were then stained with hematoxylin and eosin to locate the implants 
within the host tissue embedded in the paraffin blocks. Host cell infiltration was observed in all 
cellular and acellular implants. Anti-human CD31 staining was then used to identify the implanted 
human endothelial cells and distinguish them from mouse ECs. Both human and mouse vessels 
were found within the implant region, corroborating the specificity of the antibody due to the lack 
of cross-reactivity with mouse endothelial cells. Red blood cells found in the lumens formed by 
human endothelial cells demonstrate that inosculation occurred between the host vessels and the 
human vessels within the implant area. 
There were no statistical differences in number of vessels/mm2 of the cellular implants at 
day 3 or day 7. The cellular hydrogels had a higher average number of vessels/mm2 than the two 
microbead types at day 7, but a wider variability between each sample, unlike the control and pre-
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cultured microbeads. The average CD31+ area of each implant gave a measure of total vessel 
coverage within an implant section. Three days after implant injections, the pre-cultured 
microbeads had a statistically larger vessel coverage compared to the other cellular implants and 
the acellular microbeads. The vessel coverage area of the control microbeads increased when the 
implants were kept in the animal for an additional 4 days (7 days total). This area was similar to 
the area of the pre-cultured microbead implant at the same time point. Cellular hydrogel CD31+ 
area was also smaller than the pre-cultured microbeads on day 3 and did not increase by day 7, 
suggesting that cellular hydrogels compacted. 
The cellular hydrogel implant had both small CD31+ area and the highest number of 
vessels/mm2, suggesting that compaction increased vessel density. An increase in number of 
lumens/mm2 due to compaction has been previously observed in an in vitro model developed by 
Morin et al. [14]. In addition, the CD31+ area data suggests that implants containing microbeads 
did not compact as much as the cellular hydrogels, especially if pre-cultured prior to being 
embedded. Despite having the highest number of vessels/mm2, the cellular hydrogel did not have 
the highest total number of vessels.  
The CD31+ area (mm2) was multiplied by the number of vessels/mm2 to approximate the 
total number of vessels found within the implant at days 3 and 7. The total number of vessels in 
the cellular hydrogels was lower than the number of vessels found in the pre-cultured microbead 
implant. However, the control microbeads had the lowest total vessel number as it had a low 
average number of vessels/mm2 and the smallest CD31+ area. When the implants were kept for an 
additional 4 days (day 7), the total number of vessels within the control microbead implant was 
similar to that of the pre-cultured microbead implant at day 3. This suggests that it takes 4 
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additional days for the endothelial cells in the control microbead implant to form as many vessels 
as the pre-cultured microbeads.  
Many factors characterize vessel maturity and functionality including the expression of 
physiological markers and the presence of perivascular mural cells [55]. The presence of smooth 
muscle cells in the outer regions of the vessel is particularly linked to vessel maturity [56-58]. 
Therefore, day 3 and day 7 implants were stained with α-SMA to determine the maturity of the 
vessels within the implant. At day 3, mature vessels were found in the mouse tissue while the 
cellular implants contained some weak α-SMA expression. On the other hand, the cellular implants 
after 7 days in the host displayed a higher expression of α-SMA. However, it appeared that smooth 
muscle cells presence was higher in the outer regions of the implants and lower in the center (data 
not shown). Overall, pre-cultured microbeads had a higher α-SMA expression than all the other 
implants, suggesting that more mature vessels form in the pre-cultured microbeads condition.  
To characterize the compaction observed in implants in vivo, an ultrasound analysis was 
employed on implants cultured in vitro. Rather than injecting the implants into the animals, the 
same implant volume was pipetted into a cylindrical container, gelled at 37 °C, and left in culture 
overnight with media. A similar trend to in vivo implant compaction was found in vitro. Pre-
cultured microbead implants did not compact compared to an approximate 20% compaction in the 
control microbeads and ~50% compaction of cellular hydrogel implant relative to the pre-cultured 
microbead implants. Implants containing pre-cultured microbeads appeared to be denser than other 
materials based on the higher attenuation displayed in the ultrasound image of pre-cultured 
microbeads relative to the other constructs.  
The stiffness of each implant, during gelation and 24 hours after gelation, was measured 
using the rheometer. During the gelation process, the implants’ shear moduli were found to be 
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positively correlated with the implant compaction. The cellular hydrogels which had compacted 
the most over 24 hours had a higher shear modulus, while pre-cultured microbeads had less 
compaction and lower shear modulus. Control microbeads were between the two conditions in 
both compaction and shear modulus. However, when the implants’ shear moduli were measured 
after 24 hours, the positive correlation with implant compaction no longer existed; control 
microbead implants became as stiff as cellular hydrogels and stiffer than pre-cultured microbead 
implants. The cellular hydrogel implant’s shear modulus did not vary during the 24 hours. In 
addition, the shear moduli of both the acellular hydrogel and pre-cultured microbeads were not 
statistically different.  
Our lab has observed that the addition of cells to the fibrin hydrogel increases the shear 
modulus of the hydrogel (data not shown). This suggests that cells encapsulated in the pre-cultured 
microbeads may take longer to infiltrate the remaining fibrin hydrogel than the ones residing in 
the control microbeads. This idea agrees with observations of slower cell migration from pre-
cultured microbeads after 3-day and 7-day embedding in the fibrin hydrogels.  
Since the microbeads embedded in the fibrin hydrogel make up about 25% of the entire 
implant volume, the stiffnesses of the microbeads/fibrin regions were measured to determine if 
they were different from the overall implant stiffness. Regional mechanical measurements were 
taken with dual-mode ultrasound elastography to determine the stiffness in the microbead/hydrogel 
area. The areas with pre-cultured microbeads in fibrin were found to be stiffer and more viscous 
than both areas with control microbeads and also homogeneous cellular hydrogel.  
We found that nattokinase, which degrades fibrin, could not degrade the fibrin microbeads 
after 3 days of pre-culture. Therefore, cells may be remodeling the microbeads and secreting 
additional matrix during pre-culture. This cellular remodeling of the pre-cultured microbeads may 
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compact, densify (based on ultrasound images), and stiffen the microbeads. Previous studies have 
shown that cell migration and matrix remodeling are dependent on material properties including 
ECM density and stiffness [59-62]. Likewise, the encapsulation of cells within stiffer/denser pre-
cultured microbeads may slow down further cell remodeling and migration into the remaining 
fibrin hydrogel compared to control microbeads and homogeneous cellular hydrogels. 
 
4.5  Conclusion 
This study demonstrated that pre-cultured microbeads embedded in fibrin hydrogels 
provide a wider implant area with a higher number of vessels, prevent further implant compaction 
upon implantation, and improve vessel quality compared to other cellular implants. By 
encapsulating HUVECs and NHLFs in fibrin microbeads, vessel formation within the microtissues 
can occur if pre-cultured statically, prior to injection. This is particularly important for future 
studies that will investigate the re-vascularization potential of the pre-cultured microbeads in 
ischemic regions, since cell survival time may be limited by the lack of oxygen and nutrients in 
the injection site of ischemic tissues [41]. Whereas immature cells might not survive long enough 
to form vessels from scratch, these pre-cultured microbeads could jump-start inosculation with 
pre-formed vessels to rapidly supply oxygen and nutrients for cellular implant survival. 
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Alternative Microbead Development for Distributed Vasculogenesis 
 
* Parts of Chapter 5, Copyright © 2017 Elsevier B.V. or its licensors or contributors 
 
5.1  Introduction 
Peripheral arterial disease (PAD) is caused by the obstruction/reduction of blood flow in 
the arteries due to atherosclerotic plaque formation. As PAD progresses, patients begin to 
experience pain in the limbs even at rest. This chronic and final stage of PAD, critical limb 
ischemia (CLI), can result in the loss of the affected limb due to ulceration or gangrene [1, 2]. 
Though CLI patients represent only 1% of all PAD sufferers, this condition is associated with 
significant rates of mortality (nearly 50% after 5 years) as well as a substantial economic burden 
[2]. 
CLI treatment involves restoration of blood flow to the extremities to prevent tissue 
necropathy and eventual amputation. While pharmaceutical options such as statin therapy are 
available to treat CLI [3], surgical interventions are sometimes employed if the patient is healthy 
enough for surgery. However, patients with medical co-morbidities may be poor candidates for 
highly invasive surgical procedures [2]. For these patients, it is advantageous to treat the ischemic 
tissue directly by repairing the microvasculature in a minimally invasive manner. Treating CLI in 
a more localized fashion may reduce ulceration and improve outcomes in diabetic patients.  
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Currently there is no specific treatment for the repair of damaged microvasculature that 
causes ulceration in CLI. However, by combining cells, growth factors and biomaterial scaffolds, 
a tissue engineering strategy offers a compelling and potentially minimally invasive means of 
promoting the repair of microvasculature in ischemic tissues. A variety of materials, cells, and 
growth factors have been employed to treat ulcers [4-6]. Modular tissue engineering offers a 
refinement of the tissue engineering strategy in which small scaffold “building blocks” can be 
generated and assembled into larger engineered constructs [7]. The use of engineered microtissues 
has been shown to reduce the oxygen and nutrient diffusion limitations that hamper larger 
constructs [8-13]. Moreover, microtissues can be designed to be delivered in a minimally invasive 
manner or assembled into macrostructures. 
A key consideration when developing engineered vascular microtissues is enabling the 
establishment of vascularization in vitro prior to implantation.  After implantation in an ischemic 
site, pre-vascularized microtissues could accelerate the restoration of the microvasculature by 
jump-starting anastomosis with blood vessels in the surrounding healthy tissue. In addition, pre-
vascularization may also improve the survival of the cells within the construct. A variety of 
materials and cell populations can be employed to engineer microtissues, depending on the 
application [14-21]. For re-vascularization strategies, pure fibrin and composites made from fibrin, 
agarose, collagen, and gelatin have been used to develop engineered tissues capable of supporting 
endothelial vessel formation [22-25]. 
Past work by our group has shown that cell-encapsulating fibrin and collagen-fibrin 
microtissues can foster endothelial sprout formation and inosculation in a three-dimensional (3D) 
in vitro model [25, 26]. In particular, we have used co-cultures of endothelial cells and stromal 
cells to promote vessel formation in engineered tissues. Paracrine signals provided by fibroblasts 
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or other stromal cells are important in the formation and stabilization of endothelial cell networks 
[23, 27-33]. In vitro studies have shown that endothelial sprout length is dependent on a variety of 
conditions, including extracellular matrix properties and stromal cell type [23, 25, 34].  
In the present study, we build upon our previous work by developing microtissues designed 
to promote widespread vascular network formation, using a defined combination of naturally-
derived, biomimetic biomaterials. Agarose is a relatively inert polysaccharide used in a variety of 
tissue engineering applications for structural support [21, 35]. It does not permit cell attachment, 
and therefore is often used in combination with other materials that facilitate cell adhesion and 
proliferation [36-38]. Hydroxyapatite (HA) is a main component of mineralized biological tissues 
that has been shown to adsorb and retain proteins [39-41], and may also promote vasculogenesis 
[42-44]. Fibrinogen (FGN) is a circulating precursor of the blood clotting protein fibrin, which is 
known to bind growth factors and proteins through its heparin-binding domain [45]. Incorporation 
of HA and FGN into agarose microtissues therefore provides a mechanically robust environment 
with the ability to sequester proteins and provide sites for cell attachment. Our goal was to combine 
these materials to create novel “microbeads” that exhibit: 1) higher production yield through a 
reduction in adhesion and aggregation, 2) improved injectability through reduced size and 
increased sphericity, and 3) more widespread vascular network formation via inosculation between 
sprouts from neighboring microbeads. 
 
5.2  Materials and Methods 
5.2.1 Cell Culture 
Human umbilical vein endothelial cells (HUVECs) from two different sources were used 
in these studies. For microbead characterization experiments, HUVECs were isolated from 
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umbilical cords obtained via an IRB-exempt process from the University of Michigan Mott 
Children’s Hospital using previously described methodology [34]. Umbilical cords were rinsed 
with phosphate buffer saline (PBS) prior to digestion. Collagenase type I solution (195 U/mL, 
Worthington Biochemical, Lakewood, NJ) was utilized to digest cords for 20 minutes at 37 °C. 
Digested tissues were rinsed with PBS and centrifuged at 200 g for 5 minutes. HUVECs were 
plated in T25 flasks with endothelial growth media (EGM-2, Lonza). Flasks were rinsed with PBS 
three times, the next day, prior to media change. Additional media changes were done every 2 
days. HUVECs from a commercial source (Lonza Inc, Walkersville, MD), were utilized for 
network length studies. We employed two different HUVECs sources to ensure the robustness of 
the observed phenomena independent of endothelial cell source. All experiments employed 
HUVECs from passages 4-7.  
Normal human lung fibroblasts (NHLFs, Lonza Inc., Walkersville, MD) from passages 9-
14 were cultured in Media 199 (M199, Life Technologies, Grand Island, NY) with 10% fetal 
bovine serum (FBS). Culture media of HUVECs and NHLFs were replaced every other day prior 
to experimental processing. EGM-2 is composed of 500 mL of endothelial basal medium, 10 mL 
of FBS (2% concentration), 0.5 mL of vascular endothelial growth factor (VEGF), 0.5 mL of 
gentamicin, amphotericin-B (GA-1000), 0.2 mL of human fibroblastic growth factor (hFGF-B), 
0.5 mL of R3-IGF-1, 0.5 mL of ascorbic acid, 0.5 mL hydrocortisone, 0.5 mL of human epidermal 




5.2.2 Production of Agarose-based Microbeads 
Cell-encapsulating, agarose-based microbeads were produced using a water-in-oil 
emulsification process (Fig 5-1) [46]. Emulsification was carried out in autoclaved 100 cSt 
polydimethylsiloxane (PDMS) oil (Clearco Products Co. Inc. Bensalem, PA).  
In preparation for microbead production, HUVECs and NHLFs were detached using 0.05% 
Trypsin-EDTA (Gibco), re-suspended in endothelial growth media (EGM-2), and counted using 
an automated cell counter (Multisizer 3, Beckman Coulter, Brea, CA). Fibrinogen (Sigma Aldrich, 
St. Louis MO) was dissolved in serum-free endothelial growth media (SFEGM-2) at 37 °C (4.0 
mg/mL active clottable protein concentration), sterile filtered and kept on ice until ready for use. 
Agarose was warmed to 65 °C. 
Microbeads components included HUVECs and NHLFs (1x106 of cell type per mL of 
aqueous components), agarose (8.0 mg/mL final concentration), fetal bovine serum (FBS), 
hydroxyapatite (HA), and fibrinogen (FGN). The components were loaded into a 10 mL syringe 
and injected into the PDMS through a 25-gauge needle. A two-paddle impeller stirred the mixture 
at 700 rpm for 6 min at 37 °C and then for 30 min on ice to gel the resulting microbeads. Previous 
work has shown that use of FBS acts as a surfactant that facilitates the separation of the beads from 
the oil phase during production, and also aids in maintaining high cell viability [17, 21]. 
After mixing, the microbeads were separated from the PDMS using three centrifugation 
and PBS wash steps. The microbeads were then re-suspended in EGM-2 and cultured in 15 mL 
vented conical tubes (CELLTREAT Scientific Products, Shirley, MA). Media of constructs was 




Figure 5-1: Microbead production and culture. Agarose-based, cell-encapsulating microbeads were produced using a 
water-in-oil emulsion process.  HUVECs and NHLFs were incorporated in a 1:1 ratio at 2x106 total cells per mL of 
aqueous microbead components. Microbeads were pre-cultured for Days 1 and/or 7 and then embedded in fibrin 
hydrogels. Some images were adapted from Servier Medical Arts clipart (www.servier.com). 
 
5.2.3 Embedding of Microbeads in Fibrin (FIB) Hydrogels 
Microbeads were embedded in fibrin hydrogels similarly to what was previously done [25]. 
The 15 mL vented conical tubes containing the media-microbead solution were centrifuged prior 
to the separation of the supernatant from the microbeads. All tubes were aliquoted the same way 
to keep comparison between batches consistent. 255 µL of microbeads were transferred from the 
culture tubes and placed into new tubes. 100 µL of FBS (10% final), 20 µL of 50 U/mL thrombin 
(1 U/mL final), and 625 µL of fibrinogen stock (2.5 mg/mL final clottable protein concentration) 
were added atop of the microbeads and mixed thoroughly to make 2 fibrin hydrogels with 
microbeads. 500 µL of the total solution was added to each well of a 24-well plate and left in the 
incubator for approximately 30 minutes to allow complete gelation of the fibrin hydrogels. 1 mL 
of media was added to each hydrogel after the gelation process. Media was replaced the next day 
and every other day until the experimental end points.  
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5.2.4 Microbead Characterization  
Prior to microbead size quantification, images of microbeads were taken using Nikon DS-
Ri2 camera. The rectangular selection tool in ImageJ (National Institutes of Health, Bethesda, MD) 
was utilized to measure microbead size. The average horizontal and vertical diameter of the first 
25 microbeads per image (100 microbeads total) were quantified to determine the average 
microbead diameter of each batch.  
To calculate microbead yield, microbeads were counted using a hemocytometer in the same 
manner cell counting is done. Ten independent counts were done per microbead batch. A single-
blind study was used for both microbead size and yield quantification.  
 
5.2.5 Viability of Encapsulated Cells 
Cell viability was quantified using a fluorescent live/dead assay (Thermo Fisher) as per the 
manufacturer’s protocols. Images were captured using a fluorescent source 465-495/515-555 nm 
excitation/emission (calcein-AM, live cells) and 540/605 nm (ethidium bromide, dead cells) filter 
sets (Nikon Instruments Inc., Melville, NJ). Cells were counted using ImageJ analysis software 
and a custom macro (US National Institutes of Health, Bethesda, MD). Cells staining positive for 
calcein-AM and negative for ethidium bromide were considered live at the beginning of the assay. 
 
5.2.6 Staining and Visualization of Microbead Protein Content 
A non-specific protein-binding dye (EZBlue, Sigma-Aldrich) was used to visualize protein 
content. Microbeads were washed in PBS, and fixed overnight in buffered zinc formalin (Z-Fix, 
Anatech Ltd, Battle Creek, MI). Microbeads were then stained for 10 min at room temperature. 
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5.2.7 HUVEC Sprout Staining and Quantification   
Z-fix was employed to fix constructs 7 days after microbeads were embedded in fibrin 
hydrogels. Samples were rinsed two times before and after fixation. Ulex Europaeus Agglutinin I 
(UEA-I, Vector Laboratories, Burlingame, CA), an endothelial cell-specific marker, was utilized 
to stain the endothelial cells. Samples were stained with a 1% BSA buffer in PBS containing 10 
nM DAPI and 20 µg/mL rhodamine-labeled UEA-I. After the 45 min room temperature 
incubation, samples were washed 2-4 times with PBS.  
Prior to imaging, samples were taken out from the 24-well tissue culture plates and placed 
on slides. Coverslips were added on top prior to imaging. An optical microscope (Olympus IX81, 
Olympus, Center Valley, PA) and the scan slide tool in the Metamorph software were employed 
to take fluorescent images of endothelial networks formed in HUVECs-NHLFs microbeads that 
had been embedded in FIB hydrogels. The angiogenesis analyzer tool [71] and the ImageJ software 
were employed to measure total network length in each fibrin hydrogel. The background, 
brightness, contrast, and threshold of each hydrogel scan was adjusted preceding analysis. The 
correct scale and possible outlier parameters were also defined before running the angiogenesis 
analyzer. The aforementioned processing settings were kept constant for each hydrogel scan.  
 
5.2.8 Statistical Analysis 
Statistical analyses were performed running a one-way ANOVA with Dunnett's T3 post 
hoc test using SPSS software (IBM, Armonk, NY). Experiments were repeated at least twice and 
each contain at least three replicates for each group. Data are reported as mean ± standard 
deviation. Values of p ≤ 0.05 were considered statistically significant. 
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5.3  Results and Discussion 
5.3.1 Microbead Formulation and Production 
The goal of this study was to develop modular tissue engineering constructs that could be 
easily handled and promote vascular network formation over a broad area. Our strategy centered 
on agarose (AG)-based microbeads encapsulating a co-culture of endothelial cells and fibroblasts, 
because these cell types have been shown to form robust vascular networks in other applications. 
Agarose was chosen to form the bulk of the microbead volume because of its ability to produce 
stable, spherical microbeads while limiting the adherence of the microbeads to each other and to 
the surface of the cultureware used in processing and handling. Hydroxyapatite (HA) and 
fibrinogen (FGN) were added to the microbead formulations at defined levels to encourage cell 
adherence and spreading, and to promote cell-specific functions that can enhance vasculogenesis. 
Water-in-oil emulsification and an alternating heating/cooling cycle consistently resulted 
in spherical AG-based microbeads with mean diameters ranging from 80 to 110 μm, as shown in 
Figure 5-2. Pure 8.0 mg/mL AG microbeads (Fig. 5-2A) were clear, colorless, and highly 
spherical. Addition of HA and FGN to these AG-based microbeads resulted in incorporation of 
the active matrix components to differing degrees. HA alone dispersed evenly throughout the 
microbead (Fig. 5-2B), whereas FGN alone was not well incorporated (Fig. 5-2C) and remained 
in the supernatant when microbeads were collected. However, addition of both HA and FGN 
resulted in the formation of dense and homogenously distributed HA/FGN complexes (Fig. 5-2 D-
E). These data suggest that HA serves to bind and incorporate FGN into the microbeads. The HA 
surface lattice contains Ca2+ and PO3- ions that promote the adsorption of a wide range of proteins 
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with positively or negatively charged moieties [72]. In the context of vasculogenic microbeads, 
the use of HA was intended to improve the incorporation of FGN into the microbeads during 
production and to provide a substrate for serum proteins that could further enhance cell attachment 
and sprout formation. Fabrication of microbeads using only 4.0 mg/mL agarose resulted in fragile 
microbeads and poor encapsulation of HA and FGN (Fig. 5-2F). 
 
 
Figure 5-2: Microbead formulation characterization. Bright-field images showing incorporation of varying 
concentrations of FGN and HA into AG-based microbeads: (A) AG only microbeads and those made from 8 mg/mL 
AG + (B)HA, (C)FGN, (D)HA+ FGN, (E) 15 mg/mL HA+1.25 mg/mL FGN and (F) 4 mg/mL AG+15 mg/mL 
HA+0.25 mg/mL FGN. (G) Microbead size quantification. Lowercase letters indicate comparisons for which p≤0.05 
(one-way ANOVA). 
 
Addition of HA and FGN resulted in significantly larger microbeads compared to pure AG 
or AG+HA microbeads (Fig. 5-2G). However, there was no significant difference in diameters 
between microbeads containing AG+HA+0.25FGN and those containing AG+HA+1.25FGN. 
While average microbead diameters depended on the proportion of constituent materials, the 
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resulting microbeads were consistent with a relatively narrow size distribution, as indicated by the 
error bars in Fig. 5-2G. In all cases, the microbeads were <120 µm in diameter, such that any 
encapsulated cell would be less than 60 µm from the perimeter. This small diffusion distance is an 
advantage of the microbead format because it ensures availability of nutrients and oxygen to 
embedded cells. 
 
5.3.2 Microbead Characterization 
Protein staining was used to visualize the distribution of the active matrix components and 
cells encapsulated within AG-based microbeads, as shown in Figure 5-3. Pure AG microbeads 
(Fig. 5-3A) entrapped cells efficiently, but there was no evidence of cell spreading by Day 1 in 
HUVECs-NHLFs co-culture. Microbeads made with added FGN alone showed little incorporation 
of protein or cell spreading, though in the higher concentration some protein strands were evident 
(Fig. 5-3B, C). Addition of HA alone (Fig. 5-3D) to the microbeads indicated some entrapment of 
protein, presumably from the surrounding culture medium. However, addition of HA+FGN (Fig. 
5-3E, F) resulted in very clear and widespread incorporation of protein into the microbeads, with 
concomitant evidence of cell adhesion and spreading. FGN is a soluble plasma protein that 
contains RGD domains that permit direct binding of cells [73], and its relatively high solubility 
enables its incorporation in the microbead fabrication process. Our results further support the idea 




Figure 5-3: Greater concentrations of FGN permit the formation of homogenous, non-adherent HUVECs-NHLFs 
microbeads. (A) AG, (B) AG+0.25FGN, (C) AG+1.25FGN, (D) AG+HA, (E) AG+HA+0.25FGN, (F) 
AG+HA+1.25FGN, and (G) fibrin microbeads stained using EZ blue to visualize microbead protein content after 
processing. Microbead boundary indicated with blue circle. Scalebar = 100 μm. 
 
Pure fibrin (FIB) microbeads were also produced and cultured in the same manner as AG-
based microbeads. However, under these conditions FIB microbeads tended to agglomerate into 
masses several hundred microns in diameter in culture (Fig. 5-3G). In contrast, AG-based 
microbeads remained as discrete spherical units, and did not change appreciably in size or shape. 
Reduced aggregation allows microbeads to be cultured in vitro over time before being injected as 
a slurry. Such in vitro culture periods allow the phenotype of the embedded cells to be more 
carefully controlled, and therefore may lead to more effective function when implanted.  
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Figure 5-4: Effects of the different components on microbead yield and HUVECs-NHLFs viability. (A) HA or FGN 
content had no significant effect on the viability of encapsulated cells one day after microbead production and after 
pre-culture. (B,C) Microbead yield increase with the addition of HA and decreased with the addition of FGN, until it 
reached steady-state at 0.75FGN. (D) Microbead volume based on microbead yield and microbead diameter. 
(Lowercase letters indicate comparisons for which p≤0.05 (one-way ANOVA). 
 
Cell viability in all microbead formulations was high (Fig. 5-4A). Viability of HUVECs 
and NHLFs was generally >80% in all microbead types, with no statistical differences between 
formulations or time in culture over a one week period. These results show that the encapsulation 
process itself is not harmful to cells, and that cells can maintain their viability when being cultured 
in microbeads. The clear survival of cells over a week in culture suggests that mass transfer 
limitations are not a barrier, and it is expected that cells could therefore also survive for longer 
periods. 
Microbead composition affected the number and volume of microbeads yielded by the 
production process (Fig. 5-4B). The numerical yield of AG-only microbeads was approximately 
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4x105/mL, while the addition of HA alone increased the yield to over 7x105/mL. It is likely that 
the relatively high specific gravity of HA (3.08) reduced the buoyancy of HA-containing 
microbeads and thereby contributed to improved  separation during centrifugation [74]. 
Incorporation of FGN alone decreased the microbead yield, while including HA+FGN caused a 
recovery in numerical yield, though not to the level of the pure AG microbeads. To further assess 
the effects of the active matrix components on microbead yield, AG-based microbeads were made 
with HA and from 0.25 to 1.25 mg/mL FGN (Fig. 5-4C).   
Numerical yield dropped significantly when the FGN content was increased from 0.25 to 
0.75 mg/mL. However, further increases in FGN concentration did not significantly affect yield. 
It should be noted that while large differences were observed in the numerical yields between 
microbead formulations, the difference in the volume of microbeads collected was not as great. 
This discrepancy is due to the differences in microbead size (Fig. 5-2G), and estimation of the 
microbead volume showed no significant differences between the yields of AG-only and 
AG+HA+0.25 mg/mL FGN microbeads (Fig. 5-4D). 
 
5.3.3 HUVEC Sprouting and Network Formation 
Figure 5-5 shows images of AG+HA+0.25FGN with encapsulated HUVECs and NHLFs 
in culture. These experiments were performed to verify whether endothelial cells can form sprouts 
within and from these microbeads, as a precursor to examining more global network formation. 
When microbeads were embedded in a bulk 3D fibrin gel (Fig. 5-5A), it was evident that HUVECs 
could sprout from microbeads into the surrounding matrix over a week in culture, and nascent 
vessel networks were observed. Culture of microbeads within bulk fibrin gels is used to recreate a 
3D matrix to mimic the in vivo tissue environment, and similar systems have been employed to 
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study angiogenesis and vasculogenesis [25, 26]. When microbeads were cultured as discrete units 
without being embedded in a surrounding gel (Fig. 5-5B), small vessel fragments formed within 
the microbeads. When such microbeads were pre-cultured for 8 days as discrete modules before 
being embedded in a surrounding fibrin bulk gel (Fig. 5-5C), the vessel fragments formed within 
the microbeads could sprout into the surrounding matrix. Taken together, these experiments 
therefore established that HUVECs can form nascent vessels within AG+HA+FGN microbeads, 
and can sprout from the microbeads when embedded in a surrounding matrix. 
 
 
Figure 5-5: Proof of concept EC sprouting from Ag+15 mg/mL HA+0.25 mg/mL FGN microbeads under different 
culture conditions.  (A) After 7 days of embedding in 2.5mg/mL FIB hydrogel (no pre-culture).  (B) After 7 days 
sedimentation in conical tube (no FIB embedding). Arrowheads indicate sprouts forming within microbeads.  (C)  
After 5 days in FIB following 8 days pre-culture in conical tube.  Sprouts originated in the HA-FGN complex (black) 
located within the microbead boundaries (not visible). The inset in image A and B show endothelial cells stained in 
red. Red = UEA staining, Blue =DAPI.  Scale bar = 200 μm. 
 
The composition of the microbeads affected their ability to create distributed (i.e. spanning 
a large area) vessel networks, as shown in Figure 5-6. In these studies, microbeads were embedded 
in surrounding fibrin gels one day after microbead production, and were then cultured for seven 
days. In microbeads without HA (Fig. 5-6 A-C), sprouting was minimal and relatively local in the 
direct vicinity of the microbeads. Microbeads with HA but no FGN (Fig. 5-6D) also showed 
minimal and local sprouting. For microbeads that contained both HA and FGN (Fig. 5-6 E, F), the 
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extent of sprouting was much greater and spanned the entire volume of the surrounding fibrin 
matrix. In contrast, pure FIB microbeads that were cultured under similar conditions (Fig. 5-6G), 
exhibited robust but highly focal sprouting (Fig. 5-6G) due to aggregation of the microbeads. The 
limited aggregation of the AG-based microbeads led to greater homogeneity in the distribution of 
endothelial networks within the surrounding matrix. This effect is a potentially important feature 
of AG+HA+FGN microbeads, since upon implantation a more distributed vessel network could 




Figure 5-6: The distribution of HUVEC sprouting depends on microbead matrix components. (A) AG, (B) 
AG+0.25FGN, (C) AG+1.25FGN, (D) AG+HA, (E) AG+HA+0.25FGN, (F) AG+HA+1.25FGN and (G) fibrin 
microbeads were embedded in 2.5mg/mL FIB hydrogels and cultured for 7 days. 
 
The distribution of fibroblasts and endothelial cells in all four microbead conditions was 
assess by staining of cells 7 days after being embedded in fibrin hydrogels, as shown in Fig. 5-7. 
All four microbead conditions formed endothelial sprouts (as previously shown); however, there 
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were more fibroblasts and a higher number of microbeads with endothelial sprouts in the 
AG+1.25FGN and the AG+7.5HA+1.25FGN conditions. Fibroblasts migrated from the 
microbeads into the fibrin hydrogels in all conditions. A more homogeneous distribution of 
fibroblasts and endothelial cells was observed in the AG+7.5HA+1.25FGN condition. 
 
 
Figure 5-7: Fibroblasts surround endothelial sprouts protruding from microbeads embedded in fibrin hydrogels. One 
day after fabrication, microbeads of differing formulations were embedded in fibrin hydrogels for 7 days. Endothelial 
cells were stained with UEA-I (red) while nuclei of both endothelial cells and fibroblasts were stained with DAPI 
(blue). Scale bar = 200 μm.  
 
The effect of pre-culture on endothelial network formation was also assessed using selected 
microbead formulations, as shown in Figure 5-8. In these experiments, a lower (7.5 mg/mL) 
concentration of HA was used to reduce background fluorescence and allow quantification of 
vessel network length. Microbeads that were embedded in 3D fibrin gels one day after production 
(Fig. 5-8 A-D) showed again that only local and very modest sprouting occurs into surrounding 
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matrix, unless both HA and FGN are incorporated. In the latter case, endothelial sprouting is robust 
and distributed throughout the matrix. When microbeads were pre-cultured for seven days prior to 
being embedded in fibrin (Fig. 5-8 E-H), the degree of sprouting was decreased in both pure AG 
and AG+HA samples, but was retained in the FGN and HA+FGN microbeads.  
 
 
Figure 5-8: Fluorescence imaging reveals that HUVEC sprouting is affected by microbead composition and pre-
culture conditions. Images of endothelial sprouting (red) from AG (A,E), AG+7.5HA (B,F), AG+1.25FGN (C,G), and 
AG+7.5HA+1.25FGN microbeads (D,H) embedded in fibrin hydrogels for 1 week; with (E,F,G,H), and without pre-
culture (A,B,C,D).  
 
Quantification of total sprout network length (Fig. 5-9) confirmed these observations. 
These data show that addition of HA+FGN caused a marked increase in total network length, 
relative to the other formulations. In addition, pre-culture of the AG+HA+FGN microbeads prior 
to embedding had a modest positive effect on network length, compared to AG+HA+FGN 
microbeads that had not been pre-cultured. 
The fate of microbeads and the embedded cells after implantation in vivo will depend on 
the matrix formulation. The materials examined in this study assisted with achieving distributed 
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vascularization, and they can be further optimized to provide desired rates of cell delivery and 
concomitant matrix degradation. Agarose is resistant to proteolytic degradation, but can be broken 
down hydrolytically over time, and is susceptible to some lysosomal enzymes. It is therefore likely 
to be broken down slowly in vivo, and can impart stability to the microbeads while promoting cell 
function. Future work will examine the remodeling and degradation of microbeads after 
implantation, and will also investigate other materials that can mimic the distributive effects of 
agarose while offering more control over degradation rate. The tailoring of matrix material 
properties can be used to control the distribution of vessel networks, and potentially to thereby 
promote more rapid and efficient inosculation with host tissue after implantation. 
 
 
Figure 5-9: Quantification of total network length confirms that HUVEC sprouting is affected by microbead 
composition and pre-culture conditions. Quantification of microbeads, with/without pre-culture, embedded in fibrin 
hydrogels for 1 week. Endothelial network length increased significantly when cells were encapsulated with HA and 
FGN in AG microbeads. Pre-culture had a positive effect on total network length in AG+HA+FGN microbeads only. 
(Lowercase letters indicate comparisons for which p≤0.05 (one-way ANOVA).  
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5.3.4  Supplementary Information 
 
Figure 5-10: Microbeads pre-cultured on AG then embedded in FIB. Cross sections (bottom, side panels) show 
sprouting (arrowheads) within HA+FGN comples (arrow). Endothelial cells are stained with red: UEA-I, and nuclei 
stained with blue: DAPI. Scale bar: 100 µm. 
 
AG+HA+FGN microbeads were embedded in a fibrin hydrogel for 7 days following 8 days 
of pre-culture on a non-adherent agarose hydrogel. The confocal reflectance image shows the cross 
sections on the bottom and side panels of the microbead (Fig. 5-10). The HA-FGN complex (black) 
located within the microbead boundaries (not visible) allows endothelial sprouting (yellow arrow 
heads) to occur. This EC sprouting observed both within and between the microbead, indicates 
that EC retain their function after being cultured in AG+HA+FGN microbeads alone and that an 
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adherent pre-conditioning environment surrounding the microbeads is not required for subsequent 
sprouting.  
Endothelial cells (UEA-I, red) and NHLFs encapsulated in AG, AG+HA, AG+FGN, and 
AG+HA+FGN microbeads, were pre-cultured for 1, 3, and 7 days, and embedded in fibrin 
hydrogels for 1, 3, and 7 days (Fig. 5-11). The longer the embedding time, the longer the EC 
sprouts grew within the fibrin hydrogels. More sprouting also occurred in the AG+HA+FGN 
conditions that the other microbead conditions; while EC morphology may differ depending on 
the microbead the cells were originally encapsulated in.  
 
 
Figure 5-11: Effects of pre-culture on HUVEC sprouting from microbeads embedded in fibrin hydrogel. Images of 
endothelial sprouting (red) from Agarose (a-f), AG+HA (g-l), AG+FGN (m-r), and (AG+HA+FGN) microbeads 
embedded in fibrin hydrogel after 1 day (a,g,m,s,d,j,p,v), 3 days (b,h,n,t,e,k,q,w), and 7 days (c,i,o,u,f,l,r,x) and 
cultured for 1-2 weeks.  Scale bar: 200 µm. 
 
These same four types of microbeads were pre-cultured for 1 and 7 days at different 
microbead concentrations (0.5 mL: 1:2 bead:media volume, and 1 mL: 1:1 bead:media volume) 
and stained with EZ blue to determine protein content – qualitatively (Fig. 5-12). After 1 day of 
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pre-culture, microbeads did not show a lot of protein content, except for the AG+HA+FGN 
condition). Pre-culturing the AG and AG+HA microbeads for 1 day versus 7 days did not affect 
their microbead content (qualitative). On the other hand, the AG+FN and AG+HA+FGN 
microbeads pre-cultured for 7 days at a 0.5 mL or 1 mL had more protein, not only within the 
microbead, but also surrounding multiple microbeads suggesting a possible interaction between 
the cells of neighboring microbeads.    
 
 
Figure 5-12: Protein content of AG, AG+HA, AG+FGN, and AG+HA+FGN microbeads that had been pre-cultured 
for 1 and 7 days (0.5ml and 1ml). Scale bar: 100 µm.   
 
148 
Endothelial sprout length and pre-culture medium volume was investigated by pre-
culturing the four microbead types (AG, AG+HA, AG+FGN, and AG+HA+FGN) for 7 days in 
different medium volumes (1x: 1:1 bead:media volume, 2x: 1:2 bead:media volume, and 4x: 1:4 
bead:media volume) followed by their embedding in a fibrin hydrogel for an additional week. 
Quantification of this data was done by hand (one-side blind study). Figure 5-13 shows that total 
sprout length increased when AG+HA+FGN were pre-cultured with more media for 7 days prior 
to embedding.   
 
 
Figure 5-13: Total sprout length increased in AG+HA+FGN microbeads pre-cultured with more EGM-2 media. 
ANOVA + Dunnett T3 post-hoc % shows differences for p<0.05 of AG+HA+FGN only condition 
 
Fig. 5-14 displays the same total sprout length graph shown above, but comparing only the 
sprout length of microbeads pre-cultured with the same microbead:media volume “*”. 
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AG+HA+FGN microbeads had a higher total sprout length than other microbeads cultured with 
the same 2x, and 4x bead:media volume. While total EC sprout length of AG+HA+FGN pre-
cultured with 1x bead:media volume were only significant higher “a” than AG and AG+HA 
condition, not AG+FGN condition.  
 
 
Figure 5-14: Endothelial sprout length based on pre-culture media volume. ANOVA + Dunnett T3 post-hoc “*” 
compared to others of same volume for p<0.05, and “a” for p<0.05 compared to AG, and AG+HA of same volume. 
 
5.4  Conclusion 
AG+HA+FGN microbeads can support endothelial sprouting and provide even distribution 
of endothelial network formation, via inosculation of endothelial sprouts between adjacent 
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microbeads embedded in fibrin hydrogels (Fig. 5-15). The use of AG in the matrix prevents 
aggregation and contributes to the formation of spherical microbeads, which facilitates the culture, 
collection, and injection processes. The incorporation of HA and FGN within the microbeads 
permit cell adhesion and spreading within the non-adherent AG. By developing these 
AG+HA+FGN microbeads, we have increased microbead yield production, improved 
injectability, and achieved a more homogeneous vascular network. In addition, pre-culture of these 




Figure 5-15: Graphical figure summarizing the study. 
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Conclusions and Future Directions 
 
* Figure 6-5, Copyright © 2016 American Chemical Society 
 
This chapter summarizes the work done in this dissertation including the motivation of the 
project and the current solutions that exist to resolve the problems caused by the disease within 
and outside the tissue engineering field. It includes the major findings discovered with the newly 
developed vascular microbeads and suggestions for future work. Some preliminary data collected 
for future work is also included to provide insight on the future directions. 
 
6.1  Conclusion 
This work aims to develop a potential re-vascularization therapy for patients suffering from 
critical limb ischemia (CLI). Current solutions for CLI patients include pharmaceutical therapies 
and surgical interventions. Although less invasive surgeries such as percutaneous transluminal 
angioplasty are successful at removing plaque from the arterial walls, open bypass surgery still 
provides better outcomes for CLI patients (improved life quality) than other solutions.     
The tissue engineering field began with work to engineer artificial tissues/organs that can 
replace diseased ones from the body. Although there are many tissue engineering techniques that 
have re-vascularization potential including in vivo and in vitro pre-vascularization, patients must 
still have open surgery for these techniques to work. Unfortunately, there are many patients 
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who are inoperable due to comorbidities, such as in the case of diabetic patients who develop CLI. 
These patients often rely on experimental clinical trials to prevent limb amputation and death. 
This dissertation describes a method to engineer vascular microbeads capable of forming 
endothelial sprouts during a pre-culture step and that inosculate with one another when embedded 
in fibrin hydrogels, both in vitro and in vivo. In the in vitro model, the fibrin hydrogel fixes the 
microbeads in a physical space and provides a controlled structural environment permitting the 
investigation of the cells’ behavior and response to stimuli, and facilitating sprout quantification. 
In the in vivo model, the fibrin precursor was mixed with the microbeads to facilitate microbead 
injection [1]. 
Prior to this work, fibrin microbeads had not been engineered and preliminary studies 
focused on finding a collagen-fibrin composite for vascular microbeads that could achieve 
comparable endothelial sprout length to pure fibrin matrices. This study found that endothelial 
sprouting from embedded endothelial cells and mesenchymal cells was similar in a 40-60wt% 
COL-FIB matrix and a pure FIB matrix [2].  
Our work began by making 40-60 wt% COL-FIB microbeads containing human umbilical 
vein endothelial cells (HUVECs) and human fibroblast that could sprout when embedded in fibrin 
hydrogels [3]. We then developed fibrin microbeads and compared them to the existing 40-60wt% 
COL-FIB microbeads to find differences in endothelial sprouting [4]. Both microbead types were 
embedded in fibrin hydrogels, cultured for 1 to 2 weeks, and quantified in terms of endothelial 
tube length. This study found that fibrin microbeads provided a higher endothelial sprouting that 
the 40-60 wt% COL-FIB microbeads (See Chapter 3). We also demonstrated that microvascular 
endothelial cells (MVECs) could be used in the fibrin microbead system developed [5]. 
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 We established that fibrin microbeads could be pre-cultured to allow endothelial sprout 
formation to occur within these microbeads without the necessity of embedding them into an 
additional matrix. We found that fibrin microbeads provided a better endothelial sprout coverage 
when cultured for 3 days instead of 1, 5, and 7 days prior to embedding them into fibrin hydrogels. 
A subcutaneous model was then used to determine whether this new modular vascular approach 
would facilitate vessel formation in vivo similarly to what had previously been shown with the 
delivery of endothelial cells with stromal cells in a fibrin matrix (cellular hydrogels) [6]. 
In addition to both pre-cultured fibrin microbeads and cellular hydrogels, control (non-pre-
cultured) microbeads and acellular microbeads were also investigated with this in vivo model. The 
four groups of implants were injected for 1, 3, 7, and 14 days. However, all data shown in this 
dissertation comes from day 3 and day 7 implants. Day 1 implants did not provide much 
endothelial sprouting while some day 14 implants were difficult to find following remodeling 
(degradation). No vessel density differences were found in cellular experimental groups at either 
day 3 nor day 7. There was no surprise that human vessels were not found in the acellular 
microbead implants. Although there were no statistical differences in D7 cellular hydrogels and 
the fibrin microbeads, the average vessel density was higher in cellular hydrogels compared to the 
microbeads. However, the high variability between each independent implant meant there were no 
statistical differences between the cellular implants (See Chapter 4). 
One of the most surprising findings was that the pre-cultured microbeads in fibrin 
hydrogels did not compact as much as the cellular hydrogel implants and the control microbeads 
after 3 and 7 days in situ. These results were confirmed by measuring implant’ volume with 
ultrasound imaging in vitro one day after their production. No correlation was found between the 
implant mechanical properties, measured with a rheometer, and compaction, as it was found that 
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cellular hydrogels were stiffer than control microbeads and pre-cultured microbeads. However, 
pre-cultured microbeads were found to be stiffer than control microbeads, and cellular hydrogels 
when measuring regional stiffness using a dual-mode ultrasound elastography (DUE) technique.  
We hypothesize that cells near the microbeads sense a stiffer matrix and take longer to 
degrade the matrix and migrate towards the remaining fibrin hydrogel as shown with the bright-
field images comparing the pre-cultured and control microbeads embedded in fibrin hydrogels in 
vitro. Consequently, additional experiments must be done to test whether our hypothesis is correct.  
Nevertheless, we found that pre-cultured microbeads prevent implant compaction and provide a 
higher absolute number of vessels than the other cellular conditions tested. These results indicate 
that pre-cultured microbeads may be more useful than the other implants in an ischemic 
environment as it may be necessary for the implant site injected in the ischemic region to not 
compact while anastomoses between the host and implanted vessels occur.   
Agarose-based microbeads were also developed to improve microbead yield and prevent 
microbead aggregation during pre-culture [7]. Microbead yield decreased when incorporating 
proteins in the microbead formula, while the addition of hydroxyapatite recovered some of the 
decrease in microbead yield. The combination of agarose (AG), hydroxyapatite (HA), and 
fibrinogen (FGN) in the microbead formula produced a more homogeneous distribution of 
endothelial sprouts compared to other microbead types embedded in fibrin hydrogels. Pre-culture 
was found to be slightly beneficial in AG+HA+FGN microbeads and not in the other agarose-
based microbeads that did not support endothelial sprouting. Although this method can be 
employed for further pre-culture studies, its results can’t be directly compared to the results from 
fibrin microbeads shown above as they were developed using a variation in the emulsification 
process. However, the behavior of different endothelial cells and stromal cells may be studied 
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using AG+HA+FGN to determine which co-culture can provide more endothelial sprouting (See 
Chapter 5).  
 
6.2  Future Directions 
Further testing is necessary to determine the clinical potential of the modular therapy for 
ischemia, including injectability studies, suitability with clinically relevant cells, clinically feasible 
pre-culture technique, evaluation in hind-limb ischemia model, and muscle function 
measurements. There are multiple in vitro and in vivo experiments described below to further 
demonstrate therapeutic potential and help provide additional understanding of this modular 
vascular system.  
Injectability Studies 
The model described in this dissertation employed fibrin as a delivery vehicle. The effects 
of shear stress on the stability of the formed networks can be calculated as previously done by 
Aguado et al. [8] to determine whether the mechanical properties of the fibrin microbeads need to 
be enhanced to augment cell viability and sprout integrity within the microbeads during the 
injection process. If this turns out to be the case, then increasing the fibrin concentration of the 
delivery vehicle and/or the microbeads themselves may be the solution to this problem.  
Using More Clinically Relevant Cells 
HUVECs as a therapeutic cell type are hampered by their limited availability. Endothelial 
progenitor cells (EPC) from cord blood, bone marrow, or peripheral circulation may be more 
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readily available and autologous [9, 10]. Therefore, future microbead studies should determine if 
sprout formation varies significantly depending on the endothelial and mural cell types utilized.   
 
 
Figure 6-1: Images of endothelial networks in fibrin hydrogels after 7 days of culture. (A) HUVECs-NHLFs, (B) 
EPCs-NHLFs, (C) HUVECs-MSCs, and (D) EPCs-MSCs embedded in fibrin hydrogels at a 1:1 ratio at a total cell 
concentration of 500K/mL. Scale bar – 500 µm.   
 
Preliminary studies in 3D fibrin hydrogels (vasculogenesis assay) demonstrated 
endothelial network formation is dependent on the endothelial cell source and mural cell types. 
Images of HUVECs-NHLFs (Fig. 6-1A), EPCs-NHLFs (Fig. 6-1B), HUVECs-MSCs (Fig. 6-1C), 
and EPCs-MSCs (Fig. 6-1D) embedded in a 1:1 ratio at 500K cells/mL show endothelial network 
differences. At least three individual experiments with 3 or more fibrin hydrogels per 
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condition/experiment were quantified using the angiogenesis tube module from the Metamorph 
software. The quantification of the different endothelial tubes/sprouts formed from HUVECs and 
EPCs co-cultured with NHLFs or MSCs in 3D fibrin hydrogels at three different total cell 
concentrations (125K, 250K, and 500K cells per mL of fibrin hydrogel solution) are displayed in 
Fig. 6-2 and Fig. 6-3.  
The higher number of cells embedded in the fibrin hydrogel (initial cell concentration) 
formed a longer total tube length, except for the EPCs-NHLFs condition which total tube length 
went from ~ 79888 µm ± 15114 µm at 125K/mL to 71351 µm ± 17914 µm at 500K/mL (Fig. 6-
2A). The EPCs-NHLFs condition also formed a longer total tube length than the other conditions 
embedded at 125K cells/mL. EPCs-NHLFs were also higher at 250K/mL; however, only 
statistically higher than the EPCs-MSCs condition. When co-cultures were embedded at 500K/mL, 
HUVECs-MSCs had the highest total tube length of all the conditions, but only statistically higher 
than the EPC-MSCs condition. (Fig. 6-2A). 
 
 
Figure 6-2: Quantification of (A) total endothelial tube length and (B) average tube length of different cell 
concentrations of endothelial and stromal cells. HUVECs-NHLFs, HUVECs-MSCs, EPCs-NHLFs, and EPCs-MSCs 
were embedded in fibrin hydrogel at three different cell concentrations (125K, 250K, and 500K/mL) in a 1:1 ratio.  
 
Fig. 6-2B shows that the EPCs-MSCs condition had the highest average tube length 
compared to the other co-cultures; however, this condition was only statistically different than the 
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EPCs-NHLFs condition (at 125K/mL) and the EPCs-NHLFs condition (at 250K/mL and 500K/mL 
cell concentration). The number of segments (Fig. 6-3A), and the number of branch points (Fig. 
6-3B) were also quantified from the endothelial networks formed from the different cell co-
cultures. EPCs-NHLFs at the 125K/mL cell concentration had the highest number of segments and 
branch points of all the co-cultures (p ≤ 0.05). The HUVECs-MSCs condition was the second 
highest, followed by HUVECs-NHLFs and EPCs-MSCs.  
 
 
Figure 6-3: Average number of (A) segments and (B) branch points of endothelial cells (HUVECs and EPCs) co-
cultured with NHLFs or MSCs at 125K/mL, 250K/mL, and 500K/mL (total cell concentrations) at a 1:1 ratio in 2.5 
mg/mL fibrin hydrogels.  
 
At the 250K/mL cell concentration, the EPCs-NHLFs condition had more segments than 
other conditions, but only statistically more than the HUVECs-NHLFs and the EPCs-MSCs 
conditions (Fig. 6-3A). On the other hand, EPCs-NHLFs only had a statistically higher number of 
branch points than the EPCs-MSCs condition at the 250K/mL cell concentration (Fig. 6-3B). 
Similar to the total tube length, the HUVECs-MSCs condition had higher number of segments than 
both EPCs-NHLFs and EPCs-MSCs conditions at 500K/mL (Fig. 6-3A). No statistical differences 
in number of branch points were found at the 500K/mL cell concentration (Fig. 6-3B). All the data 
graphed in Figs. 6-2 and 6-3 are tabulated for each total cell concentration in tables 6-1, 6-2, and 
6-3. 
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Table 6-1: Endothelial network data of fibrin hydrogels containing endothelial cells co-cultured with NHLFs or MSCs 
at 125K/mL total cell concentration. 
 
Total Tube Length Mean Tube Length Segments Branch Points 
HUVEC-NHLF 4.1 ± 2.0 cm 22 ± 5 µm 1853 ± 793 897 ± 419 
EPC-NHLF 8.0 ± 1.5 cm 17 ± 2 µm 4972 ± 1388 2304 ± 652 
HUVEC-MSC 5.0 ± 1.4 cm 23 ± 12 µm 2863 ± 1568 1299 ± 719 
EPC-MSC 3.7 ± 1.0 cm 27 ± 3 µm 1376 ± 387 614 ± 185 
 
Table 6-2: Endothelial network data of fibrin hydrogels containing endothelial cells co-cultured with NHLFs or MSCs 
at 250K/mL total cell concentration. 
 
Total Tube Length Mean Tube Length Segments Branch Points 
HUVEC-NHLF 6.4 ± 2.2 cm 22 ± 4 µm 2894 ± 944 1452 ± 499 
EPC-NHLF 8.6 ± 1.0 cm 17 ± 2 µm 5071 ± 1007 2345 ± 502 
HUVEC-MSC 7.3 ± 1.2 cm 22 ± 11 µm 4089 ± 1778 1873 ± 769 
EPC-MSC 5.9 ± 9.7 cm 27 ± 2 µm 2212 ± 376 1009 ± 188 
 
Table 6-3: Endothelial network data of fibrin hydrogels containing endothelial cells co-cultured with NHLFs or MSCs 
at 500K/mL total cell concentration. 
 
Total Tube Length Mean Tube Length Segments Branch Points 
HUVEC-NHLF 7.5 ± 2.5 cm 20 ± 3 µm 3852 ± 1291 1940 ± 699 
EPC-NHLF 7.1 ± 1.8 cm 17 ± 2 µm 4275 ± 941 1834 ± 511 
HUVEC-MSC 9.3 ± 1.6 cm 22 ± 7 µm 4569 ± 1258 2200 ± 576 
EPC-MSC 6.5 ± 1.0 cm 25 ± 1 µm 2561 ± 386 1153 ± 232 
 
The EPCs-NHLFs condition shows potential for HUVECs-NHLFs replacement as it 
provides almost double the total tube length (8.0 cm ± 1.5 cm versus 4.1 cm ± 2.0 cm) at the lowest 
total cell concentration tested. However, the behavior of endothelial cells and fibroblasts 
encapsulated in microbeads may be different than in fibrin hydrogels as has been shown in Chapter 
4. Therefore, it is important to study whether the above co-cultures will behave similarly in the 
modular vascular system.  
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Preliminary work using this modular system showed that EPCs-NHLFs microbeads (Fig. 
6-4A, C) can form endothelial sprouts similarly to the HUVECs-NHLFs (Fig. 6-4B, D) conditions, 
whether with additional fibroblasts during embedding (Fig. 6-4C, D) or without (Fig. 6-4A, B).    
 
 
Figure 6-4: COL-FIB Microbeads with NHLFs co-cultured with HUVECs or EPCs. Scale bar – 220 µm.  
 
Both Fig. 6-4 and Fig. 6-5 show microbeads in green (FITC) and endothelial cells in red 
(UEA-I). The staining procedure is described in Chapter 3. Microvascular endothelial cells 
(MVECs) are also an endothelial cell source than can be used in clinical studies. To determine if 
they would sprout, MVECs were also encapsulated with NHLFs in microbeads and embedded in 
fibrin hydrogels [5]. Fig. 6-5 shows MVEC sprouts come out of the microbeads and into the fibrin 
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hydrogels like all other endothelial conditions. However, to assess which endothelial cell works 
best in the microbead system, endothelial network from all the three different endothelial cell types 
must be studied in a controlled, side-by-side experiment as in the fibrin hydrogel study (Figs. 6-1, 
6-2, 6-3). In addition, since MSCs have been shown to provide more stable vessels than NHLFs in 
animal studies [6], MSCs should also be employed to determine if they can provide a similar 
degree of network formation as NHLFs in the microbead system. 
 
 
Figure 6-5: MVEC fibrin microbeads form sprout formation after 7 days in fibrin hydrogel immediately after their 
fabrication process. Scale bar – 250 µm. **Image from Ramkumar TA, Ana Y. Rioja, et al. ACS Biomater. Sci. 
Eng., 2016 [5]. 
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Pre-culture Techniques 
Microbead pre-culture has improved sprout length in both protein-based and agarose-based 
microbeads. Consequently, it is important to investigate the pre-culture conditions for alternative 
endothelial cell types and determine if endothelial sprouts can form when encapsulating these other 
endothelial cells with fibroblast in microbeads and pre-culturing them in the same manner as the 
HUVECs-NHLFs microbeads. Preliminary work showed that EPCs-NHLFs fibrin microbeads can 
form sprouts after being cultured statically for 7 days (Fig. 6-6). In addition, other pre-culture 
conditions can be explored including dynamic culture via the use of spinner flasks.  
 
 
Figure 6-6: EPCs-NHLFs were encapsulated in fibrin microbeads and pre-cultured for 7 days. Scale bar – 100 µm. 
 
Fig. 6-7 shows that HUVECs-NHLFs microbeads aggregated when pre-cultured for 7 days 
in a spinner flask prior to being embedded in fibrin hydrogels. Fig. 6-7A, B demonstrate that these 
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cellular microbeads can sprout when embedded immediately, as previously shown; however, once 
microbeads are pre-cultured for 7 days in the spinner flask at either at (Fig. 6-7C) 30 RPM or (Fig. 
6-7D, E) 80 RPM, endothelial sprout formation does not occur after embedding in fibrin hydrogels. 
 
 
The protein microtissues may not be useful in dynamic culture as they tend to aggregate 
during spinner flask culture. On the other hand, the AG+HA+FGN developed in Chapter 5 may 
be employed for pre-culture studies since they prevent aggregation, which could have a negative 
impact on endothelial sprouting. Microbead aggregation may decrease cell viability due to oxygen 
and nutrient diffusion limitations. By using the AG-based microbeads, studies can determine if 
dynamic culture improves sprout formation over static culture. It’s also important to investigate 
how media volume affects the endothelial sprouting during pre-culture, as previous studies 
described in Chapter 5 showed that more media volume added to the microbeads led to more 
Figure 6-7: Dynamic microbead pre-
culture inhibits endothelial vessel 
formation after embedding. (A) 
Bright-field and (B) UEA-I images of 
COL-FIB microbeads, embedded in 
fibrin hydrogel right after fabrication, 
and kept in culture for 2 weeks. COL-
FIB microbeads cultured for 7 days in 
spinner flask at (C) 30 RPM and (D,E) 
80 RPM and embedded in fibrin gels 
for 1 extra week. Scale bar – 500 µm. 
169 
endothelial sprouting after embedding in fibrin hydrogels. However, there may be a limit to this 
effect. 
Use of Hind-limb Ischemia Model 
Since the pre-cultured microbeads have been shown to prevent compaction and form a 
higher number of human endothelial vessels than control (no pre-culture) microbeads and fibrin 
hydrogels, it is important to study their behavior in ischemic conditions. A hind-limb ischemia 
model can be employed to evaluate the efficacy of the pre-cultured microbeads to inosculate with 
the host vasculature in an ischemic region. The model can also show whether HUVECs-NHLFs in 
fibrin hydrogels or in microbeads can re-vascularize and stabilize the network in an ischemic 
region in a similar time frame that it takes for the pre-cultured 
microbeads to do so.  
An adaptation of the murine model of hind-limb ischemia 
described by Niiyama et al. 2009 [11] can be employed to assess 
blood flow restoration in 7- to 9-week-old male SCID mice 
(CB17/SCID, Taconic Labs, Germantown, NY). In brief, this 
model consists of surgically ligating of one of the mouse’s deep 
femoral arteries. The procedure must be done carefully to avoid 
compromising additional vessels and nerves found in the hind limb 
region. Animals need to be anesthetized properly via 
intraperitoneal injection or isoflurane inhalation prior to surgery.  
Each sample would be injected into the ligated region of the mouse to determine if the 
inosculation rate of pre-cultured microbeads with the host vasculature is faster than the control (no 
pre-culture) microbeads, acellular microbeads (negative control), and the cellular hydrogels. Each 
Figure 6-8: Laser Doppler 
perfusion imaging (LDPI) of 
ligated limb post-surgery. 
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implant type should be injected in a separate animal since one of the limbs from each animal must 
be kept as a basis of comparison. LDPI will be used to measure blood vessel perfusion during 
study (Fig. 6-8). 
Muscle Activity Measurements 
Cells residing within an ischemic area begin to die and stop their normal functions. 
Therefore, in addition to measuring re-vascularization, it is important to assess muscle activity 
within the region. Mice studies have implemented treadmills or running wheels to determine 
normal physical activity in mice [12], and they can indirectly measure muscle functionality after 
ischemia. Electromyography (EMG) analysis can also be used to analyze limb movement during 
hind-limb ischemia studies [13]. 
Additional methods such as the one described by Pipinos et al. [14] can also be employed 
to remove the muscle from the ischemic and control limbs to determine if muscles in the ischemic 
regions exhibit myopathy or whether the pre-cultured microbeads or other implants can re-
vascularize the ischemic region fast enough to prevent muscle myopathy. Western blots and 
histological analysis can be done to determine muscle myopathy. Superoxide anion production in 
tissues will be measured using dihydroethidium staining. The main source of superoxide (a 
reactive oxygen species) production, is mitochondria, best known for energy production [15]. A 
possible link between improper mitochondria function and superoxide overproduction has been 
found, as superoxide anion production is higher in ischemic muscles. [15] Triphenyl tetrazolium 
chloride histochemistry is also used to determine if there are skeletal muscle infarctions in muscles 
close to the ischemic regions. [15] In addition, manganese superoxide dismutase (MnSOD) is a 
mitochondrial antioxidant whose expression decreases in ischemic versus normal muscle [14, 15]. 
MnSOD expression can be measured via western blot analysis as previously described [15].  
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Mechanistic Studies 
Although most future studies will mainly focus on developing the vascular microtissues as 
a clinical therapy, the microbead model can also be used to study angiogenesis in vitro. The 
microcarrier bead assay [16] developed in 1995 is still being employed for mechanistic 
angiogenesis studies. However, since our model allows cell encapsulation inside microbeads, 
future mechanistic insight can be gained from the migration of cells from these microbeads and 
how microvessels form depending on the protein matrices they are encapsulated in or surrounded 
by.  
One mechanistic study that we started uses a 3D collagen model containing pre-
cultured/pre-vascular microbeads with gelatin microspheres. Gelatin microspheres are often used 
for growth factor delivery. This model was created to determine if the gelatin microspheres alone 
or loaded with growth factors like VEGF could increase endothelial vessel sprouting. Preliminary 
data show pre-cultured/pre-vascular HUVECs-NHLFs fibrin microbeads (Fig. 6-9A) embedded in 
either a 1.0 mg/mL (Fig. 6-9B) or a 2.5 mg/mL (Fig. 6-9D) collagen hydrogel with un-loaded (no 
growth factor) gelatin microspheres. Some pre-vascular microbeads were also embedded in a 1.0 
mg/mL collagen hydrogel without any gelatin microspheres (Fig. 6-9C) to determine if the gelatin 
microspheres affected endothelial sprouting before growth factors were loaded in the gelatin 
microspheres. It was interesting to find that the addition of un-loaded gelatin microspheres 
promoted endothelial sprouting in collagen hydrogels made at 1.0 mg/mL and 2.5 mg/mL final 
concentrations. Future work is necessary to understand how these gelatin spheres affect the cells 
and promote sprouting within the collagen hydrogels. 
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RNA extraction can also be used to measure the levels of angiogenic markers (CD-31, CD-
34, and vWF) from all samples via quantitative RT-PCR. These results would supplement the 
immunohistochemical data shown in the dissertation.  
 
 
Figure 6-9: CD31 staining of pre-cultured/pre-vascular microbeads (A) after 3 days in static culture, (B) after being 
embedded and kept in culture in a 1 mg/mL collagen hydrogel (B) with and (C) without gelatin microspheres. These 
pre-vascular microbeads were also embedded in a (D) 2.5 mg/mL collagen hydrogel with gelatin microspheres. The 
addition of gelatin microspheres in both collagen hydrogel concentrations promoted endothelial sprouting within the 
hydrogel unlike in the collagen hydrogel that did not have any gelatin microspheres. Insets show a wider region of the 
collagen hydrogel containing multiple microbeads. Scale bar of main images – 50 µm and of insets – 100 µm. 
 
In Vitro Inosculation 
As previously described, inosculation is the process of vessels connecting to each other. 
This process is easy to assess in vivo as red blood cells can found within the lumens of human 
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vessels. The only way for red blood cells to be within those lumens is by the connection of the 
human vessels and the host vasculature. Inosculation in vitro is more difficult to demonstrate since 
the connection between two different endothelial sprouts must be proven. While the data in the 
previous chapters show that cells appear to be connecting to each other, 3D projections (z-stack) 
images would perhaps highlight that these connections, and lumen formation, are occurring in our 
model.  
We have shown that lumen formation can occur in vitro as MVECs-NHLFs microbeads 
are embedded and cultured in fibrin hydrogels [5]. However, additional studies can be done to 
demonstrate that inosculation is occurring in vitro. An experimental study using two different 
endothelial cells with different fluorescent dyes can be utilized to demonstrate that inosculation 
occurs in vitro. In addition, a time-lapse microscope with 3D projection capabilities would show 
that a connection is occurring from two different endothelial sprouts in the fibrin hydrogels.  
Physical and Chemical Characterization 
Nuclear magnetic resonance (NMR) spectroscopy is often employed to study protein 
conformation [17]. For this reason, preliminary studies were conducted using NMR to determine 
if physical and chemical differences could be detected between different samples employed in the 
dissertation. First, (from left to right) fibrinogen, fibrin microbeads, and fibrin hydrogels with no 
cells were dissolved in deuterium oxide (Fig. 6-10). Fibrin hydrogels were more soluble in 
deuterium oxide (D2O) than fibrin microbeads (Fig. 6-10). D2O is water, where its two hydrogen 
atoms are replaced by their isotope deuterium. To avoid spectra dominated by the solvent signal, 
most 1H NMR spectra are recorded in a deuterated solvent. However, deuteration is not 100%, so 
signals for the residual protons are observed. In water solvent (D2O), the corresponding DHO peak 
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as a singlet signal is observed at 4.65 ppm. A detailed protocol of sample processing and NMR 
analysis can be found in appendix M.   
Fibrinogen only (Fig. 6-11A), acellular fibrin 
microbeads (Fig. 6-11B), fibrin hydrogels (Fig. 6-11C), 
control (no pre-culture) microbeads (Fig. 6-11D), and pre-
cultured microbeads (Fig. 6-11E) NMR spectra are shown in 
Fig. 6-11. Both the (Fig. 6-11D) control and the (Fig. 6-11E) 
pre-cultured microbeads were embedded in a fibrin hydrogel 
and left in culture overnight prior to the NMR spectra analysis. 
The first difference between the NMR spectra of all the 
samples is that acellular microbeads did not have an N-H peak 
unlike all other samples (Fig. 6-11B). In addition, the multiple 
peaks between 0 to 4 ppm found in both fibrinogen (Fig. 6-11A) 
and fibrin hydrogels (Fig. 6-11B) are missing in the acellular 
microbeads spectrum (Fig. 6-11B).  
The control microbeads embedded in fibrin hydrogels (Fig. 6-11D) have similar, but 
slightly bigger peaks than the ones found in the fibrin hydrogel NMR spectrum (Fig. 6-11C). On 
the other hand, the pre-cultured microbeads embedded in a fibrin hydrogel displayed more peaks 
between the 0 to 4 ppm area (Fig. 6-11E) than both the control microbeads within a fibrin hydrogel 
(Fig. 6-11D), the acellular microbeads (Fig. 6-11B), and fibrin hydrogels (Fig. 6-11C). This result 
suggests that there may be additional matrix modifications done by cells encapsulated and left in 
culture for additional 3 days prior to embedding. Additional NMR descriptions of each sample can 
be found in Appendix M.  
Figure 6-10: Solubility of (A) 
fibrinogen, (B) fibrin microbeads, and 








Future studies will continue to characterize physical and chemical properties of these 
materials including control and pre-cultured microbeads alone to determine how the 
conformational changes affect the behavior of the endothelial cells in particular the endothelial 
sprouting.  
 
Figure 6-11: NMR spectrum of (A) fibrinogen, (B) 
acellular fibrin microbeads, (C) fibrin hydrogel 
immediately after fabrication. Both (D) control (no pre-
culture) microbeads and pre-cultured (D3) microbeads 
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o SFEGM-2: Serum free EGM-2; FIB: Fibrin 
 
• Initial Fibrin Stock (5.4 mg/mL), mix in SFEGM-2.  
o Place fibrinogen powder in 50 mL conical tube 
o Add SFEGM-2 to get a 5.4 mg/mL final concentration (4.0 mg/mL clottable factors) 
o Mix tube well and place it in water bath to help dissolve the fibrinogen 
o Filter the fibrinogen solution and place it on ice 
 
• Fibrin Recipe (2 hydrogels → 1 mL):  
• SFEGM-2:    255 µL 
• FBS:     100 µL 
• Thrombin (1 UT/mL):   20 µL 
• FIB (4.0 mg/mL clottable stock): 625 µL  
 
• Procedure: 
• Trypsinize cells (e.g. HUVECs, NHLFs) 
• Count cells and re-suspend cells with appropriate media [1 Million cells/mL] 
▪ HUVECs re-suspend in EGM-2 media 
▪ NHLFs re-suspend in M-199 media 
• Add 1x106 desired cells into new 15 mL conical tube   
▪ If you use 1:1 HUVECs:NHLFs, then add 500k (500 µL) of each cell type 
• Centrifuge tube at 200g for 5 minutes 
• Take out and label 24 well (non-tissue culture treated) plate 
• Aspirate supernatant and begin adding the components mentioned above in the 
following order: SFEGM-2, FBS, Thrombin, and Fibrin 
• Mix cells wells after adding FBS and once again after adding fibrin 
• Add 500 µl of cell/fibrin solution to each well of a 24-well plate 
• Leave the 24 well plate in the hood for 5 minutes and then transfer it to the incubator 
for an additional 20 minutes (minimum) 




• Maximum 3 gels can be made at a time prior to gelation to occur. 
• Make fibrin stock every time you make new gels. 





Appendix B – Isolation of HUVECs from umbilical cords 
 
Materials [Storage]: 
• 2 Haemostats     [Tissue Culture room, in drying rack] 
• 1 pair of scissors    [Tissue Culture room, in drying rack] 
• 2 L beaker     [Glass cabinet] 
• Foil and autoclave tape   [Tape drawer, next to office supply drawer] 
• 2, 5 mL syringe     [Drawer below pH meter] 
• 1, 33 mm Millex filter   [Shelf on top of centrifuge in culture room] 
• 2, 20 mL syringes     [Drawer below pH meter]  
• Butterfly needle     [Shelf - above Marina’s desk] 
• 1, 18-gauge needle (or 16-gauge needle) [Shelf next to chemical airflow cabinet] 
• 40 mL of sterile PBS    [Cell culture fridge] 
• 5 mL of 0.1% collagenase (sterile-filter) [Cell culture fridge, top-left corner] 
• 5 mL of EGM-2    [Cell culture fridge] 
• Umbilical Cord    [Must be stored in 4 °C fridge A] 
 
Protocol: 
Day before doing this protocol:  
• Place 2 haemostats, and 1 pair of scissors in a 2 L beaker. One pair of scissors doesn’t work 
properly; therefore, it’s better to add the 2 pairs of scissors to the beaker. 
• Cover the beaker with aluminum foil and then tape one side of the aluminum foil to the 
beaker using autoclave tape. 
• Autoclave beaker using the textiles setting. 
a. Sterilization time: 45 minutes  
b. Drying time: 10 minutes 
• Check to make sure water level of pipe in the autoclave is at the specific set level. Then 
start the process.  
______________________________________________________________________________ 
1. Place the umbilical cord and the sterile PBS in the water bath. Make sure that the cord is in the 
biohazard delivery bag to avoid contaminating the water bath. 
2. Make 5 mL of 0.1% of collagenase in PBS. Make sure to make this solution every time this 
protocol is repeated, DO NOT store solution after experiment is completed. [Concentration = 




0.1% collagenase in PBS 
1 mL of PBS  
0.001 0.1%collagenase 
0.001 G  
1 mg of Collagenase 
Concentration: 1mg of collagenase/mL of PBS 
Note- Make 6 mL just to make sure you have enough after sterile filtering. 
3. Sterile filter the 0.1% collagenase solution using a 5 mL syringe with a 33 mm Millex filter. 
4. Connect an 18-gauge needle to a 5 mL syringe and suction 5 mL of the sterile-filter 
collagenase. Place the syringe back in its wrapper for storage. 
5. Remove the needle from the syringe carefully and throw it in the sharps needle biohazard 
container. Make sure you don’t recap the needle. 
6. Suction 20 mL of PBS in each 20 mL syringe. Put the syringes back in their wrappers for 
storage. 
7. Sterilize the hood and all the materials needed in this protocol prior to putting them in the hood. 
8. Place paper towels inside the hood (use sufficient amount to cover your working area 
properly). 
9. Soak the towels with bleach (make sure surface is completely wet with bleach). 
10. Put on a second pair of gloves prior to placing the umbilical cord in the container and especially 
prior to opening the umbilical cord container. 
11. Take out the umbilical cord and PBS from the water bath and place them inside the hood after 
wiping them down with ethanol.  
12. Take out the umbilical cord from its container and wipe off the clotted blood in the paper 
towels. 
13. Locate the lines where they clamped the haemostats on both ends of the cord. Cut the cord 
below the clamp marks. Use cord container as a waste container for the pieces cut from the 
cord. The cleaner the cut is the easier it is to locate the veins and arteries. 
14. Gently slide half of the butterfly needle into the vein and clamp the cord with the needle using 
the haemostat. You must spiral the needle around because vein spirals around the outside. 
NOTE – Leave the plastic casing of the butterfly needle covering the needle when inserting it 
into the vein. The vein looks like a stretch mark. You shouldn’t have to put a lot of force when 
inserting the needle to the vein, there should be no resistance. 
15.  Remove the extra part of the butterfly needle so that you only have the tube connected to the 
butterfly needle. Attach the first 20mL syringe of PBS and inject all of it slowly into the vein 
making sure there are no clots. Make sure the cord is on top of the waste container.  
16. Attach the collagenase syringe and begin injecting the solution until the liquid coming down 
changes its color to gold. (It takes approximately 1 mL of collagenase of color change to occur). 
Make sure to put the cord on top of the white towel to make it easier to notice the liquid color 
change. 
17. Clamp the other end of the cord and very carefully re-inflate the vein with the 4 mL of 




18. Carefully place everything in the autoclaved beaker which initially contained the haemostats 
and scissors. Cover the top with the aluminum foil taped at one side of the beaker.  
19. Remove your outer pair of gloves and take the 2 L beaker to the bottom shelf of the incubator. 
If there is no space, then use the top incubator instead. Don’t clean up workspace yet. 
20. Leave the cord in the incubator for 20 min. 
21. Put on a second pair of gloves and take out the cord from the incubator. Remove the haemostat 
that is not holding the needle and then attach the last 20 mL syringe of PBS. 
22. Place the cord on top of a 50 mL centrifuge tube and begin injecting the PBS in the vein very 
slowly to wash off the cells but avoid bursting the vein. Collect the entire solution in the 50mL 
tube and then discard the cord in the waste container after removing the needle and the 
haemostat holding it in place. 
23. Centrifuge the tube in Setting 1 (200g for 5 min). 
24. Make sure all waste goes in the biohazard bag. Clean up the hood with bleach and ethanol 
(rinsing).  
25. Take out a 25 mL flask and place it in the clean hood.  Label it: “HUVEC P.0, Date, Your 
initials”. 
26. Remove the 50 mL tube from the centrifuge and aspirate off the supernatant. Make sure to do 
it carefully to avoid aspirating off the HUVECs.  
27. Add 5 mL of EGM-2 into centrifuge tube and mix well. Put the cell-media solution into the 25 
mL flask.   
28. Place the flask in the incubator overnight.  
29. Place flask in the hood and aspirate off the medium. Add 5 mL of PBS and rock the flask.  
30. Aspirate off the PBS and add 5 mL of PBS (2X). 
31. Remove PBS and add 5 mL of EGM-2. 
32. Look at the HUVECs under microscope. Let them grow on the T-25 flask and make sure to 
check on them every day. Cells should be confluent in less than 1 week. If not, throw the cells 
away. 
33. Once the cells are confluent, trypsinize and passage them into 2 T-75 flasks.  




Appendix C – Collagen-Fibrin Microbeads Protocol 
 
• Composition of 40-60 Col.- Fib. Beads (Total Volume: 3 mL): 
o Collagen   750μL 
o Fibrinogen   1125μL 
o Thrombin   60μL 
o NaOH   150μL 
o FBS   300μL 
o 5X DMEM  300μL 
o Glyoxal   36μL 
o Media (SFEGM-2) 279μL 
 
• Storage of Ingredients: 
o 5.4 mg/mL of Fibrinogen from bovine plasma  ThermoScientific refrigerator (top), 
outside the tissue culture room. Big container. 
o Thrombin 50 UT/mL  ThermoScientific refrigerator. 
o Oil (PDMS 100 C.S.)  Bench where the hot plate is. 
o Ice Machine is in the autoclave room. 
o Media, 5X DMEM, FBS, glyoxal, and collagen  Refrigerator in the Tissue Culture 
(TC) room. 
o PBS-L101  Refrigerator in the TC room. 
 
• Notes: 
o If you need 2 mL of fibrin solution, make 3 mL solution instead if 2 mL because you 
may lose some volume during the experimental process.  
o For vasculogenesis beads use EGM-2 without serum (SFEGM-2) to make the fibrin 
(this will allow you more time to mix all ingredients before the solution gels 
completely). For MSC Col-fib beads use serum free DMEM media.  
 
• Bead Preparation Procedure: 
o Weight the necessary amount of fibrin (Fibrinogen from bovine plasma) needed for the 
experiment in a 50 mL tube. 
o Dissolve the fibrin in SFEGM-2 at 5.4 mg/mL concentration, sterile filter it, and then 




o Spray the bead processing area with 70% ethanol and then place the propeller, beaker, 
and ice container on their appropriate places. (The propeller has to be place in the mixer 
apparatus.) 
o Fill half of the water container with sterile water (autoclaved water or DI water), and 
place it on top of the hot plate. The temperature of the water should be at 37 ºC prior to 
beginning the experiment.  
o Rinse both endothelial cells (EC) and fibroblasts’ flasks with DPBS and then add 3 mL 
of trypsin to the EC flask (T-75), and 5 mL of trypsin to the NHLFs flask (T-150). 
(Standard – 3 mL of trypsin in T-75, 5 mL of trypsin in T-150, 10 mL of trypsin in T-
225). 
o Place flasks in incubator for 4 to 5 minutes.   
o Check under microscope to make sure that all/most cells have lifted off the plate. 
o Neutralize trypsin by adding and mixing the appropriate media to each flask. (EGM-2 
to ECs and M-199 to NHLFs). [Standard – 7 mL of media in T-75 flask, 5 mL in T-150 
flask, and 10 mL in T-225 flask.] 
o Transfer the media/cell solution from each flask into 15mL conical tubes. After mixing 
the solution, take out 200 µL and add it into a plastic coulter container that has been 
filled with 19.8 mL of Isoton solution (use one container per cell type).  
o Centrifuge both ECs and NHLFs 15 mL tubes for 5 min at 200g. While cells are in the 
centrifuge, count the number of cells using the Coulter Counter system.  
o Carefully remove the 15mL tubes from the centrifuge and remove the supernatant from 
each tube. Make sure not to disturb the cell pellet when removing the supernatant.  
o Add the necessary media to each tube in order to acquire a final cell concentration of 1 
Million cells/mL. (Make sure to add the appropriate media to each cell type – EGM-
2 for ECs, and M-199 for NHLFs.)  
o Combine both cells types in a new 15mL tube at the desired concentration and place it 
in the centrifuge for 5 min at 200g. 
o Place the thrombin in the water bath. (Can do this during the centrifugation process, 
after the cells have been trypsinized). 
o While the cells are in the centrifuge, add 75 mL of oil (PDMS 100C.S.) into a 100 mL 
beaker that has been placed on top of ice. 
1. Ice is placed in an orange rectangular container that has two rubber bands. Make 
sure that ice does not fall in the beaker and that the beaker does not move when 
the propeller is working. 
2. Use the 25 mL pipette to add the PDMS to the beaker; once the last 25 mL of 
oil has been added to the beaker, remove the automatic pipette and let the oil 
drip down the pipette. 
o Place ice and beaker on the blue platform and raise the platform up until the propeller 




1. Make sure both parts of the propeller are submerged in the oil without touching 
the bottom or the sides of the beaker. 
o Barnant Mixer Controller  Can adjust time and speed (both variables change the size 
of the beads). Make sure the speed is set to 600 rpm. 
o When making the bead solution, add the following components: 
1- Media. 2- FBS. 3- 5X DMEM. 4- NaOH, 5- Glyoxal. 6- Thrombin. 7- Collagen. 8- 
Fibrin. 
o Mix solution well with a 5 mL sterile pipette. Keep the pipette in the tube and remove 
both the tube and the pipette from the hood. Make sure to cover the container with your 
other hand. 
o Start the propeller and begin adding the solution to the beaker. 
1. Note- When adding the collagen-fibrin solution, make sure the pipette is close 
to the shaft to avoid clump formation. 
2. Turn on/off the mixer a couple of times after all the solution has been added to 
the PDMS. 
o After running the solution for 5 min on ice. Remove the beaker and place it on top of 
the 37 °C water.  
1. Note- First, hold the beaker with your left hand close to the propeller, and then 
bring the platform down with the ice container. 
2. Remove the orange container with ice from the blue platform and replace it with 
the hot plate that has the 37 °C water. 
3. Place the beaker containing the PDMS/COL-FIB cell solution on top of the hot 
water and raise the beaker making sure that the solution is submerging both 
shafts of the propeller. 
o Secure the beaker with a clamp to make sure that it doesn’t move during the mixing 
process. Let the solution mix for the remaining time (25 min.) 
o A few minutes before the mixing process is complete, take out the PBS with the 
surfactant (L101) [PBS-L101], and place it inside the hood.  
o Take out two 50 mL conical tubes and place it on the rack.  
o Once the mixing process is done, remove beaker with solution and place it inside the 
hood. Make sure to cover the top of the beaker with one hand to avoid any 
contamination that may occur while transporting the solution into the hood. 
o  Add 25 mL of the oil solution to each 50mL conical tube.  
1. Note- Move the pipette clockwise (continuously) while aspirating the solution. 
o Remove the remaining solution from the beaker and distribute it evenly between the 
two tubes. 
1. Note- Move the pipette clockwise while aspirating the solution. 
o Add 5 mL of PBS-L101 to each conical tube. 
o Invert the tubes with your hand for 5 minutes.  
o Place the tubes in the centrifuge. USE SETTING 4 (200g for 5 min). 




o Once most of the oil has been removed from the tubes, wash a NEW pipette with PBS-
L101 by aspirating PBS-L101 up and down. 
o Using this NEW pipette, aspirate the bead-oil solution from each 50 mL conical tube 
and place it into a new 15 mL tube (2 tubes total). 
o Add 8 mL of PBS-L101 to one of the empty 50 mL tubes, in order to collect any of the 
remaining beads, and then rinse the second 50 mL tube with the same solution.  
o Add 4 mL of the 8 mL solution to each 15 mL tube (Note- Final solution per tube is 
approximately 12 mL when initial col-fib solution is 4.5 mL).  
o Centrifuge tubes once again at Setting 4. 
o Remove the non-bead solution from both tubes, then with a NEW pipette rinsed with 
PBS-L101, collect the beads and place them in one new 15 mL conical tube. 
o Add 5 mL of PBS-L101 and mix well. (Total solution is approximately 6 mL). 
o Place tube for 10 minutes in the incubator. Make sure the cap in the tube is loose to 
allow air flow.  
o Proceed to centrifuge the beads using Setting 4. 
o Take out the supernatant and add EGM-2 to the tube. (Add the same volume of EGM-2 
that was originally used in the COL-FIB bead solution). [If the beads were made with 
an original 3.0 mL solution, then add 3.0 mL of EGM-2 to the beads]. 
o Transfer the bead/media solution into a new labeled 15 mL conical tube, and place it 
in the incubator. Make sure the cap is loose to allow air flow. 
o Change the media of the beads the next day and then every other day until the desired 
time point.  




Appendix D – Fibrin only cellular microbead Protocol 
 
• Total Cell Density: 
• Desired: 2.0M cells/mL 
• 3.0M HUVECs, 3.0M NHLFs = 6.0M total in 3.0 mL FIB solution. 
 
• Total Fibrinogen Needed: 
• 5.4 mg/mL initial fibrinogen concentration (includes the protein and clottable 
concentration) in SFEGM-2 
 
• *** Leave in water bath to assure fibrin is completely dissolved (for a minimum of 30 
minutes). Sterile filter solution prior to making the microbeads. 
 
• FIBRIN Recipe: (Total = 3 mL) 
• SFEGM-2  765 µL 
• FBS  300 µL 
• Thrombin  60 µL 
• Fibrin  1875 µL 
 
• Same procedure as COL-FIB microbead procedure (see appendix C)  
• Normal three washes were made: 
• Wash #1:  
• Washed the 25-mL plastic pipette with PBS+L101 prior to distributing the 
beads and PDMS into the 50mL conical tubes. 
• Separated the 75 mL of beads and PDMS solution into two 50 mL conical 
tubes. 
• Added 5 mL of PBS+L101 solution into each tube and inverted tubes for 5 
minutes. 
• Centrifuged for 5 minutes at 200g acceleration and deceleration: 9.  
 
• Wash #2: 
• Aspirated off the PDMS and rinsed a 10 mL plastic pipette with PBS + L101 
solution 
• Took the remaining solution from the 50 mL conical tubes and transfer it into 
two 15 mL conical tubes. (approximately 8mL per tube) 
• Added 4  mL of PBS+L101 on top of each tube and centrifuged for 5 min 




• Wash #3: 
• Removed supernatant and rinsed a 10 mL plastic pipette with PBS+L101 
solution 
• Took the remaining bead solution from the 15 mL conical tubes and transfer it 
into a new 15 mL conical tube. 
• Added 5 mL of PBS+L101 to the bead pellet and mix well. 
• Placed the tube in the incubator for 10 minutes. 
• Centrifuged for additional 5 minutes (same parameters as previous washes). 
• Mixed microbead pellet with EGM-2 for sprout length studies. 
Notes: The 10-minute incubation time during wash 3 for FIB microbeads was no longer used (in 
Aim 2) for FIB microbeads pre-culture and in vivo studies since cell viability did not decrease 




Appendix E – Collagen Preparation 
 
Collagen TYPE I 
Storage: 4 °C [Fridge next to the CMITE cryogenic tank] 
Cat No: 150026    Lot No: 9787K 




• Autoclave a 100 mL bottle with a small stir bar (in one bag), and big tweezers (in a separate 
bag). 
 
• Do steps 2 and 3 inside the hood. Add 250 mg of collagen to the autoclaved bottle using the 
autoclaved tweezers. [An entire bottle of collagen contains 250 mg of collagen]. 
 
• Add 62.5 mL of 0.02 N of acetic acid on top of the collagen. 
 
• Close the lid of the bottle and label it appropriately. (i.e. 4 mg/mL Collagen A.Y.R.] 
 
• Leave the bottle on top of spinner that is inside the fridge located next to the CMITE 












Appendix F – Preparation of M199 Medium 
 
Note- The following protocol has been taken from the Invitrogen website (see link below); 
however, some minor changes have been made to it.  
1. Measure 5% less distilled water than the desired total volume of medium. Use a mixing 
container that is as close to the final volume as possible. 
2. Add powdered medium to room temperature (15 °C to 30 °C) water with gentle stirring. Do 
not heat the water. 
3. Rinse out the inside of package to remove all traces of powder. Use the same water that is in 
the beaker to rinse out the package. It’s easier if you employ a pipette to do this step. 
4. Add 2.2 g of sodium bicarbonate (NaHCO3) per liter of medium. 
5. Dilute the desired volume with water. Stir until dissolved by putting the beaker and the stirring 
bar on top of a stirring plate. DO NOT over-mix and do not apply heat. 
6. Adjust the pH to 0.2 and 0.3 units below the desired final working pH by slowly adding, with 
stirring, 1 N NaOH or 1 N HCl. The pH may rise 0.1 to 0.3 units upon filtration.          
 Desired pH = 7.4. 
7. After pH is adjusted keep container closed until medium is filtered. 
8. Adjust the final volume with distilled water. 




10. Once the 199 Media has been filtered, take out the desired amount needed for your 
experiments.  
11. Add 10% FBS, 1% penicillin-streptomycin (P/S), and 0.1% Gentamicin reagent solution. 
Both Media 199 with and without FBS and antibiotics can be stored in the refrigerator where all 
the other media is stored. 
 







Appendix G – Immunofluorescent staining of microbeads and hydrogels 
 
1. Wash samples with PBS for 5 minutes by adding 300 µL of PBS to each well or Eppendrof 
tube. 
2. Fix cells in 10% formalin for 10 minutes at room temperature by adding 200 µL of formalin 
to each well/Eppendorf tube. 
3. Wash samples with PBS for 5 minutes (4X  20 minutes total). (300 µL of PBS for each 
sample). 
4. Swirl container to make sure samples are rinsed thoroughly.  
5. Permeabilize cells with Tris-buffered saline (TBS) + 0.5% Triton X-100 for 10 minutes 
(4X  20 minutes total). Add 200 µL of TBS + 0.5% Triton X-100 solution to each sample. 
6. Swirl container to make sure samples are rinsed thoroughly.  
7. Wash samples with TBS-T (TBS +0.1% Triton) for 5 minutes by adding 400 µL of TBS-T 
to each sample. (4X  20 minutes total).  
8. Swirl container to make sure samples are rinsed thoroughly.  
9. Block with 2%BSA in TBS-T (Abdil) for 20 minutes at 4°C. Add 400 µL of Abdil to each 
sample. [4 grams of albumin in 200 mL of TBS-T). 
10. Primary incubation at 4°C.  
• Primary Antibodies (AB): (1:100 dilution  1 µL of pAB in 100 µL of Abdil) Use 
one of the following primary antibodies: 
1. Mouse laminin [Stored in Fridge A, -20°C, in -20 °C Antibodies box]. 
2. Rb to pAB laminin [Stored in Fridge A, -20°C in –Albert’s box -20 °C]. 
(Rabbit to primary antibody laminin). 
• Phalloidin: (1:250 dilution  1 µL of phalloidin in 250 µL of Abdil)  
1. Oregon Green 488 Phalloidin [Stored in Fridge XX]  
11. Leave overnight. 
12. Wash samples for 5 minutes in TBS-T (4X  20 minutes). 400 µL of TBS-T on each 
sample. 
13. Incubate with secondary antibody for 1 hour at 4°C. 
6 Secondary Antibodies: (1:450 dilution  1µL of 2°AB in 450 µL of Abdil) Use 
one of the following secondary antibodies: 
1. Goat Anti-mouse Alexa 488 
[Storage: Fridge B, 4 °C, antibody box, side door] 




[Storage: Fridge B, 4 °C, antibody box, side door] 
3. Goat Anti-mouse Alexa 594  
[Storage: Fridge B, 4 °C, antibody box, side door] 
4. Goat Anti-rabbit Alexa 594  
[Storage: Fridge B, 4 °C, antibody box, side door] 
 
**NOTE- Make sure that if primary antibody is anti-rabbit, then secondary must be anti-
rabbit too. You can’t use Rb to pAB laminin for 1° antibody and Goat-anti-mouse for 2°. 
 
14. Wash samples for 5 minutes in TBS-T (4X  20 minutes). 400 µL of TBS-T on each 
sample. 
15. Use DAPI to stain the nuclei of the samples (1:10,000 dilution in PBS) for 10 minutes at 4 
°C.  [Stored in Dr. Stegemann’s fridge]. 
7 0.5 µL in 5 mL PBS 
**NOTE- You can use 1:1000 dilution for better results. 
 
16. Wash samples for 5 minutes in TBS-T (4X  20 minutes). 400 µL of TBS-T on each 
sample. 
17. Store samples with TBS-T at 4 °C. Cover the samples with parafilm and foil to make sure 
that the TBS-T does not evaporate over time and that the samples are not exposed to light. 
Check over time to make sure TBS-T does not evaporate.  




Appendix H – Cell count microbead analysis 
 
• Open Bright-field and DAPI images using ImageJ 
• Open cell count analysis excel file 
 
• Measure Bead Diameter: 
 
• Select bright-field image 
• Draw a horizontal line across the bead, hit CTRL+M to measure the diameter of the 
bead 
• Draw a vertical line across the bead, hit CTRL+M to measure the diameter of the 
bead 
 
• Measure Cell Count: 
 
• Select DAPI image 
• Click Image → Lookup Tables → Blue 
• If there are more than 2 beads, then overlay bright-field image 
• Image → Overlay → Add Image  
• Select Image to add: bright-field image, change the opacity to 50% 
• Click OK 
• Select Plugins → Analyze → Cell Counter 
• Hit Initialize, and then type 1 counter 
• Begin selecting each nucleus 
• The final number will appear on the rectangle to the right of the type 1 
counter. 












Appendix I – H&E histology staining protocol 
Note – This protocol is based on Ethan Daley’s optimized protocol  
 
Dewaxing slides 
1. Wash slides with Xylene 2x (5 min/wash) [Dewaxed with Xylene] 
 
Re-hydration of slides 
2. Wash slides with 100% ethanol 2x (3 min/wash) 
3. Wash slides with 95% ethanol 2x (3 min/wash) 
4. Wash slides with 70% ethanol 1x (3 min/wash) 
5. Wash slides with DI water 1x (3 min/wash) 
 
Staining of slides 
6. Hematoxylin - 15 minute incubation time 
7. Tap water (running water and rinsing) - 15 minutes 
8. 95% Ethanol - 1x (30 seconds) 
9. Eosin - 1x (1 minute) 
 
Dehydration of slides 
10. 95% Ethanol - 1x (1 min/wash) 
11. 100% Ethanol - 2x (1 min/wash) 
 
Clearing of slides 
12. Wash slides with Xylene 2x (3 min/wash) 
 
Mounting coverslips on slides 
• DO NOT wash coverslips with xylene (dip them in xylene) 
• Add 3 to 4 small drops on the coverslip and place it on top of the slides 




o Mayer's Hematoxylin (Electron Microscopy Sciences 26252) 
o Eosin Y (Sigma HT110132) 
• Use absolute ethanol to make reagents 
• Always go left to right direction 






Appendix J – Antigen Retrieval, CD31 Immunohistochemistry Staining 
 
Deparaffinization and Rehydration:  
* Protocol from P. 8 of Dako General Instructions For Immunohistochemical Staining 
November 2009 
 
1. Place tap water in the food steamer and turn on while slides are being deparaffinized and 
rehydrated (steps below) 
2. Take out target retrieval solution from the fridge and place it in a 100 mL beaker (enough 
volume to cover the cassette with the slides). 
3. Place slides in the cassette. 
4. Place slides in a xylene bath and incubate for 5 minutes. Transfer to a new xylene bath and 
leave for 5 minutes.  
5. Tap off excess liquid and place slides in 100% ethanol for 3 minutes. Transfer to a new 100% 
ethanol bath and leave for 3 minutes.  
6. Tap off excess liquid and place slides in 95% ethanol for 3 minutes. Transfer to a new bath 
and leave for 3 minutes.  
7. Tap off excess liquid and place slides in distilled water for 30 seconds. 
 
Antigen Retrieval:  
* Protocol designed with Anu David’s helpful tips (Shikanov Lab’s Post Doc)  
 
8. Place cassette in beaker containing the target retrieval solution. Use gloves to place the 
beaker in the food steamer.  
9. Leave the beaker in the steamer for 35 minutes (it takes about 13 minutes for the temperature 
in the beaker to turn 90 degrees C). 
10. While your slides are in the steamer, prepare the slide chamber for the staining protocol. 
a. Cover the bottom of the slide chamber with tissues. 
b. Completely wet tissues with water, make sure some of the water remains in the   
chamber.  
c. Close the chamber and leave it on the counter until Step 15. 
11. Take out beaker and let it cool for 30 minutes. 
12. Wash slides with TBS-T (2 minutes, 3x). Change baths for every TBS-T wash. 
13. Remove moisture from slides and tissues carefully. 







* Protocol designed with Anu David’s helpful tips (Shikanov Lab’s Post Doc) and from Dako 
Envision+ System-HRP (DAB)  
15. Add enough peroxidase block to cover specimen completely. Place slides in slide chamber 
prepared to avoid slides from drying. Incubate for 5 minutes.  
16. Rinse gently with TBS-T (2 minutes, 3x). Change baths for every TBS-T wash. 
17. Remove moisture from slides and tissues carefully. Add primary antibody to cover entire 
specimen. 1:50 (i.e 5 µL CD31:245 µL of TBS-T). 
18. Place each slide in slide chamber, prepared to avoid slides from drying. Incubate for 16 hours 
at 4 deg C.  
 
 
19. Try to remove antibody carefully (one slide at a time,, 1st dip each slide in TBS-T to remove 
primary antibody). Then rinse gently with TBS-T (2 minutes, 3x). Change baths for every 
TBS-T wash. 
20. Tap off excess buffer, place slides in slide chamber, and add peroxidase labelled polymer. 
Incubate for 30 minutes. Start making the Liquid DAB+ Substrate needed in step 23 when 
there are 10 minutes left of the incubation time. 
21. Try to remove peroxidase labelled polymer carefully (one slide at a time). Then rinse gently 
with TBS-T (2 minutes, 3x). Change baths for every TBS-T wash. 
22. Remove moisture from slides and tissues carefully.  
23. Place slides in slide chamber and add prepared Liquid DAB+ substrate-chromogen 
solution to slides. Incubate for 5 minutes.  
   
  Preparation of Liquid DAB+ substrate-chromogen solution: 
    **To make 1 mL of the solution (for up to 10 tissue sections) 
1. Transfer 1 mL aliquot of buffer substrate into provided calibrated test 
tube (~40 µL/drop) [approximately ~33-35 drops] 
2. For each 1 mL of buffer, add one drop (20 µL) of liquid DAB+ 
Chromogen   
3. Mix immediately and apply to tissue section with pasteur pipette. 
   Note - Prepared solution is stable for 5 days when stored at 4 deg C. Make sure   
   solution is well mixed prior to adding to tissues. 
 
24. Rinse gently in distilled water. Collect waste in hazardous waste container.   
25. Immerse slides in hematoxylin and incubate for 15 minutes. 
26. Wash gently with tap water for 10 minutes (water container, water should be clear) 
27. Two washes with 95% ethanol (1 minute per wash) 
28. Two washes with 100% ethanol (1 minute per wash)  
29. Two washes with xylene (3 minute per wash) 




Appendix K – Alpha-smooth muscle actin immunohistochemistry 
staining 
Same protocol as Appendix J, except: 
• Primary antibody used: Smooth muscle actin monoclonal antibody (1A4 (asm-1)) 
[Invitrogen: Thermo Fisher Scientific] 
• Concentration of antibody: 1:800 in TBS-T 




Appendix L – CD31 Vessel Quantification (Single-blind study) 
 
• Open 20x Images from each individual CD31 folder 
o Make sure you select every other 20x image (Images 1, 3, 5, 7, and 9).  
o Some folders may have more images, if this occur then divide the number of images 
by 5 to get a number “N”. Analyze every Nth image (five images total). 
▪ Example: 40 images then 40/5 = 8, so images that will be analyzed are 8, 16, 
24, 32, and 40. 
o Do NOT calibrate images 
 
• Quantify: Excel Template  
 
o Vessel: Brown CD31 rim with erythrocytes  
o The number of vessels with hollow lumens (V_L) 
o The number of vessels with hollow lumens and erythrocytes inside the lumen (V_LE)  
o Measure the diameter of each vessel, make sure you keep track of which diameter 
belongs to which type of vessel (diameter of V_L vs. diameter of V_LE) 
▪ Some vessels are positioned longitudinal. In this case, make sure to measure the 
diameter that represents the entire vessel. 
o Keep track of the number of individual V_L/V_LE vs number of V_L/V_LE connected 
(i.e. you have a total of 10 V_L, 3 of them are by themselves, 1 group has 2 V_L 




o Open 20x image in ImageJ 




▪ Click area, shape descriptors, Feret’s diameter, add to overlay, limit to 
threshold, and display label. 
▪ Decimal places: 2 
▪ Click OK 
o (You can start with diameter measurements first) Measure the diameter of the V_L and 
V_LE conditions Select the Straight line tool to begin measuring the diameters of V_L 
and V_LE. 
▪ Select the inner diameter of the vessel and hit CTRL+M 
▪ Important Notes 
• Keep track of the numbers for the V_L and V_LE diameters and then 
write it down in excel.  
o Plugins  Analyze  Cell Counter 
▪ Click on the image, click keep original and then click initialize 
▪ A new window will pop-up with a copy of your image 
▪ Click on the Type 1 counter (blue) in the cell counter window and add every 
V_L  
▪ Click on the Type 7 counter (red) in the cell counter window and start from the 
beginning counting every V_LE  
▪ Hit the Results button in the cell counter window and record the numbers from 
both Type 1 and Type 7 counter in the excel sheet 
▪ Close the cell counter window 
o Quantify the number of independents vs joint lumens 
▪ You can use either the first or second image. The cell counter can help facilitate 
this quantification. 
o Keep a copy of each image after analysis (save as JPEG).  
o Save the diameter results in a different excel file prior to adding these numbers to the 
CD31 vessel quantification excel sheet. 
▪ This will be important in case we need to remove some of the data points based 
on a diameter size threshold. 
o There is a Notes column in case you have any questions/comments about certain 
images. 





Appendix M – Nuclear Magnetic Resonance (NMR) analysis 
Note – Based on Gopinath Tiruchinapally’s protocol and analysis. 
 
• Prepare fibrin constructs and transfer into dialysis bags (8 kDa MWCO). 
• Dialyze samples with DI water for 2 days, then proceed to lyophilized to obtain dry samples 
• Take 1.2 mg of each sample and dissolve it in 0.5 mL of D2O. 
o Some samples required an additional 0.1 mL of solvent to dissolve properly.   
• 1H NMR spectra in D2O were recorded on 700 MHz Varian Mercury systems (Palo Alto, 
CA) at room temperature.  
o NMR spectra were referenced using Me4Si (0 ppm), residual D2O at δ 1H-NMR 4.65 
ppm. 
 
Pure fibrinogen: We observed amide NH-protons at 6.5-7.6 ppm. These are characteristic peaks 
for Aspartic acid (Asp), Glutamic acid (Glu), Glycine (Gly) and Lysine (Lys) peptide bonds. We 
observed several multiplets for carbohydrate portions of the protein at 3.00-4.50 ppm. These peaks 
are for Mannose (Man), Galactose (Gal) and N-acetylgalactosamine (GlcNAc) protons. Other 
characteristic peaks at 2.00 ppm and 2.60-2.80 ppm were observed for N-acetyl neuraminic acid.  
 
Fibrin hydrogel: All peaks observed were similar to the ones found in pure fibrinogen NMR, but 
slightly distorted. For example, the amide NH peaks observed at 6.20-7.40 ppm were less intense 
than what we observed in pure fibrinogen. This could be because several NH peaks may be trapped 
inside the cross-linking network, and also might be participating in the network formation. We 
found almost all other peaks for amino acids and carbohydrates to be similar to the fibrinogen 
NMR. Interestingly two singlet peaks were observed at 2.58 ppm and 3.42 ppm, which is typically 
found if there is a methylation. We did not use any methylating agent during gel preparation, so 
this might be due to conformational changes in the sugar which exposes N-acetylneuraminic acid 
and mannose O-methyl groups.  
 
Fibrin (acellular) microbeads: This NMR data was very different to the previous two NMRs. No 
NH peaks were found at 6.5-7.4 ppm. This indicates that the protein changed its conformation 




(PDMS). During the emulsification process, the oil will most likely interact with the hydrophobic 
portions of the proteins and the hydrophilic portion (carbohydrate) of the protein may eventually 
get trapped inside the microbeads. This may be one of the reasons why we don’t observe the amide 
protons. In other words, the inner portion of the protein did not experience the D2O. Some of the 
carbohydrates peaks are also missing, which validates the theory that the microbead preparation 
method has an impact on how the fibrinogen protein individual molecules will arrange (cross-link) 
during the microbead formation (polymerization). To test our hypothesis, a hydrophilic solvent 
must be used for the microbead preparation to determine if we can see the NH amide protons.  
 
Cellular control fibrin microbeads (non-pre-cultured) embedded in fibrin hydrogel for 1 
day: We detected some low intense NH peaks for amides at 6.50- to 7.40 ppm, which is most 
likely attributed mainly to the hydrogel amides and not from the microbeads. The control 
microbeads’ NMR was very similar to the fibrin hydrogel NMR with some modifications including 
some extra peaks at 0.4-1.50 ppm, which may be due to some cell debris (lipids) [1]. Some 
aliphatic fatty acid (lipids) peaks were found around 0.5-2.00 ppm. The low intensity of these 
peaks indicates that the more cells are more likely inside the microbeads than within the remaining 
fibrin hydrogel.  
 
Cellular pre-cultured fibrin microbeads embedded in fibrin gel for 1 day: A more intense NH 
peak for amides at 6.50- to 7.40 ppm was found compared to the control microbead samples. A 
reason may be that microbeads may be opening in some areas and the amides from microbeads 
may be exposed to D2O solvent, increasing the peak intensity. More aliphatic lipid peaks were 
observed around 0.5-2.2 ppm than in the control microbeads implant, which may indicate that 
more microbead openings are taken place during the 3 days. We also see some characteristic 
carbohydrate peaks around 3.30-3.80 ppm, which indicating that there is more exposure of the 
carbohydrates portion from the microbeads and the hydrogel. These peaks were not observed in 
pure fibrin hydrogels, acellular fibrin microbeads and control microbeads. This result suggests that 
there may be additional matrix modifications done by cells encapsulated and left in culture for 
additional 3 days prior to embedding. 
There are two interesting outcomes from control and pre-cultured microbeads embedded in fibrin 
hydrogels’ NMRs:  
1. The time taken to dissociate some portions of the outer layer of the microbead  
is approximately 3 days. 
2. The amount of debris (lipids) from the cells may indicate the amount of the cells  
come out of the beads into the gel/matrix.  
Reference: 
1. Duarte, I.F., et al., Analytical approaches toward successful human cell metabolome studies by 




Appendix N – Fibrin Microbead Pre-culture 
Protocol: 
1. After microbead production, re-suspend the microbead pellet in 10 mL of EGM-2 media. 
 
2. Place the microbead/media solution in 15 mL Eppendorf tubes with air filters (CELLTREAT 
Scientific Products, Shirley, MA). Add each batch to a separate Eppendorf tube. 
 
3. Place tubes up-right in the incubator at 37°C overnight. 
 
4. Change media of microbeads, the next day and every other day after that. 
 
5. Media changes are done by first centrifuging the tubes containing the microbeads for 1 min at 
200xg to allow microbeads to settle to the bottom. 
 
6. Remove media with plastic pipettes to prevent microbead aspiration.  
Note – Some left over media will be left in the tube ~1 to 1.5 mL of microbeads/media left in  
tube after media removal. 
 
7. Re-suspend microbeads with 10 mL of fresh EGM-2. Make sure to mix well, at least 3 times 
up and down with plastic pipette. 
 
8. Place tubes back in the incubator and change media every other day until experimental studies.  
Important Notes: 
• Fibrin microbeads may aggregate a lot, especially right after their fabrication process.  
Make sure to mix the microbeads with a plastic 10 mL pipette coated with EGM-2  
 
o Aspirate EGM-2 with pipette up and down a few times before mixing the media 
with microbeads to prevent microbeads sticking to the pipette. 
 
o Make sure NOT to use a P1000 to avoid additional aggregation of microbeads into 
P1000 tips. 
 
• Media volume added to microbeads is important. Not adding enough media during pre-




Appendix O – AG+HA+FGN Microbead Processing 
Protocol designed by Ana Y. Rioja and Ethan L.H. Daley 
 
• Cells:  
o 2M total cells/mL in a 1:1 ratio of HUVECs:NHLFs co-cultures. 
o Each batch was made with 3 mL of solution 
o 2 batches of microbeads were made at a time. 
 
• Recipes (units in μl) 
o 8 mg/mL AG 
▪ 1200 AG 
▪ 480 FBS 
▪ 1320 SFEGM-2/cells 
 
o 8 mg/mL AG+15 mg/mL HA 
▪ 1200 AG 
▪ 150 HA 
▪ 330 FBS 
▪ 1320 SFEGM-2/cells 
 
o 8 mg/mL AG+0.25 mg/mL FGN 
▪ 1200 AG 
▪ 480 FBS 
▪ 1132.5 SFEGM-2/cells 
▪ 187.5 FGN 
 
o 8 mg/mL AG+1.25 mg/mL FGN 
▪ 1200 AG 
▪ 480 FBS 
▪ 382.5 SFEGM-2/cells 
▪ 937.5 FGN 
 
o 8 mg/mL AG+15 mg/mL HA+0.25 mg/mL FGN 
▪ 1200 AG 
▪ 150 HA 
▪ 330 FBS 
▪ 1132.5 SFEGM-2/cells 






o 8 mg/mL AG+15 mg/mL HA+1.25 mg/mL FGN 
▪ 1200 AG 
▪ 150 HA 
▪ 330 FBS 
▪ 382.5 SFEGM-2/cells 
▪ 937.5 FGN 
• Protocol: 
o Load the components above into a 10 mL syringe and inject (25-gauge needle) into 100 
cSt polydimethylsiloxane (PDMS) oil (Clearco Products Co. Inc. Bensalem, PA). 
o Mix solution in PDMS at 700 rpm for 6 min at 37 °C and then for 30 min on ice to gel 
the resulting microbeads 
o Wash all microbeads with PBS and re-suspended to a total 9 mL volume (EGM-2 + 
beads) 
o Place 1 mL aliquots in 15 mL conical tubes with air filters caps (green caps) and leave 




o HA= hydroxyapatite nanoparticles 
o FGN=fibrinogen 
o Agarose must be heated to 65 °C prior to use 
o HA needs to be sonicated for 15-20 min prior to use 
o FGN must be prepared the day of use 
o Total aqueous component volume= 3000 μL 
o Concentrations given in recipes are in 3000 μL volume 
 
• Stock solutions: 
o AG: 20 mg/mL in dH20 
o HA: 300 mg/mL in FBS 
o FGN: 4 mg/mL (clotting components) in serum-free EGM-2 (5.4 mg/mL total) 
 
• Notes - 
o Microbeads gelled too fast prior to adding the entire cell/solutions from the recipe 
above into the PDMS bath. This occurred because AG was added last instead of FGN. 
Fibrinogen (FGN) must be added last. 
 
o All FGN was made fresh per batch to avoid fast gelation. FGN was left in the water 




Appendix P – Subcutaneous Injections, Implant Removal and Fixation 
 
Materials: 
• BD 1/2 cc Insulin Syringe U-1000 28G 1/2" needle Ref 309306 (Fisher Scientific 
Company LLC, Pittsburgh, PA) 
• Puralube® Vet Ointment – Sterile ocular lubricant (Dechra, Overland Park, KS) 
• Small cotton-tipped applicators Cat. No. 23-400-115 (Fisher Scientific) 
• Sterile alcohol prep pads (Fisherbrand®) 
• Sterling nitrile sterile powder-free exam gloves. KC300 (Kimberly-clark, Roswell, GA) 
• Polylined sterile drape field. (18 in. x 26 in.) Ref No. 697 (Bosse, Hauppauge, NY) 
• Drugs: Ketamine, xylazine, buprenorphine 
• Additional materials: Cap, gown, mask, shoe covers, warming pad/blanket, heating lamp, 
nair hair removal, hair clipper, betadine antiseptic solution, forceps, and scissors, formalin, 
20 mL vials, 70% ethanol.  
 
Subcutaneous Injection Protocol: 
1. Mice must be left in their housing facility for 3 days to acclimate prior to surgery 
2. Appropriate gown, gloves, face mask, cap, and shoe covers must be worn prior to handling 
animals 
 
All steps below were done under the hood, except for step #4 
3. Administer drugs to each mouse before surgery via intraperitoneal (IP) injection 
 
Drug Dosage (Anesthetic/analgesic): 
• Ketamine  80-120 mg/kg IP  
• Xylazine   5-10 mg/kg IP 
• Buprenorphine: 0.05-0.01 mg/kg IP 
 
4. Transfer each mouse into a cage placed under a warming blanket  
5. Apply ointment to eyes of mice, once anesthesia takes effect 
6. Shave the back of the mouse and then apply Nair hair removal to make sure injection site 
does not have any remaining hair 




8. Apply betadine antiseptic solution with small cotton-tipped applicators and alcohol prep pads 
twice to sterilize the area  
9. Make a sterile area by placing a polylined sterile drape in the hood.  
10. Drop syringes and needles (two of each) onto the sterile area (step 9) 
11. Remove gloves and put on sterling nitrile sterile powder-free exam gloves. In the meantime, 
second person should prepare samples by adding fibrinogen and thrombin 
Note – Thrombin shouldn’t be added until person injecting samples is prepared to do so 
12. Mix samples thoroughly and inject each implant subcutaneously on flank of the mouse – one 
sample per flank. (Lift mouse skin with forceps to create a tent in order to facilitate injection) 
13. Let the samples gel for 30 seconds and the rinse the injection site with ethanol alcohol pads. 
14. Take Laser Doppler Perfusion Imaging (LDPI) of each mouse 
15. After 12 hours, inject mice with a second dose of buprenorphine to prevent surgical pain 
 
Implant Removal and Fixation Protocol: 
16. After 1, 3, 7, and 14 days, inject the same drug dosage to mice as done prior to subcutaneous 
injections (see step 3 from section above) 
17. Take Laser Doppler Perfusion Imaging (LDPI) of each mouse 
18. Place mice in cage and turn on CO2 
19. Once mice are euthanized, make sure to perform a bilateral pneumothorax to ensure animal 
does not revive from carbon dioxide overdose 
20. Wipe injection are with 70% ethanol  
21. Open mouse to remove implant. Make sure to separate as much of the extra tissue from the 
implant prior to fixation 
22. Place each implant into 20 mL vials containing Z-fix formalin 
23. Store beakers in fridge for 24 hours 
24. Rinse implants with phosphate buffer saline (2 to 4 times) 
25. Add 70% ethanol to 20 mL vials containing implant and place it in fridge until tissue 
processing  
 





Appendix Q – Preliminary Studies on Effects of Gelatin Spheres on 
Endothelial and Stromal Cells 
Work done by Ana Y. Rioja and Paul A. Turner  
 
Overall Project Goal: 
Develop gelatin A microspheres crosslinked with genipin to load growth factors such as 
vascular endothelial growth factors (VEGF) and augment overall sprout length. 
 
Preliminary Study: 
 Prior to starting VEGF delivery studies, preliminary studies were started to determine 
whether endothelial cells and other stromal cells could degrade the gelatin microspheres required 
to release the growth factors, once loaded. First, human umbilical vein endothelial cells 
(HUVECs), normal human lung fibroblast (NHLFs), adipose stem cells (ASCs), and mesenchymal 
stem cells (MSCs) were plated on two-dimensional (2D) tissue culture dishes with 200 µg 
microspheres per well to determine microsphere degradation. The gelatin microspheres were 
crosslinked with genipin (590 nm /620 nm, Cy5 filter) to measure degradation based on fluorescent 
readings using a plate reader (Biotek).   
Bright-field images of microspheres alone or with HUVECs and NHLFs shows how 
HUVECs and NHLFs interact with microspheres. The microspheres alone are visualized in the 
Texas-red fluorescent images (Fig. Q-1). HUVECs degraded the microspheres the most, followed 
by ASCs, MSCs, and NHLFs (Fig. Q-1G). Microsphere degradation by HUVECs-NHLFs and 
HUVECs-ASCs were measured and compared to the stromal cells alone. These two stromal cells 
were used since one provided the least degradation while the other provided the most degradation 





Figure Q-1: Cell type affects microsphere degradation (2D). Representative bright-field images of microspheres 
with (C, E) and without cells (A), and microsphere Texas-red fluorescent images (B, D, F). Quantification of 




Figure Q-2: Co-cultures affect microsphere degradation (2D). (A) Microsphere degradation was higher when 
HUVECs-NHLFs were mixed rather than having NHLFs alone. (B) Degradation of microspheres by ASCs was higher 
than when combined with HUVECs (HUVECs-ASCs).  
 
 HUVECs-NHLFs co-cultures degraded the microspheres more than NHLFs alone (Fig. Q-
2A), but not as much as HUVECs alone (Fig. Q-1G). On the other hand, ASCs alone degraded 
more microspheres than HUVECs-ASCs co-cultures (Fig. Q-2B), but once again not as high 
compared to HUVECs microsphere degradation. Three-dimensional (3D) studies were done to 
quantify endothelial sprouting and microsphere degradation in both fibrin and collagen hydrogels 





Figure Q-3: Study on effects on EC sprouting and gelatin microsphere degradation when embedding microspheres 
with stromal cells in three-dimensional fibrin and collagen hydrogels.  
 
 
Figure Q-4: Microsphere degradation depends on matrix type. 
 
To determine microsphere degradation on 3D systems; HUVECs, NHLFs, and ASCs were 
embedded in 2.5 mg/mL fibrin and 2.5 mg/mL collagen hydrogels (Fig. Q-4). The three cells 




in collagen degraded microspheres the most, followed by NHLFs, and the least by HUVECs. This 
was surprising as HUVECs degraded the microspheres the most on the 2D system (Fig. Q-1G).   
Vasculogenesis assays require both HUVECs-stromal cell co-cultures for proper vessel 
formation. For this reason, we embedded HUVECs co-cultured with NHLFs or ASCs. Previous 
studies done by our lab showed that sprout formation does not occur in collagen hydrogels. 
Therefore, HUVECs-NHLFs (Fig. Q-5 A-D) and HUVECs-ASCs (Fig. Q-5 E-H) were embedded 
with (Fig. Q-5 B-D, F-H) and without (Fig. Q-5A, E) microspheres in 2.5 mg/mL fibrin hydrogels 
only to determine effects of microspheres and stromal cells on sprout formation. HUVECs were 
stained with UEA-I, nuclei with DAPI, and microspheres (Texas-red)., After 10 days, total sprout 
length in HUVECs-NHLFs was higher than HUVECs-ASCs condition. However, the addition of 
microspheres caused a decrease in total sprout length in the HUVECs-NHLFs condition, and an 
increase in total sprout length in HUVECs-ASCs condition.   
 
Figure Q-5: Microspheres affect endothelial sprouting in 3D fibrin hydrogels. (A-D) HUVECs-NHLFs or (E-H) 
HUVECs-ASCs were embedded in fibrin hydrogels (A, E) alone or with (B, F) 0.625, (C, G) 1.25, (D, H) 2.5 vol% 
of microspheres. (I) Quantification of endothelial sprouting of HUVEC-stromal cell type co-cultures after 10 days. 
Scale bar – 250 µm. 
 
Since HUVECs and NHLFs formed the highest sprout length when embedded in fibrin, 




sprout formation to occur (vascular microbeads). In addition, since microspheres were degraded 
the most by ASCs, then we embedded the pre-cultured microbeads with ASCs and microspheres 
with or without VEGF in 1.0 mg/mL and 2.5mg/mL collagen (Fig. Q-6).   
 
Figure Q-6: Microsphere degradation, VEGF release, and vessel formation studies of fibrin vascular microbeads 
containing HUVECs-NHLFs embedded with ASCs, and microspheres loaded with and without VEGF in 3D collagen 
hydrogels. 
 
Loading microsphere with VEGF did not alter microsphere degradation by cells. In 
addition, an increase in microsphere degradation was found if cells were embedded in lower 
collagen concentrations (Fig. Q-7). The cumulative VEGF release was low in vascular microbeads 
embedded with unloaded microspheres in collagen hydrogels (Fig. Q-8) suggesting that VEGF 
release was due to the ASCs and vascular microbeads (HUVECs-NHLFs) interaction. In addition, 
the collagen hydrogel concentration (1.0 mg/mL vs. 2.5 mg/mL) did not affect the VEGF release. 
VEGF-loaded microspheres were embedded without cells in a 2.5 mg/mL collagen hydrogel, and 
had a higher cumulative VEGF release than cellular constructs with unloaded microspheres. Based 
on these results, it appears that VEGF-loaded microspheres have an initial burst release and then 
it reaches steady-state. This release is higher than what’s secreted by the cells alone (Fig. Q-8).  
Once vascular microbeads were embedded with VEGF-loaded microspheres in collagen 
hydrogels, the cumulative VEGF release increase even more than the previous conditions. In 
particular, embedding them in a lower collagen concentration (1.0 mg/mL) resulted in an even 





Figure Q-7: Degradation of microspheres decreases with collagen concentrations. 
 
 
Figure Q-8: Cells degrade microspheres and release VEGF into 3D collagen hydrogels. 
 
 Sprout formation did not occur when collagen hydrogels contained no microspheres (see 
chapter 6). However, the addition of microspheres with (Fig. Q-9) or without VEGF (see chapter 






Figure Q-9: Microspheres with VEGF promote EC sprouting in (A) 1 mg/mL collagen hydrogel and (B) 2.5 mg/mL 
collagen hydrogel. Insets of each image show a wider area containing human endothelial sprouts. Scale bar – 50 µm, 
100 µm of insets.   
 
Conclusions: 
We found that microsphere degradation is affected by the cells and materials they are 
interacting with (Fig. Q-10). These cells will degrade the microspheres differently whether they 
are in 2D or 3D systems. Both NHLFs and MSCs behaved similarly on 2D systems, while ASCs 
displayed an opposite trend when cultured with HUVECs. This system will continue to be explored 
to determine whether microspheres loaded with VEGF augment overall vessel formation in 3D 
collagen hydrogels. It was surprising to find the microspheres alone had an effect on sprout 
formation. 
 
Figure Q-10: Overall summary of preliminary work. 
